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 ABSTRACT 
Cytochrome P450 3A4 (CYP3A4) is the most abundant cytochrome P450 in humans. It 
metabolizes a broad range of substrates that are of pharmaceutical and toxicological interest and 
exhibits complex atypical substrate interactions. To reduce and eventually avoid harmful drug-drug 
interactions and adverse drug effects in pharmacotherapies, it is important to discern the variety and 
complexity of the kinetics of CYP3A4. Commonly, atypical kinetics of cytochromes P450 are 
explored via enzyme catalysis studies in vitro, and, in the case of homotropic cooperativity, via 
studies of the substrate dependence of the spin transition in the heme iron. 
CYP3A4 is responsible for the metabolism of the anticonvulsive drug carbamazepine (CBZ). 
To explore the mechanism of interaction between CYP3A4 and CBZ, we generated several active 
site mutants. These were generated based on a model of a putative productive binding mode of the 
CBZ-CYP3A4 complex and screened for their CBZ epoxidation activity. The results elucidate the 
existence of concurrent cooperativity and substrate inhibition in the epoxidation of CBZ. Whereas 
wild-type CYP3A4 exhibits predominant substrate inhibition, the cloned mutants reveal either more 
pronounced substrate inhibition kinetics (the I369F and I369L mutants) or S-shaped profiles 
indicative of homotropic cooperativity (the S119A, A370V, and A370L mutants). Analysis of the 
kinetic profiles of CBZ metabolism with a novel model combining the formalism of the Hill 
equation with an allowance for substrate inhibition demonstrates a mechanism of CYP3A4-CBZ 
interactions that encompasses the association of multiple substrate molecules. 
The produced enzyme variants were also applied to binding studies with further CYP3A4 
ligands. The S119A mutant shows novel types of inverse and bidirectional spin transitions upon 
ligand association. CYP3A4 I369F exhibits on average a 2-fold higher affinity and a several-fold 
increase in turnover at low substrate concentration (<< S50) towards a group of structurally diverse 
substrates. The I369F mutant therefore constitutes an optimized enzyme variant with the intriguing 
possibility to be employed in cytochrome P450-based biosensors for the detection of drugs and their 
prospective applications in personalized medicine. This comprehensive study introduces novel 
enzyme mutants whose study allows an improved understanding of the complexity and functional 
diversity of CYP3A4. 
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 KURZFASSUNG 
Cytochrom P450 3A4 (CYP3A4) ist das häufigste Cytochrom P450 im Menschen. Es 
metabolisiert ein breites Spektrum an Substraten, die von pharmazeutischem und toxikologischem 
Interesse sind, und weist komplexe atypische Substrat-Wechselwirkungen auf. Die Vermeidung 
ungünstiger Wechselwirkungen zwischen Medikamenten und deren gesundheitsschädlicher Effekte 
in Pharmakotherapieen erfordert ein Verständnis der Vielfalt und Komplexität der CYP3A4-
Kinetiken. Atypische Kinetiken werden üblicherweise mithilfe von enzymkatalytischen Studien in 
vitro und, im Falle von homotroper Kooperativität, mithilfe von Studien der Substratabhängigkeit 
des Spin-Übergangs im Häm-Eisen erforscht.  
CYP3A4 ist verantwortlich für den Metabolismus des Antiepileptikums Carbamazepin 
(CBZ). Um die Wechselwirkungen zwischen CYP3A4 und CBZ zu untersuchen, wurden mehrere 
Mutanten basierend auf dem Modell eines mutmasslich produktiven CBZ-CYP3A4-
Bindungsmodus generiert und die Mutanten hinsichtlich ihrer CBZ-Epoxidierungs-Aktivität 
untersucht. Die Resultate verdeutlichen, dass die komplexen Kinetiken der CBZ-Epoxidierung 
sowohl Kooperativität als auch Substratinhibition beinhalten. Während im Wildtyp 
Substratinhibition vorherrscht, enthüllen die Mutanten entweder verstärkte Substratinhibition 
(Mutanten I369F und I369L) oder S-förmige Profile, welche auf homotrope Kooperativität 
schliessen lassen (Mutanten A370V, A370L und S119A). Die Analyse der Kinetiken des CBZ-
Metabolismus mit einem neuen Modell, welches den Formalismus der Hill-Gleichung unter 
Berücksichtigung von Substratinhibition anwendet, demonstriert einen Mechanismus für die 
Wechselwirkung zwischen CBZ und CYP3A4, welcher die Assoziation mehrerer Substratmoleküle 
beinhaltet. 
Die produzierten Enzymvarianten wurden ebenfalls hinsichtlich ihrer Interaktion mit weiteren 
CYP3A4-Liganden untersucht. Die S119A-Mutante zeigt neuartige Typen inverser und 
bidirektionaler Spin-Übergänge unter Assoziation von Liganden. Die I369F-Mutante weist 
(gegenüber dem Wildtyp) eine im Mittel verdoppelte Affinität und eine um ein Mehrfaches 
gesteigerte Enzym-Aktivität bei geringer  Substratkonzentration (<< S50) gegenüber einer Gruppe 
von strukturell verschiedenen Substraten auf. Die I369F-Mutante stellt deshalb eine optimierte 
Enzymvariante dar für die Verwendung in Cytochrom-P450-basierten Biosensoren mit deren 
prospektiven Anwendungen in der Detektion von Medikamenten und in der personalisierten 
Medizin. Diese umfassende Studie präsentiert neuartige CYP3A4-Mutanten, deren Studium ein 
besseres Verständnis der funktionellen Komplexität und Vielfalt von CYP3A4 ermöglichen.  
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 ABBREVIATIONS 
7BQ 7-benzyloxyquinoline 
ALA 5-amino-4-oxo-pentanoic acid (δ-aminolevulinic acid, δ-ALA) 
AMP adenosine monophosphate 
BCT bromocriptine 
CHAPS 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate 
CYP3A4  cytochrome P450 3A4 
CPR  NADPH-cytochrome P450 oxidoreductase 
DMSO dimethyl sulfoxide 
DTT  dithiothreitol 
EDTA  ethylenediaminetetraacetic acid 
ERY  erythromycin 
EST estradiol 
FAD  flavin adenine dinucleotide 
FMN  flavin mononucleotide 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
NADPH nicotinamide adenine dinucleotide phosphate 
PC principal component 
PCA principal component analysis 
PCR polymerase chain reaction 
PMSF phenylmethanesulfonyl fluoride 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate (SDS) polyacrylamide gel-electrophoresis 
TRIS tris(hydroxymethyl)aminomethane hydrochloride 
TST testosterone 
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 FOREWORD 
This PhD thesis deals with functional aspects of the 3A4 isozyme of the cytochrome P450 
superfamily, which has been stated to undoubtedly be the most popular research topic in 
biochemistry and molecular biology over the 2nd half of the 20th century due to its importance for 
the pharmaceutical industry (1). It has been more than fifty years since Garfinkel (2) and 
Klingenberg (3) first reported the existence of an unusual cytochrome with a characteristic Soret 
absorption maximum of its carbon monoxide adduct (4) at 450 nm. Hence, it was later named 
cytochrome P450. Cytochromes P450 comprise a vast family of heme-thiolate enzyme proteins that 
are able to activate molecular dioxygen into highly oxidizing forms of oxygen. The activated 
oxygen is subsequently inserted into a non-activated substrate; hence the other name, mono-
oxygenases, for cytochromes P450. The popularity of cytochrome P450 in research may also 
partially stem from their ubiquitous nature. Even though they are represented in all five biological 
kingdoms and are found in most organisms, they seem to have diversified from a single ancestral 
protein during the course of biological evolution (5). Cytochromes P450 share a common protein 
fold but vastly differ in substrate selectivity. Processes catalysed by cytochromes P450 range from 
drug metabolism to the biosynthesis and metabolism of fatty acids, steroids, prostanoids, vitamins D 
and bile acids, alkaloids, terpenes, the detoxication of carcinogens, pesticides, and other 
xenobiotics, the metabolic activation of procarcinogens, and the generation of potentially harmful 
oxidizing agents (1). 
Cytochrome P450 families metabolize more than 200,000 chemicals and catalyse many 
different types of reactions including oxidations, epoxidation, N- and O-demethylations, and 
reductions, including dehalogenations. Some 1200 cytochromes P450 had been isolated up to 2001, 
and the number is expected to have greatly increased by today due to significant advances in 
sequencing technologies and the radical transformation of the field in the age of next-generation 
sequencing (6-10). 
In the 21st century, cytochromes P450 continue to attract a high level of interest; 2013 has 
been a particularly active year in the field. A survey into the number of publications per year that 
contain the keyword ‘P-450’ or ‘CYP3A4’ on PubMed reveals that the number of publications 
comprising any of the two keywords is still increasing1 (Figure 1). In 2013 alone, there were more 
than 2000 citations of ‘P-450’ per year. CYP3A4, the most abundant cytochrome P450 in human 
liver, has seen a remarkable boost in attention in the last year, which is reflected in a jump by 
1 data retrieved on April 28, 2014 from http://www.ncbi.nlm.nih.gov/pubmed 
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 almost 200 hits. Due to its unique importance for the pharmaceutical industry, such as its relevant 
role in drug-drug interactions and adverse drug reactions, CYP3A4 has become the most considered 
cytochrome P450. The list of approved drug products of the U.S. Food and Drug Administration 
(FDA) from December 2012, that starts with abacavir and ends with zyvox, encompasses 60 pages 
with ca. 60 drug products per page (→ totally ≈ 3600 drugs). As CYP3A4 is estimated to 
metabolize ~ 50% of all currently marketed drugs, we may conclude that a vast number of at least 
1800 substrates and these are just the pharmaceuticals (!) - is metabolized by this isoform. 
Moreover, such transformations may result in an incredible number of potential drug-drug 
interactions, i.e. situations where the activity of a drug is affected in the presence of another drug: 
1800∙1799
2
= 1′530′000. From such astronomic numbers, it is easily understood why CYP3A4 has 
maintained its role as an extensively studied enzyme. Given the steady increase in the number of 
available pharmaceuticals, the interest in CYP3A4 is likely to increase even more. 
 
 
Figure 1: Increase of the hits for the search terms “P-450” and “CYP3A4” over time. While the 
first papers on CYP3A4 have appeared in 1975, the share of the total number of publications that 
deal with CYP3A4 in some form has risen over the past decades. Note that cytochrome P450 was 
mostly referred to as ‘P-450’ before the mid-1980s. 
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Chapter 1 
1.1 CYTOCHROME P450 
Cytochromes P450 (P450s, CYPs) are a diverse group of heme-thiolate enzymes found in 
almost all organisms across all kingdoms of life (1). Members of the enzyme superfamily catalyse a 
wide variety of mono-oxygenation reactions. Cytochromes P450 are arranged into families (> 40% 
sequence identity) and subfamilies (> 55% sequence identity) based on their amino acid sequence 
similarity (11). The first purification of a cytochrome P450 was achieved in 1970 for a soluble 
enzyme from Pseudomonas putida, P450cam (12). It was the first to be characterized via x-ray 
crystallography (13) and is one of the most extensively investigated of all cytochromes P450. 
Membrane-bound cytochromes P450 from animal and plant sources were more difficult to purify in 
the beginning due to their instability towards solubilization with detergents that converted the 
enzyme to its inactivated P420 form. A breakthrough in the purification of membrane-bound P450s 
was the discovery that high concentrations of glycerol stabilize the enzyme (14), which marked the 
beginning of an era of successful purifications of various forms that started in the 2nd half of the 
1970s. 
The term “cytochrome P450” stems from the characteristic spectrophotometric property of the 
enzymes to absorb at 450 nm when bound to CO in the iron (II) form of the heme cofactor (4). Most 
cytochromes P450 rely on a protein partner that delivers one or more electrons to the heme iron to 
be transferred subsequently to molecular oxygen. Based on the type of the electron transfer protein, 
cytochromes P450 can be classified into several groups (15) (Table 1). 
Table 1: Cytochrome P450 systems and their electron sources. 
Cytochrome P450 System Source of Electrons 
Bacterial P450 Ferredoxin reductase and ferredoxin 
CYB5R/cyb5/P450 Cytochrome b5 (both electrons) 
FMN/Fd/P450 FMN-domain-containing reductase (fused to P450) 
Mitochondrial P450 Adrenodoxin reductase, adrenodoxin 
Microsomal P450 NADPH (via cytochrome P450 reductase, CPR) 
P450-only No external reducer 
 
The major families of cytochromes P450 are CYP1A, 2A, 2B, 2C, 2D, 2E, 3, 4, 5, 7, 11 
(animals), 51-66 (fungi), 71-100 (plants), 101-120 (bacteria) (1). While mitochondrial and the bulk 
of bacterial cytochromes P450 are highly selective in their choice of substrates and the specificity of 
their reactions, the mammalian microsomal enzymes exhibit a high level of promiscuity in 
substrates and reactions. The latter have important roles in the oxidative detoxification of drugs and 
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environmental chemicals as well as in pathways of endogenous metabolism, including steroid 
biogenesis and the metabolism of retinol and retinoic acid.  
In humans, 57 genes coding for cytochromes P450 have been identified. The human forms are 
primarily membrane-associated enzymes that are either located in the inner membrane of 
mitochondria or in the endoplasmatic reticulum of cells. The liver exhibits the highest content of 
cytochromes P450, although they are found in most tissues including kidney, breast, prostate, skin 
and nasal epithelium, gonads, placenta, brain, lung, spleen, pancreas, and gastro-intestinal tract (1). 
12-15 % of the endoplasmatic reticulum is composed of cytochromes P450, accounting for about 1-
2 weight % of an individual hepatocyte (1). The major human forms are CYP1A1, CYP1A2, 
CYP2C9, CYP2D6, CYP2E1, and CYP3A4 (16).  
1.2 THE CATALYTIC CYCLE OF CYTOCHROME P450 
Cytochromes P450 catalyse the incorporation of one atom of molecular O2 into a substrate 
RH, while the second atom is reduced to H2O obeying the stoichiometry: 
 
RH + O2 + NAD(P)H + H+ → ROH + H2O + NAD(P)+ 
 
In microsomal P450s such as CYP3A4, electrons are transferred via a route involving the co-
factors nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), 
and flavin mononucleotide (FMN) from cytochrome P450 oxidoreductase (CPR) via P450 onto the 
substrate (15): 
 
NADPH → FAD → FMN → P450 → O2/ RH 
 
Some microsomal forms may obtain the second electron from NADH through cytochrome b5 
reductase and cytochrome b5 (15). 
The catalytic cycle of cytochrome P450 (displayed in Figure 2) has been object of remarkable 
research for more than four decades. The iron (III) resting state binds the substrate that displaces a 
water molecule as the sixth heme ligand. The reduction of the iron (III) complex with one electron 
from CPR leads to the (deoxy-) iron (II) state, which is then able to bind molecular oxygen. Binding 
of molecular oxygen subsequently forms an oxyiron (II) complex. The addition of the second 
electron from CPR and a proton to oxyferrous cytochrome P450 results in a hydroperoxo-iron (III) 
intermediate (Fe3+OOH- or Compound 0). The second protonation leads to O-O bond cleavage with 
9 
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concomitant loss of water and is thought to generate the active oxygen π-cation radical oxoferryl 
state (Fe4+=O or Compound I). Similar to Compounds I and II, this is a highly electrophilic 
intermediate that leads to the insertion of the oxygen into the substrate to form the oxidized product, 
and cytochrome P450 returns to its initial resting state via unbinding of the product (17). 
 
 
Figure 2: Catalytic cycle of cytochrome P450 showing the various iron oxygen intermediates. 
Unproductive pathways are depicted with dashed arrows (reproduced with permission of Willem H. 
Koppenol). 
 
All intermediates of the reaction cycle except Compound II have been observed (Compounds 
0, and I only under non-physiological conditions though) and most of them have been thoroughly 
characterized (17-22). It has been generally agreed that oxoferryl cytochrome P450 is the key 
intermediate in alkane hydroxylations, but it has also been proposed that multiple electrophilic 
oxidants other than the oxoferryl state may be involved in P450-catalyzed reactions, such as the 
peroxo- and hydroperoxo- iron (III) state in olefin epoxidations (17, 23) as well as in hydroxylations 
(24). The terminal electrophilic species, i.e. the oxoferryl state, has remained elusive until recently. 
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It has been generated by reacting iron (III) CYP119 with m-chloroperbenzoic acid (21) or by 
oxidizing CYP119 or CYP2B4 to their Compound II species (the iron(IV) hydroxide or iron(IV)-
oxo intermediate) with peroxynitrite and then irradiating with 355 nm light (25-28). The relative 
importance of the individual oxidative intermediates for substrate oxidations has remained subject 
to controversial discussions. 
1.3 NADPH CYTOCHROME P450 OXIDOREDUCTASE  
The enzyme NADPH-cytochrome P450 oxidoreductase, abbreviated as CYPOR or CPR (here 
we will use the notation CPR), is essential for electron donation to microsomal cytochromes P450 
(reference (29) pp. 115 – 148). It receives electrons from NADPH and transfers them via FAD and 
FMN. FMN hydroquinone transfers the electrons, one at a time, to CYP3A4 or other redox partners, 
which include microsomal heme oxygenase, cytochrome b5 and, although not in a physiological 
environment (in vivo), cytochrome c (30). The latter is commonly used in oxidised form for 
quantification of CPR contents in complex samples where a spectroscopic determination is 
impossible (see also chapters 2 and 3) (31). Similar to microsomal cytochrome P450, CPR has two 
functional domains: a hydrophobic membrane-binding domain at the N-terminus and a hydrophilic 
C-terminal catalytic domain, which in turn is comprised of several structural domains. The N-
terminal domain of CPR is a hydrophobic 6 kDa polypeptide that anchors the protein to the 
endoplasmatic reticulum and nuclear envelope (32) and facilitates spatial interaction for electron 
transfer from CPR to P450. Without the hydrophobic anchor, the hydrophilic and soluble C-
terminal domain still passes electrons to cytochrome c, but is not capable of reducing cytochrome 
P450 (30).  
CYP3A4 receives electrons from CPR at two separate steps in the reaction mechanism (see 
chapter 1.2) (33). Deletion of the POR gene that encodes CPR essentially leads to inactivation of all 
microsomal cytochromes P450. This has been exploited in evaluating cytochrome P450 function in 
normal homeostasis, drug pharmacology, and chemical toxicity in vivo (29). Twenty-six missense 
mutations/polymorphisms of the POR gene have been described and were associated with the 
Antley-Bixer syndrome and/or disordered steroidogenesis, which lead to defects in bone 
development and sexual dimorphisms (33-36). 
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1.4 CYTOCHROME P450 3A4 (CYP3A4) 
Cytochrome P450 3A4 (CYP3A4) is the most abundant form in most adult humans. It 
metabolizes about 50% of all marketed drugs (37), which is a huge number in view of the list of the 
approved drugs by the U.S. Food and Drug administration, a report that currently contains ~3600 
drug products2. CYP3A4 has the heme group in the active site and consists of a small β-strand N-
terminal and a larger α-helical C-terminal domain (38), and adopts the typical fold of the 
cytochrome P450 superfamily (39). The three other members of the 3A family are CYP3A5, 
CYP3A7, and CYP3A43. CYP3A5 has 85% sequence identity with CYP3A4 and is thought to have 
a much lesser pharmacological importance than CYP3A4, as are the other two. However, CYP3A5 
has a polymorphic and racial distribution with possible relevance to clinical issues (29). CYP3A7 is 
the major cytochrome P450 in human fetal liver and also present in other fetal tissues, but decreases 
in abundance during the first week of life and plays no major role in the metabolism of adults (29). 
CYP3A43 makes most likely contribution to drug metabolism, even though it may have specialized 
roles in extrahepatic tissues. 
The heme iron in CYP3A4 is ligated by the side-chain group of the conserved cysteine 
residue Cys442 at its proximal ligand binding site. The propionates of the heme are in contact with 
the side chains of Arg105, Trp126, Arg130, Arg375 and Arg440 (38). The structure of CYP3A4 
(Figure 3) differs in a number of features from other cytochrome P450 structures (38, 40). A 
hydrophobic region (residues 36 – 50) is located around the loop following a helix that is not 
observed in other cytochrome P450 structures, helix A’’. This region is thought to mediate the 
interaction of CYP3A4 with the microsomal membrane along with the G’-helix and the 
hydrophobic GG’ loop. Another unexpected structural feature of CYP3A4 is the F-helix that is 
markedly short compared with other cytochrome P450 structures. It is followed by an ordered 
polypeptide stretch that does not conform to any secondary structure motif. This stretch is 
perpendicular to the I-helix and contains several amino acid residues that play a direct or indirect 
role in CYP3A4 function. Leu211, Asp214, and Leu210 are implicated in allostery as well as regio- 
and stereoselectivity of CYP3A4 (41-44) and are situated in this region. The side chains of these 
residues are pointing away from the active site in the structure 1W0G (see Figure 3b-c) (38). Two 
other residues in this extended loop region that were shown by site-directed mutagenesis to have no 
role in cooperativity (42), Phe213 and Phe215, point toward the active site and form the 
“phenylalanine cluster” along with Phe108, Phe219, Phe220, Phe241, and Phe304. This 
2 http://www.fda.gov/Drugs/default.htm 
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phenylalanine cluster is another characteristic feature of CYP3A4 and lies above the active site. Its 
aromatic side chains stack against each other to form a highly ordered hydrophobic core. The 
position of the phenylalanine cluster causes a closed conformation of the active site in the first 
reported x-ray structure of CYP3A4 (1W0G) (38) similar to the closed conformation of cytochrome 
P450 EryF (39). However, the spatial arrangement of the F-G loop and the F helices is not 
conserved. The F-G region is part of a portion of CYP3A4 that is predicted to reside within the lipid 
bilayer along with the N-terminal membrane anchor α-helix (11). Helices F and G and the 
intervening loops underwent the most prominent conformational changes upon binding of 
erythromycin (CYP3A4 substrate and inhibitor) and ketoconazole (CYP3A4 inhibitor) (45). The F-
F’-G-G’-sequence of α-helices is assumed to be the primary interaction site of CYP3A4 with 
substrates. 
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Figure 3: X-ray structure 1W0G of CYP3A4 (38). Some of the most important structural features 
are highlighted. Panel (a) shows the overall structure of CYP3A4 with the F/F’-helices (orange), the 
G’/G-helices (marine) and the I-helix (green). The FF’- and GG’-loops are shown in black. In panel 
(b), residues of the FF’/GG’ region important for substrate recognition are highlighted (Phe residues 
are shown in orange, Leu211, Arg212, and Asp213 are shown in yellow). The inhibitor metyrapone 
(shown in violet) is ligated to the heme iron (shown in red) via direct N-ligation and is likely to be 
hydrogen-bonded to the side chain hydroxyl of Ser119 (shown in light blue). In panel (c), a view of 
the structure along the axis of the black arrow in (b) is presented. Side chains of residues discussed 
in the text are shown and labelled; the Phe residues constituting the Phe-cluster are shown in 
orange, residues Leu211, Arg212 and Asp214 of the FF’-loop involved in allostery are shown in 
yellow, Ser119 is shown in light blue. 
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Molecular dynamics simulations have predicted this sequence to undergo large-scale movements 
upon interaction with the lipid bilayer, which allow for opening and closing of the substrate access 
channel (46, 47). This region has also been suspected to harbor a peripheral effector binding site 
(48, 49) close to the progesterone binding site identified in the 1W0F X-ray structure (38). It is 
however likely that this area binds potentially harmful hydrophobic substances (such as toxins) non-
specifically, which are then directed to the active site for possible oxidation and neutralization (11). 
An important feature is the accessibility of the heme in the active site of CYP3A4, which is 
greater than in, for instance, CYP2C9 (38). This allows CYP3A4 to accommodate either large 
ligands or several smaller ligands, which may all have access to the activated distal oxygen. This is 
in agreement with a large body of data indicating that CYP3A4 can simultaneously bind and/or 
metabolize several molecules of certain substrates or inhibitors, such as pyrene (forming pyrene-
pyrene complexes with excimer emission) (50) or ketoconazole (45) (see also chapter 1.5). The total 
solvent-accessible volume of the active site undergoes large changes depending on the presence and 
identity of a ligand (45). The volume in the ligand-free structures was estimated to amount to 
≈ 950 Å3. In a complex with ligands, the volume increased to 1650 Å3 for erythromycin (structure 
2J0D) and to ≈ 2000 Å3 in the presence of two ketoconazole molecules in the binding pocket 
(structure 2V0M). 
As a consequence of its flexibility and its large active site, CYP3A4 is a highly unspecific and 
promiscuous enzyme and can accommodate and metabolize substrates of large diversity in size and 
chemical structure. This makes CYP3A4 a key player in drug metabolism and gives rise to a 
sensitivity of drug metabolism to changes in CYP3A4 activity (e.g. due to inhibition or activation of 
its metabolism) and expression level. Through fast or slow degradation, CYP3A4 can lower or 
increase the drug disposition or bioavailability of pharmaceuticals. One of the co-administered 
drugs may increase the plasma concentration of another drug and lead to toxic drug plasma levels, 
but may also induce cytochrome P450 gene expression and thus upregulate protein production or 
directly activate drug metabolism and lead to low, ineffective drug levels. For instance, low levels 
of an immunosuppressant (e.g. cyclosporine) will not prevent organ tissue rejection after 
transplantation, but high levels may cause renal toxicity (29). Because many pharmaceuticals have 
narrow therapeutic indices and are CYP3A4 substrates, their dose needs to be adjusted for optimal 
therapy; preferably their concentrations are monitored continuously to prevent adverse drug 
reactions (see p. 29). Interactions between simultaneously administered drugs may affect drug 
clearance and the outcome of drug therapies and are therefore also of major importance for the 
pharmaceutical industry. 
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Carbamazepine, an anticonvulsive and CYP3A4-substrate (Figure 4), is an example of a 
narrow therapeutic index drug with a target blood plasma concentration of 17 – 70 μM (51). The 
CYP3A4-dependent metabolism of carbamazepine is the subject of chapter 4. CYP3A4 is 
furthermore involved in steroid biosynthesis and bioactive metabolite production, for instance 
vitamin D and retinoic acid metabolites (reference (29) pp. 423 – 430). Atypical functional 
properties of CYP3A4 are addressed in chapter 1.6 (see p. 19). 
 
Figure 4: Chemical structure of carbamazepine (CBZ). The numbered carbon atoms mark the 
epoxidation site in the CYP3A4-dependent reaction. 
1.5 LIGAND BINDING TO CYP3A4 AND REGULATION 
Iron catalysis in biology is potentially dangerous, because lethal levels of reactive oxidants 
can be formed. Such catalysis is not restricted to hemoproteins and iron thus needs to be tightly 
regulated by the organism. In cytochromes P450, catalytic activity is regulated through the change 
in the electrode potential of the heme iron that accompanies the spin transition upon binding of the 
substrate in the active site of the enzyme. In the substrate-free resting state of most cytochromes 
P450, heme iron (III) is predominantly present in the (S = 1/2) low-spin state. Some exceptions (e.g. 
CYP1A2) are predominantly isolated in the high-spin state (S = 5/2) in the absence of substrates. 
They are therefore not amenable to the typical spectral analysis methods of substrate binding to 
cytochromes P450 that are based on a change of spin state (52). In the resting state in the absence of 
ligand, the coordination of water at the sixth (distal) ligand position stabilizes Fe (III) in the low-
spin hexacoordinated state (S = 1/2). Type I substrates bind to the active site near to the distal 
ligand binding site with a hydrophobic moiety and can displace the bound water molecule. They 
account for the common type of substrates that are metabolized by cytochromes P450. Binding of 
type I ligands effect a shift in the Soret band from ~ 416 nm to ~ 391 nm, and induces a change in 
the spin state of the heme iron from low-spin (S=1/2) to high-spin (S=5/2). For most soluble 
bacterial cytochromes P450, the substrate-induced spin shift is correlated with a change in the 
electrode potential of the protein (53-55). For CYP3A4 incorporated into nanodiscs, a protein 
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scaffold that simulates a native-like membrane bilayer (56), the type I spin shift accompanies a shift 
in the reduction potential of the heme (iron (III) → iron (II)) of ~ +80 mV for substrates such as 
bromocriptine and testosterone that are capable to induce a strong spin shift (see chapter 5) (57). 
Binding of a type I ligand therefore facilitates the reduction of heme, which then favors binding of 
molecular dioxygen. Substrate binding also contributes to a stabilization of the iron adduct with the 
activated oxygen species (58). In most cases, O2 only binds at the sixth iron coordination site when 
substrate is bound to the active site. This ensures that highly oxidizing species are only formed in 
the presence of substrate and, therefore, that only the substrate is oxygenated. The stronger the type 
I ligation of heme (the higher its ability to perturb water ligation), the larger is the spin shift. The 
reduced oxyiron (II) CYP3A4 is predominantly present in the high-spin pentacoordinated state. The 
local dielectric constant at the heme can also affect the electrode potential of the heme protein. Iron 
(II) heme is neutral, while iron (III) heme exhibits a net positive charge (57). Additionally, the local 
dielectric constant may also interfere with the spin equilibrium of iron (III) CYP3A4 via disruption 
of the water network that provides the (sixth) water ligand (see chapter 5). 
Inhibition of CYP3A4 is an issue for the pharmaceutical industry due to a number of 
clinically important drug-drug interactions. A well-known example is the inhibition of CYP3A4 by 
grapefruit juice with its furanocoumarins bergamottin and 6’,7’-dihydroxybergamottin, both 
mechanism-based inhibitors, such that warning labels contain this contraindication for many drugs 
(29). Herbal medicines often interact with cytochrome P450 metabolism. One of the most studied 
examples is St. John’s wort, which is a strong inducer of CYP3A4 and reduces the effectiveness of 
oral contraceptives. The induction of CYP3A4 expression led to pregnancies, which were the result 
of an increase in the rate of elimination of 17α-ethynylestradiol, previously also reported for the 
induction caused by rifampicin and barbiturates. 
Inhibitors of CYP3A4-dependent metabolism (see (29) pp. 247 – 325) can be divided into 
three groups: (a) reversible inhibitors, (b) quasi-irreversible inhibitors (that form complexes with 
the heme iron), and (c) mechanism-based inhibitors (that irreversibly bind to the cytochrome P450 
or accelerate degradation or oxidative fragmentation of the heme). Reversible inhibitors show one 
or more of the following characteristics: they bind to the hydrophobic regions of the active site, they 
engage into hydrogen bonding or ionic interaction with active site residues, they directly coordinate 
to the heme iron. Most of the time, reversible inhibition encompasses two or more types of 
interactions. Ligands that undergo direct ligation to the heme iron atom via nitrogen - provided by 
imidazole, pyridine or primary amino groups - are called type II ligands. Binding of type II ligands 
induces a shift in the Soret band from ~ 416 nm to 420 – 424 nm and concomitantly lowers the 
electrode potential of cytochrome P450, which prevents both electron donation by a redox partner 
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and oxygen binding (11). Some antidepressants, steroids, macrolide antibiotics and other types of 
drugs are CYP3A4 inhibitors that do not act through nitrogen ligation, but inhibit the enzyme via 
reversible or irreversible binding and mechanism-based inhibition (11, 59). 
Two very potent inhibitors of CYP3A4 are ketoconazole, a widely used antifungal drug, and 
ritonavir, a peptidomimetic HIV protease inhibitor that is also administered as a booster for the 
enhancement of the pharmacokinetics of other HIV protease inhibitors that are otherwise quickly 
metabolized by CYP3A4 (11, 60, 61) (Figure 5). For both inhibitors, X-ray structures of their 
complexes with CYP3A4 have been solved. Both inhibitors ligate active-site heme iron via their 
azole nitrogens. While ritonavir binds to CYP3A4 as one molecule in the X-ray structure 3NXU 
(62), the most interesting feature of the crystal structure of the ketoconazole-bound CYP3A4 
(2V0M) is the presence of two drug molecules in the active site in antiparallel tandem configuration 
(45). Notably, in both structures, residue S119 contributes to the stabilization of ligand binding via 
hydrogen bonding to the ligand.  
 
Figure 5: Structures of the two CYP3A4 type-II ligands (inhibitors) ketoconazole (a) and 
ritonavir (b). 
Cytochrome P420 (63-69) is a cumulative term used to designate several stable, but inactive 
species with a changed sphere of ligation of the heme iron that can be produced spontaneously and 
generated via numerous chemical and physical means, such as increased temperature or pressure or 
addition of salts, denaturants or organic solvents (64). All these species have the Soret band of the 
ferrous iron (II) carbonyl complex positioned around 420 nm, instead of its positioning at 447-452 
nm as in the P450 state of the heme protein. The nature of the proximal heme ligand of P420 has 
been subject to speculations. Still, it is generally accepted that the major P420 state represents the 
protonated form of the native cysteinate ligand, and it has been suggested that a ligand switch 
a b
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replaces the protonated cysteine for a histidine to form a myoglobin-like heme coordination (64, 
69). In the oxidized, ferric iron (III) state, both type II-ligated cytochrome P450 and the major, most 
commonly occurring cytochrome P420 form exhibit a similar Soret band maximum at 424-426 nm 
(63, 70) and discrimination between the P420 and the type-II ligand-bound cytochrome P450 state 
requires the examination of the spectra of the reduced carbonyl complex.  
1.6 COOPERATIVITY AND ATYPICAL KINETICS IN 
CYP3A4 
1.6.1 COOPERATIVITY AND ALLOSTERY 
A large number of comprehensive reviews have been published on atypical kinetics in 
cytochrome P450. For a deeper understanding, the reader may wish to consult these reviews (58, 
71-75). Most key biological processes are highly cooperative. Examples are as diverse as the 
formation of native biomolecules and their functional assemblies or cellular signalling and 
regulation (58, 76). Cooperativity and allostery result from a mutual perturbation of the functional 
properties of a biological macromolecule interacting with two or more ligands. This feature is 
exploited by many living systems to improve the sensitivity to perturbations and to amplify the 
response of their receptors and macromolecular transporters (58). 
Cooperative functional properties and allosteric regulation play important roles in xenobiotic 
metabolizing systems, including cytochromes P450, and are regarded as one of the main underlying 
mechanisms of drug-drug interactions (58). In numerous biochemical and biophysical experiments 
with cytochrome P450 including NMR, calorimetry, surface plasmon resonance, time-resolved 
fluorescence, rapid kinetic approaches, and equilibrium spectroscopy, more diverse complex 
functional responses have been discovered and summarized under the term atypical, or non-
Michaelis-Menten kinetics (71, 77). However, the plethora of data that has been published has 
rendered the term inappropriate. Manifestations of non-Michaelis-Menten kinetics in cytochrome 
P450 include substrate cooperativity (i.e. the stimulation of substrate turnover or substrate binding 
of an enzyme) and substrate inhibition. Homotropic cooperativity is revealed in sigmoidal (S-
shaped) dependencies of the rate of metabolism (or of a spin shift upon substrate binding) on the 
concentration of the substrate. In heterotropic cooperativity, the functional response of the enzyme 
(in cytochrome P450 in terms of substrate binding or turnover) to ligand A is stimulated in the 
presence of ligand B. In this sense, homotropic cooperativity may be seen as the special case where 
the two molecules are identical (A = B). In heterotropic cooperativity, the functional response of the 
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P450 system is modulated in the presence of a molecule, which can be a substrate itself, such as α-
naphthoflavone (ANF) (78-81) or testosterone (TST) (79, 82, 83), or an alternative ligand (non-
substrate) such as glutathione (84, 85). If the binding of molecule B is not involved in catalytic 
action for the case of substrate turnover, it is referred to as allosteric: B is an allosteric effector that 
binds to an allosteric binding site. The effector is called activator if the catalytic activity of the 
enzyme towards the substrate is enhanced, and it is called inhibitor, if the activity is reduced. 
Cooperativity represents one possible type of allosteric regulation. Unfortunately, cooperativity and 
allostery are often used interchangeably in the literature on cytochrome P450. An important 
characteristic of cytochromes P450 is, in contrast to the vast majority of allosteric proteins 
discovered so far, that they show cooperative behavior also in their monomeric form (58, 86).  
Protein as well as non-protein effectors are involved in allostery of microsomal cytochromes 
P450, including cytochrome b5 (87-91) and glutathione (84), or inhibitors such as erythromycin and 
ketoconazole. Some divalent metal ions were also reported to enhance catalysis in microsomal 
cytochromes P450 (92). In the case of CYP3A4, in particular Mg2+ and Ca2+, and to a lesser extent 
Sr2+, stimulate some of the CYP3A4-catalyzed reactions (85, 92, 93). Mg2+ appears to  increase the 
rate of electron transfer from NADPH-P450 oxidoreductase to cytochrome b5 and CYP3A4 (85). 
The effect of the specific mutations L211F/D214E in CYP3A4 abolished cooperativity in CYP3A4 
with the effectors ANF or testosterone (44). While wild-type CYP3A4 showed cooperativity in 
spectral binding studies with testosterone (as shown by a sigmoidal binding curve), the double 
mutant displayed hyperbolic behavior. The latter also displayed increased rates of testosterone and 
progesterone 6β-hydroxlation at low substrate concentrations and a decreased level of heterotropic 
stimulation by ANF.  
Human CYP3A4 is a textbook example of a cooperative cytochrome P450, along with human 
CYP2C9 and CYP107 of Bacillus subtilis (94). CYP3A4 has a large and flexible substrate binding 
pocket capable of binding relatively large substrates with molecular weights >1000 Da (e.g. 
erythromycin, Mr = 1203 Da). The size and the flexibility of the binding pocket also allow for the 
simultaneous binding of several small (identical or different) organic molecules like carbamazepine 
(Mr = 236 Da, chapter 4) instead of one large molecule (45). The common conclusion in studies of 
CYP3A4 cooperativity is therefore that two or possibly more ligands co-occupy the large binding 
site as a requirement for one of the molecules to adopt a productive binding mode. Indeed, for some 
substrates, the simultaneous presence of several molecules has been established (72, 95, 96). This 
model is able to explain most cases of homotropic cooperativity, but fails to account for some cases 
of heterotropic cooperativity, where the turnover is stimulated many times (74). In such a case, an 
increase in activity towards a substrate occurs at low concentration of the other ligand (effector), but 
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this effect vanishes (or substrate turnover may even be inhibited) at saturating concentrations of the 
effector. The particular type and mechanism of allostery in CYP3A4 therefore depends on the 
specific substrate(s) or effector(s). As the homotropic and heterotropic cooperativity models are 
mutually incompatible, it is not possible to explain all instances of allostery in cytochromes P450 by 
a single mechanism. 
From EPR and absorbance spectroscopy experiments, Roberts et al. concluded that binding of 
the first testosterone molecule occurs with the highest affinity and is “spectrally silent”, i.e. it does 
not lead to a significant spin shift (96). Following their conclusion, the binding of the second 
testosterone molecule induces only a partial spin shift, and a third molecule is required for the 
maximum shift. Independently, Denisov and co-workers applied global analysis to equilibrium 
substrate binding and steady-state NADPH consumption kinetics, which resolved the fractional 
contributions to turnover of CYP3A4 with one, two, and three testosterone molecules bound. The 
first binding led to an increase in NADPH consumption, but did not induce a strong spin shift nor 
did it lead to significant product formation. A second testosterone molecule was required to reach 
maximum rate in catalysis, whereas the third molecule mainly increased the coupling efficiency of 
redox equivalent usage (72). 
In normal vernacular, cooperativity implies changes in ligand affinity induced at one site in a 
macromolecule by binding at one or more additional sites (94). It was however suggested that a 
sigmoidal, seemingly cooperative effect can also be explained without the requirement of functional 
cooperativity (58, 72, 79, 96-98). A non-hyperbolic response only requires several binding sites for 
the substrates and/or effectors and the catalytically active binding site to have the lowest affinity for 
the substrate (58). In this model, the high-affinity sites are saturated first during substrate titration 
but only offer a small fractional contribution to the total spectral response in spin shift or a 
negligible fraction of the total product formation rate. The binding of a second molecule to a lower 
affinity site would result in the formation of a catalytically competent enzyme-substrate complex. 
Only when the substrate binds to the immediate vicinity of the catalytically active heme can this be 
detected by spectral or functional responses (such as spin shift, NADPH consumption, or 
appearance of product). All of these functional readouts unambiguously indicated non-hyperbolic, 
apparently cooperative responses in the case of testosterone. In this example, an apparently 
cooperative effect (sigmoidal substrate dependence) may be explained by the differential functional 
contributions of the individual enzyme states, namely CYP3A4 with one, two or three testosterone 
molecules bound. This model provides a robust foundation to explain sigmoidal dose-response 
functions in the case of steroids. The model may however not be applicable to other substrates. In 
particular, the assumption that the spectrally silent binding site is associated with high affinity 
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binding is not maintained in the case of Nile Red, a fluorescent allosteric substrate of CYP3A4. Nile 
Red was found to exert a sigmoidal spin shift in CYP3A4 (99). However, with the help of a 
fluorochromic effect upon binding to CYP3A4 in the active site (emission maximum is blue-
shifted: λred ~ 660 nm to λblue ~ 620 nm), but not at the peripheral site, the authors concluded that the 
high-affinity binding site (KD ≈ 50 nM) is in the active site, whereas the low-affinity binding site 
(KD ≈ 2.2 μM) lies at the periphery of  CYP3A4 (100). In chapter 5, we report multiple binding of 
cooperative substrates to the CYP3A4 S119A mutant and their bidirectional effects on the spin 
state. 
An X-ray structure of a complex of CYP3A4 with progesterone established a location in the 
flexible FF’GG’ region on the CYP3A4 globular surface as a potential place for a peripheral 
binding site (38) for an allosteric effector. The two helices F’ and G’ are absent in cytochrome P450 
BM3, EryF, and other structures of the bacterial forms (38). A study involving Förster resonance 
energy transfer (FRET) suggested that the peripheral ligand binding site is in a region close to the 
progesterone binding site (49). High-affinity binding at the periphery may exert important effects on 
the functional response of CYP3A4 and be involved in heterotropic cooperativity (48, 49). For 
CYP3A4 incorporated into the lipid bilayer of microsomes, this site is likely located at the 
solvent/membrane interface and is therefore thought to interact with the components of native 
membranes such as lipid head groups, steroids and fatty acids (58). The interaction of this site with 
the lipid bilayer or effector molecules is expected to affect the large-scale conformational change 
(‘open-close’ movement) of CYP3A4 that is thought to be important for substrate binding and 
release (101-103). On the other hand, direct participation of the tentative peripheral ligand binding 
site in substrate turnover or spin shift is thought to be insignificant, as studies on testosterone 
binding suggest (58, 72, 79, 97, 98). In fact, binding to the tentative peripheral ligand binding site 
caused only a negligible perturbation of the spin state of the heme iron (less than 20% spin shift for 
TST (72) and less than 4 % for ANF (79)) and did not lead to product formation. 
Observations of several-fold increased substrate turnover in the presence of allosteric 
effectors (heterotropic cooperativity) have been attributed to an effector-induced redistribution of a 
pool of cytochrome P450 conformers with dissimilar activity and substrate specificity (74, 78, 81). 
Evidence for conformational heterogeneity was obtained from kinetics studies on the reduction of 
the heme iron in cytochrome P450 by sodium dithionite (Na2S2O4, tetraoxidodisulfate sodium) 
(104-106) or other artificial electron donors, or the kinetics of CO binding (107). Some allosteric 
effectors may induce a conformational change in CYP3A4. The existence of non-interconverting 
subpopulations suggests that the expression ‘spin equilibrium’ is not applicable to the pool of 
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CYP3A4 taken as a whole, but rather to the several stable subpopulations of the enzyme. In chapter 
7.2, some of the results of ref. (105) are reproduced, but with the mutants generated for this thesis. 
The formation of cytochrome P450 oligomers in membranes has been shown in several 
studies on rotational diffusion (74). Recently, the effect of oligomerization of CYP3A4 on the 
kinetics of the reduction of the enzyme with the flavin domain of cytochrome P450-BM3 (BMR) as 
a model electron donor partner (108) and on the degree of activation by the heterotropic activator 
ANF (α-naphthoflavone) (78) have been studied. Besides homo-oligomerization, CYP3A4 also 
forms hetero-oligomers with CYP1A1, CYP2B4 or CYP1A2. For instance, CYP3A4-mediated 
metabolism of testosterone was stimulated when co-reconstituted with CYP1A1 or CYP1A2, but no 
effect was found in reconstitutions with CYP2C9, CYP2D6, or CYP2E1 (109). For detailed 
discussions on the formation of cytochrome P450-P450 complexes in membranes and their effect 
on the function of the enzymes, the reader is referred to recent review articles (16, 73, 74).  
Whereas CYP3A4 cooperativity has initially been understood as a case of pseudo-allostery 
due to multiple substrates binding into a large, rather static, binding pocket, the allosteric 
mechanism is now acknowledged to be much more complex. The mechanism is most likely a 
combination or overlay of the results of multiple substrate binding (space-filling mechanism) 
combined with ligand-induced changes in the conformation and redistribution of a set of enzymatic 
states that are maintained in the membrane due to oligomerization (74). 
1.6.2 MATHEMATICAL FRAMEWORKS FOR ALLOSTERY IN CYTOCHROMES 
P450 
Mathematical frameworks for the handling of multi-site substrate binding have been proposed 
in the form of sequential ordered binding or sequential random binding models. We will consider 
the simplest case of a two-site sequential ordered model of substrate binding to one macromolecule 
(96). Since binding affinities of the individual binding sites in CYP3A4 are often assumed to 
substantially differ, the use of the simplified sequential ordered model in these cases is permissible 
(Scheme 1). 
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SCHEME 1 
An enzyme E can bind a single substrate S to form a complex ES with an equilibrium 
dissociation constant KD1 = K1. The complex ES can then bind a second substrate molecule S to 
form ESS, a ternary complex with a dissociation constant KD2 = K2. As per definition the two 
binding sites in a single cytochrome P450 are non-identical, binary and ternary complexes may be 
denoted by writing SES or ES1S2 instead of 𝐸𝑆𝑆 ≡ 𝐸𝑆2. However, for simplification, we forego the 
distinction between the binding sites in the formalism of the derivation. ES and SES can both react 
to irreversibly form product P with rate constants kcat1 and kcat2, respectively. In the following, the 
derivation for the functional responses of a system according to the sequential ordered two-site or 
three-site model is reproduced (58, 77, 96). 
Via transformations, the concentrations of [𝐸𝑆] and [𝐸𝑆𝑆] are obtained from the definition of 
the dissociation constants:  
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The fractions of singly- and doubly-occupied enzymes can be expressed as:  
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[ET] is the total concentration of enzyme in free form and in the binary and ternary complex 
([𝐸𝑇] = [𝐸] + [𝐸𝑆] + [𝐸𝑆𝑆]). The total functional response (in this case the enzymatic turnover) 
for the system is given by: 
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If v1 (for the binary complex ES) is much higher than v2 (for the ternary complex ESS), the 
equation predicts substrate inhibition kinetics. If v2 is much higher than v1, sigmoidal kinetics will 
be observed.  
Equation 1.7 holds true for the turnover by an enzyme with two binding sites for a substrate 
with different reactivities from the two states [ES] and [ES2]. It can easily be adapted to obtain the 
equilibrium binding equation by replacing all vi parameters with appropriate scaling factors ai for 
the observed signal. In the case of substrate binding to CYP3A4 (monitored via spin shift), a1 and 
a2 represent the fractional contributions to the total spin shift of singly- and doubly-occupied 
CYP3A4 (Eq. 1.9) 
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In the case of three sequential ordered binding steps, Scheme 2 applies.  
 
SCHEME 2 
Accordingly, the overall reaction velocity (1.10) and equilibrium binding (1.11) of the three-
site binding model are given as: 
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The two-site and three-site models are useful in cases where binding of two or three substrate 
molecules occurs, respectively. In some cases with S-shaped binding isotherms and turnover 
profiles (v vs. [TST]) on the basis of three binding sites, such as in testosterone (TST) binding and 
hydroxylation by CYP3A4, the predicted functional response conforms well with the data (72). 
However, in general, the exact number of binding sites for specific small and moderate-sized 
substrates is not known. 
If the number of binding sites and therefore the binding stoichiometry is unknown, the Hill 
equation (110) is often applied for fitting of sigmoidal data in cytochromes P450. Fitting yields an 
averaged binding parameter, the Hill coefficient h. The Hill equation was originally derived to 
describe the binding of oxygen and carbon monoxide by haemoglobin (110). The protein was 
correctly assumed to consist of h of subunits which bind ligands simultaneously (Scheme 3). 
 
SCHEME 3 
K is the dissociation constant for the h-th order binding equilibrium. In the original formalism 
of Hill this constant is substituted with the parameter S50, which is defined as 50 h DS K= . The Hill 
equation describes the binding isotherm for such a binding: 
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By definition, the Hill coefficient h represents the number of the molecules of ligand which 
bind to the enzyme (or an oligomer consisting of h subunits) simultaneously (110). This is the case 
of infinite cooperativity, which represent an ultimate simplification and barely occurs in the real 
mechanisms. However, the fitting of titration curves to the Hill equation provides a convenient 
means to judge as to how much the system deviates from the hyperbolic binding model and to 
presume the number of binding sites. It was shown that the Hill coefficient is always less than or 
equal to the number of subunits or binding sites, and therefore may be used to assess the minimal 
number of binding sites involved in the cooperativity mechanism (94). The parameter S50 on the 
other hand represents the midpoint of the binding isotherm. It does not correspond to any individual 
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dissociation constant, but rather represents a composite of the real dissociation constants that 
characterizes the averaged affinitiy. 
Importantly, the Hill equation has been developed for an aggregate system that consists of 
identical subunits with identical binding affinities. In the case of cytochrome P450, neither 
conditions of the original model of hemoglobin are met, since sigmoidal behavior is seen in 
monomers of cytochrome P450 that do not comprise identical binding sites (72, 86), and since it is 
known that these binding sites usually exhibit different affinities for the substrate. Despite major 
limitations, the Hill equation is a common and simple model often used for the fitting of 
cooperative functional aspects of cytochromes P450 in order to obtain information about the extent 
to which a system is “cooperative” (111).  
Chapter 4 addresses cooperativity in cases, when the number of substrate binding sites is 
unknown, such as for carbamazepine. An equation is derived that combines the phenomenological 
nature of the Hill equation with substrate inhibition (see p. 54). In this model, substrate inhibition 
by an additional substrate molecule occurs upon cooperative binding of an unknown number h of 
substrates (Scheme 4). 
 
SCHEME 4 
 
The law of mass action is expressed as: 
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The equation for turnover as a function of substrate concentration is given as (a complete 
derivation is shown on p. 54ff): 
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1.7 RECONSTITUTION OF THE ACTIVITY OF PURIFIED 
CYTOCHROME P450 
In order to study the activity of individual hepatic microsomal cytochromes P450, it is 
necessary to isolate and purify a particular isozyme, and to reconstitute its activity. The activity of 
microsomal cytochromes P450 can be reconstituted by mixing purified cytochromes P450, NADPH 
and cytochrome P450 reductase (CPR) with purified phospholipids and certain detergents. Optimal 
conditions for reconstitution of activities vary with the studied cytochrome P450 isozyme (see ref. 
(112)). The activity of CYP3A4 has been found to be a complex function of diverse factors: a 
particular lipid environment, cytochrome b5, divalent metal ions such as Mg2+, and reduced 
glutathione (GSH) all enhance catalytic activity of CYP3A4 (85, 88, 92, 93, 113, 114). Most 
additives (except for phospholipids) are, however, not required to study the activity of CYP3A4, 
and may even alter the complex kinetics, e.g. GSH (84) or Mg2+ (D. R. Davydov, personal 
communication). For the reconstitution of CYP3A4, a detergent such as sodium cholate or 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS; Figure 6) is usually added. In 
some instances, the use of detergent has been made unneccessary by incubating purified CYP3A4 
with commercial microsomal lipid preparations (Supersomes) containing CPR (78, 105). Under 
suitable conditions, CYP3A4 co-integrates into the reductase-containing microsomes during 
incubation and establishes monooxygenation activity. 
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Figure 6: Structure of the detergent (CHAPS) that is commonly used for reconstitution of the 
activity of microsomal cytochromes P450 such as CYP3A4. 
1.8 COUPLING OF CYTOCHROME P450 TO ELECTRODES 
The requirement of cytochrome P450-dependent monooxygenation for NADPH-cytochrome 
P450 reductase (CPR) and NADPH as a source of reducing equivalents can be circumvented 
through immobilization of the enzyme on solid electrode supports that serve as electron donors 
(115-118) (Figure 7). In some cases, the detection of the reaction products (in addition to the 
catalytic currents to the immobilized cytochrome P450) in the presence of substrates has been 
achieved (118-121). The broad spectrum of substrates that are metabolized by cytochromes P450 
make these enzymes interesting for the application as a recognition element for biosensing. On the 
other hand, the broad substrate-specificity of some cytochromes P450 hampers the development of 
specific biosensors. A further limitation is the low native or target plasma concentration of most 
analytes in humans that could be relevant to cytochrome P450-based biosensing, such as steroid 
hormones or most pharmaceutical drugs, respectively. Nevertheless, adverse effects in multi-drug 
treatments as a result from complex drug-drug interactions or polymorphisms in drug-metabolizing 
enzymes are of high importance and represent a major problem for the pharmaceutical industry. 
Biosensors that employ electrodes with immobilized cytochromes P450 may therefore eventually be 
used for detection of drug substrates as an enabling technology in drug development and for 
therapeutic monitoring in clinical settings (115, 118, 122). 
 
CHAPS
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Figure 7: Coupling of CYP3A4 and CPR to electrodes. Membrane-bound CYP3A4 and CPR 
deposited onto screen-printed electrodes that were covered with carbon nanotubes (CNT). Small 
orange arrows denote electron flow via CPR to CYP3A4 to initiate metabolism upon substrate 
binding (small blue arrow, carbamazepine in the figure). The blue sensor is connected to a 
potentiostat (fat orange arrow).  
1.9 SCOPE OF THIS THESIS 
The aim of this work was to probe the interaction of CYP3A4 with carbamazepine by an 
approach of simulation-guided cloning of CYP3A4 (active-site) point mutants in order to generate 
variants of CYP3A4 with higher activity and/or affinity towards the anticonvulsive drug 
carbamazepine (CBZ), a small molecule drug prescribed for the treatment of epilepsy and bipolar 
disorder (Figure 4). CBZ has a therapeutic blood plasma target concentration of 17 – 70 µM (51). 
Since this qualifies CBZ as a narrow therapeutic index drug (123), continuous therapeutic 
monitoring is desirable for the optimal outcome of a therapy that involves the prescription of CBZ. 
Failure in maintaining the target plasma range may cause toxic side-effects in the course of the 
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treatment of epilepsy known under the name anticonvulsant hypersensitivity syndrome, a multi-
organ syndrome with potentially fatal outcome (124, 125).  
The engineered CYP3A4 variants were intended to be ultimately incorporated into biosensors 
for CBZ detection and for continuous therapeutic monitoring during the administration of CBZ to 
patients. Parts of the data presented in chapter 4 involve in silico studies such as molecular 
dynamics (MD) simulations and the derivation of distance trajectories or pose clustering. The data 
obtained from simulations were generated by members of our scientific collaboration (T. Knehans, 
Prof. A. Caflisch)3. The generation of the mutants relied on a simulated molecular structure of a 
binary complex of CYP3A4 with CBZ. 
The engineered CYP3A4 mutants were also applied to binding studies with other CYP3A4 
ligands, such as bromocriptine, erythromycin, testosterone, estradiol, and 7-benzyloxyquinoline 
(chapters 5-7). We also studied the kinetics of the reduction of Fe (III) → Fe (II) heme in the 
CYP3A4 mutants by sodium dithionite (Na2S2O4; chapter 7.2). In Chapter 2, computational, 
experimental, and analytical methods that were used to obtain the presented data are described. In 
chapter 3, the generated enzymes CPR and CYP3A4 including mutants of CYP3A4 are 
characterized via biochemical and biophysical techniques and the chapter also provides further 
insight into the application of some of the used methods. Chapter 8 wraps up the work and 
summarizes the major achievements of the thesis, relates them to the initial scope, and provides an 
outlook for future work. 
3 Amedeo Caflisch, PhD, and Tim Knehans, Institute of Biochemistry, University of Zürich, 
Switzerland. 
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2 MATERIALS AND METHODS 
 
 
 
 
The methods are organized with respect to their first occurrence in the chapters of the 
thesis.Equation Chapter 2 Section 2 
 
2 
 
Chapter 2 
2.1 REAGENTS 
Compound Company 
Place 
(Group)* 
L-α-phosphatidyl choline 
L-α-phosphatidyl ethanolamine 
L-α-phosphatidic acid 
Avanti Polar Lipids Alabaster, AL, USA 
3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate (CHAPS) 
nicotinamide adenine dinucleotide phosphate 
(NADPH and NADP+) 
glucose 6-phosphate (GSP) 
sodium cholate 
butane-2,3-diol-1,4-dithiol 
(dithiothreitol, DTT) 
Applichem GmbH Darmstadt, Germany 
Vivid® BOMR 
(benzyloxy-methoxy-resorufin) 
Life Technologies Carlsbad, CA, USA 
tetraoxidodisulfate sodium 
(sodium dithionite, Na2S2O4) 
Riedel-de Haën 
Morriston, NJ, USA 
(Honeywell 
International) 
Pfu DNA polymerase Fermentas 
Waltham, MA, USA 
(Thermo Fisher 
Scientific) 
potassium phosphate monobasic 
potassium phosphate dibasic 
2-[4-(2-hydroxyethyl)piperazin-1-yl]- 
ethanesulfonic acid (HEPES) 
isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
propane-1,2,3-triol (glycerol) 
Fisher Reagents 
Tris(hydroxymethyl)aminomethane 
hydrochloride (TRIS) 
5H-dibenzo[b,f]azepine-5-carboxamide 
(CBZ) 
Acros Organics 
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Compound Company 
Place 
(Group)* 
D(+)-sucrose 
erythromycin (ERY) 
HisPur Ni-NTA beads Thermo Fisher 
CM macro-prep ion exchange support 
Biobeads 
Biorad Hercules, CA, USA 
Escherichia coli (E. coli) HMS 174 (DE3) Calbiochem 
Darmstadt, Germany 
(Merck) 5-amino-4-oxo-pentanoic acid 
(δ-aminolaevulinic acid, δ -ALA) 
Merck 
carbamazepine-10,11-epoxide 
DEAE sepharose fast flow ion exchange 
adenosine 2’,5’-diphosphate agarose 
Igepal-CO630 
glucose 6-phosphate dehydrogenase 
(GSPDH) 
testosterone (TST) 
estradiol (EST) 
bromocriptine (BCT) 
cytochrome c 
imidazole 
ampicillin 
Sigma 
St. Louis, MO, USA 
(Sigma Aldrich) 
sulfanylethan-1-ol (2-mercaptoethanol) 
riboflavin 5’-monophosphate sodium 
salt dehydrate 
potassium chloride 
D-histidine 
ethylenediaminetetraacetic acid (EDTA) 
Triton X-100 
Fluka 
Oligonucleotide primers Microsynth AG Balgach, Switzerland 
10-methoxy-carbamazepine TLC PharmaChem Vaughan, Ontario, Canada 
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Compound Company 
Place 
(Group)* 
Human CYP3A4HR EasyCYP Bactosomes 
(Bactosomes with a high CPR:CYP3A4 ratio) 
CYPEX Ltd Dundee, UK 
* In case the group name is not identical with the company name. 
E. coli TOPP 3 cells for the expression of the CYP3A4 gene were provided by D. R. Davydov 
(UCSD, CA, USA). E. coli XL1-Blue cells were obtained from Dr. Algirdas Ziogas (Obstetrics 
Research Department, University Hospital of Zurich, Switzerland). 
2.2 EXPERIMENTAL METHODS 
2.2.1 RECOMBINANT DNA MANIPULATIONS 
The construct pSE3A4 encoding an N-terminally modified human cytochrome P450 3A4 with 
a tetra-histidine tag attached at the C-terminus was described previously (42) and was provided by 
Prof. James R. Halpert4. A plasmid map of pSE3A4 is shown in Figure 8. Site-directed mutagenesis 
was performed by means of the polymerase chain reaction (PCR) with the QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies, Stratagene Products Division, La Jolla, CA). 
Table 2 lists the primers that were used in the PCR protocol. 
The highly thermostable Pfu DNA polymerase from the hyperthermophilic archaeon 
Pyrococcus furiosus was used for PCR. Pfu DNA polymerase catalyzes the polymerization of 
nucleotides into duplex DNA in the 5’→3’ direction and has 3’→5’ exonuclease activity for 
proofreading (correction of nucleotide incorporation errors). The error incorporation frequency 
during PCR by Pfu DNA polymerase is given as 2.6·10
-6 
errors per nucleotide per cycle5. The 
average number of incorporated incorrect nucleotides per site-directed mutagenesis experiment with 
Pfu polymerase and the plasmid pSE3A4 is given as:  
 
4 James R. Halpert, Skaggs School of Pharmacy, The University of California San Diego, 9500 
Gillman Drive, PSB, room 2226, La Jolla, CA, 92093-0703. 
5 According to the product description of Pfu DNA Polymerase Fermentas #EP0501. 
36 
                                                 
Materials and Methods 
 / 6
5661 15 0.033
2.6 10error error nt c
P P L N ⋅= ⋅ = =
⋅
⋅  (2.1) 
 
with nt, nucleotide; L, length of plasmid; Nc, number of PCR cycles. 
 
 
Figure 8: Plasmid map of the CYP3A4 expression plasmid pSE3A4. The map shows restriction 
sites (blue), primers, promoters and terminators (green), open reading frames (ORFs; light blue), the 
ampicillin resistance gene (red), and the pBR322 origin of replication and the lac operon (black). 
This plasmid map was generated from a web application of the website www.lablife.org6. 
  
6 This platform was later incorporated into Labguru: www.labguru.com 
37 
                                                 
Chapter 2 
Table 2: List of primers that were used for the generation of site-directed mutants. 
Mutant Forward (F) and Reverse (R) Primer 
Ser119Ala F R 
5’-GAT TTA TGA AAA GTG CCA TCG CGA TAG CTG AGG ATG AAG AAT G-3’ 
5’-CAT TCT TCA TCC TCA GCT ATC GCG ATG GCA CTT TTC ATA AAT C-3’ 
Ile369Leu F R 
5’-ACG CTC AGA TTA TTC CCA CTG GCT ATG AGA CTT GAG AGG GT-3’ 
5’-ACC CTC TCA AGT CTC ATA GCC AGT GGG AAT AAT CTG AGC GT-3’ 
Ile369Phe F R 
5’-CGC TCA GAT TAT TCC CAT TTG CTA TGA GAC TTG AGA GGG T-3’ 
5’-ACC CTC TCA AGT CTC ATA GCA AAT GGG AAT AAT CTG AGC G-3’ 
Ala370Val F R 
5’-CTC AGA TTA TTC CCA ATT GTT ATG AGA CTT GAG AGG GTC TG-3’ 
5’-CAG ACC CTC TCA AGT CTC ATA ACA ATT GGG AAT AAT CTG AG-3’ 
Ala370Leu F R 
5’-CGC TCA GAT TAT TCC CAA TTC TTA TGA GAC TTG AGA GGG TCT GC-3’ 
5’-GCA GAC CCT CTC AAG TCT CAT AAG AAT TGG GAA TAA TCT GAG CG-3’ 
 
For the incorporation of point mutations into the pSE3A4 plasmid, we followed the strategy 
described in the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara 
CA, USA). Briefly, two synthetic oligonucleotide primers that contained the desired mutations were 
designed and synthesized through a third-party DNA synthesis provider (Microsynth, Balgach, 
Switzerland). The oligonucleotide primers, each complementary to opposite strands of the vector 
(see Table 2), were extended during PCR cycling by the Pfu DNA polymerase. Due to the 
incorporation of the oligonucleotide primers, a mutated plasmid containing staggered nicks was 
generated. Treatment of the PCR product with the DpnI endonuclease was used to digest parental 
(methylated and hemi-methylated) DNA, thereby selecting for the mutation-containing synthesized 
DNA. The nicked vector DNA containing the mutation was then transformed into and amplified by 
E. coli XL1-Blue cells. The nicks in the mutagenized plasmids were repaired intracellularly. The 
mutagenesis strategy is illustrated in Figure 9. 
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Figure 9: Illustration of the mutagenesis strategy. The illustration is reproduced from the 
QuikChange Site-Directed Mutagenesis Kit instruction manual (Catalog #200518, Agilent 
Technologies). 
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Protocol: Polymerase chain reaction (PCR) 
The components listed in Table 3 were placed into 0.2 ml PCR micro-
reaction tubes on ice. The forward and reverse primers used in the reactions 
are presented in Table 2. Tubes were thoroughly mixed by vortexing prior to 
the addition of Pfu polymerase. After the addition of Pfu polymerase, the 
samples were placed into the thermo-block of the thermocycler and the PCR 
program was started immediately (Table 4). 
Table 3: List of components used in site-directed mutagenesis 
experiments:*  
Component Volume, µl Final Amount 
dsDNA template 1 50 ng 
Primer 1 1 125 ng 
Primer 2 1 125 ng 
dNTP mix 1 10 mM each 
H2O to 49  Pfu Polymerase 1 2.5 U 
Total 50  
*dsDNA; double-stranded DNA template (plasmid), dNTP mix; mix of the 
four deoxynucleotide triphosphates. 
Table 4: PCR programme used in site-directed mutagenesis 
experiments: 
Part Cycles Temperature Time 
1 1 95°C 30 sec 
 
2 
 
15 
95°C 30 sec 
55°C 1 min 
68°C 12 min 
3 1 4°C Pause 
 
After the PCR, the reaction tubes were placed on ice and a sample from each PCR tube was 
loaded onto a 1%  agarose gel stained with ethidium bromide. 1 µl of 10 U/µl DpnI was added to 
the remainder of the sample and incubated at 37 °C for 1 h. A sample of DpnI-treated DNA was 
loaded onto an agarose gel and the gel was run at 140 V for ~ 45 min. An aliquot of the remaining 
sample was used to transform chemically competent E. coli XL1-Blue cells. All single-point 
mutants listed in Table 2 and the four double-point mutants that are obtained by combining the 
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described point mutations of Ile369 and Ala370 were generated. Only the single-point mutants were 
expressed.  
The products from the site-directed mutagenesis PCR were loaded on a 1% agarose gel to 
verify the amplification. For sizing of the DNA in the loaded samples, aliquots of GeneRuler 1 kb 
DNA ladder were loaded on the gel (Thermo Scientific). The ladder contains fourteen DNA 
fragments of the sizes (in base-pairs): 10,000, 8,000, 6,000, 5,000, 4,000, 3,500, 3,000, 2,500, 
2,000, 1,500, 1,000, 750, 500, and 250. A sample of the PCR product after restriction digestion with 
the enzyme DpnI was also loaded on the gel to verify the presence of the desired mutated DNA 
fragment.  
Amplified mutagenized plasmid was transformed into chemically competent cells of the strain 
E. coli XL1-Blue. Nicks in the PCR-amplified DNA are repaired in vivo. The DNA was purified 
using a commercial plasmid purification kit (GeneJET Plasmid Miniprep Kit, Thermo Scientific). 
All purified mutagenized plasmids were sequenced. 
 
Protocol:  Transformation of chemically competent cells 
50-100 µl of chemically competent E. coli XL1-Blue cells were thawed on 
ice and transferred to 1.5 mL microreaction tubes. 10-100 ng of plasmid of 
the PCR reaction were added, carefully mixed with the cells, and incubated 
on ice for 5-60 minutes. Tubes were then placed into a thermoblock set at 
42 ºC for 45 sec (heat-shock) and then again placed on ice for ≥ 2 minutes. 
A 100-200 µl sample was plated onto LB-agar plates containing 50 µg/ml 
sodium ampicillin. The plates were incubated overnight at 37 ºC.  
 
Amplified plasmids were sent for DNA sequencing by a third-party sequencing service 
(GATC Biotech AG, Constance, Germany). The received chromatograms were carefully checked to 
confirm and the DNA sequence called by the sequencing service. Nucleic acid sequences were 
translated into amino acid sequences with the genetic code. The human wild-type CYP3A4 nucleic 
acid and amino acid sequences were retrieved from the homepage of The UniProt Consortium 
(126)7. The amino acid sequences of the pSE3A4 expression construct was aligned with the 
retrieved sequence of human CYP3A4 using the Pairwise Sequence Alignment tool LALIGN (127) 
of the European Bioinformatics Institute (EMBL-EBI) (128, 129) (default settings). 
7 Website of The UniProt Consortium: http://www.uniprot.org/ 
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2.2.2 EXPRESSION AND PURIFICATION OF RAT NADPH-P450 REDUCTASE 
AND HUMAN CYTOCHROME P450 3A4 
CYP3A4 are purified and stored preferably in Good's buffers such as MOPS or HEPES due to 
the excellent buffering capacities at near-neutral pH of the latter two: pKa MOPS = 7.15 and pKa HEPES 
= 7.55 at 20 °C (130). In this work, we used mostly HEPES buffer during purification and HEPES 
or phosphate buffer in the kinetics measurements. In the titration experiments, we used HEPES 
supplemented with 1 mM dithiothreitol (DTT) and 1 mM of the multidentate chelating agent 
EDTA. 
2.2.2.1 EXPRESSION OF HUMAN CYTOCHROME P450 3A4 
Freshly transformed E. coli TOPP 3 cells were induced with 0.5 mM IPTG, and the construct 
was expressed for 48 – 72 h before cells were lysed by sonication. The expression levels were 
quantified via binding of CO to Fe2+-heme (4). The enzyme was purified from solubilized 
membranes via nickel-affinity chromatography by using Ni-NTA beads and anion exchange 
chromatography on a CM macro-prep ion exchange support, as described previously (80, 108). A 
detailed protocol of the procedure is given below.  
 
Protocol:  Expression and purification of human CYP3A4: 
Expression of human CYP3A4 - Chemically competent cells of the strain E. 
coli TOPP 3 were thawed on ice and incubated with a small aliquot of the 
plasmid pSE3A4 (and its derivatives) for 30 – 60 min. The mixture was then 
subjected to heat-shock transformation. An aliquot of the mix was then 
plated on agarose petri dishes containing 50 µg/ml sodium ampicillin. Plates 
were incubated overnight at 37 °C. The grown cells were transferred from 
the plates into lysogeny broth (LB) medium (5 g/l yeast extract, 5 g/l NaCl, 
10 g/l tryptone) supplied with 50 µg/ml sodium ampicillin and the cultures 
were grown for 2.5 – 3 h at 200 rpm in a incubation shaker (Multitron 
Standard, Infors AG, Bottmingen, Switzerland). Grown cultures were 
diluted into terrific broth (TB)8 medium and the cells were grown at 37 °C 
8 Terrific broth (TB): 12 g of tryptone, 24 g of yeast extract and 4 ml of glycerol were dissolved in 
900 ml H2O and autoclaved for 20 min at 121 °C. After cooling, 100 ml of an autoclaved solution 
of 0.17 M KH2PO4, 0.72 M K2HPO4 were added. 
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and 200 rpm until cell density reached an OD550 = 0.8 – 1.5. IPTG and 5-
aminolaevulinic acid (ALA) were added to final concentrations of 1 mM 
and 80 mg per l of culture, respectively (stock solution: of 1.19 g IPTG and 
0.4 g ALA in 10 ml water, addition of 0.5 ml of the stock to each flask). 
Cultures were grown at 30°C, 190 rpm for 48 – 72 h and then placed on ice. 
The cultures were centrifuged at 5,000 rpm at 4 °C for 15 min and the 
supernatant was decanted. The cell pellet was resuspended in 10 ml buffer A 
(see below) per 250 ml culture with 1 mM phenylmethanesulfonyl fluoride 
(PMSF) added just before resuspension. The suspension was sonicated in 2 
cycles of 45 s to 2 min per round, 80% time, 60% power in small volumes 
on a VCX 750 Ultrasonic Processor (Sonics & Materials, Inc., Newton CT, 
USA) such that the temperature of the sample thereby never exceeded 15 
°C. The samples were centrifuged at 31,000 rpm, 4 °C, for 30 min. The 
pellets were resuspended in 10 ml of buffer A with 1 mM PMSF (without 
CHAPS) per 250 ml culture. The suspension was stored in a glass vessel 
saturated with argon gas, CHAPS added to 1% (v/v) followed by stirring at 
4 °C with a magnetic stir bar for 2 – 12 h. The sample was then centrifuged 
at 31,000 rpm, 4 °C, for 30 min. The supernatant was saved for further 
purification. The content of CYP3A4 was measured by CO-difference 
spectroscopy in microsome solubilization buffer (see below).  
 
Buffer A: 100 mM HEPES, pH 8.0, 10% glycerol. 
 
Microsome Solubilization Buffer (MSB): 100 mM potassium phosphate 
(pH = 7.3), 10% glycerol, 0.5% sodium cholate, 0.4% Igepal CA-630, 1 mM 
EDTA. 
 
Purification of CYP3A4 using a three-column procedure 
 
Ni-column I: 
The solubilized CYP3A4 was loaded onto a Ni-sepharose column (1 ml 
column support per 60 nmol P450) in 100 mM HEPES, pH 8.0, containing 
0.5 M KCl and 0.5% CHAPS. The column was washed with 3 volumes of 
20 mM imidazole in the same buffer, followed by washing with 15-20 
43 
Chapter 2 
volumes of 100 mM HEPES, pH 8.0, containing 0.5 M KCl and 0.5% 
Igepal. An additional washing step with 3 volumes of 100 mM HEPES, pH 
8.0, containing 0.2% Igepal (no KCl) was followed by the elution of P450 
with 100 mM HEPES, pH 8.0, containing 0.2% Igepal and 200 mM 
imidazole. 
 
CM-Macroprep column  
The P450 solution was diluted to obtain an imidazole concentration < 10 
mM (at least 20 times) with, in the case of CYP3A4 wild type, 100 mM 
HEPES, pH 7.4 (20 mM for mutants), containing 0.2% Igepal. The 
concentration of CYP3A4 was optimally adjusted to < 5 µM. The solution 
was loaded onto a column containing the CM-Macroprep anion exchange 
material (1 ml per 100 nmol CYP3A4 wild type or 60 nmol mutant) at a 
loading rate of 10 ml/h. The column was washed with 10 volumes of the 
same buffer. Cytochrome P450 was eluted with 150 mM KCl (threshold of 
elution ca. 100 mM).  
 
Ni-column II: 
The eluate was loaded onto a Ni-column (1 ml column support per 100 nmol 
P450) at a protein concentration of 5 µM in 100 mM HEPES, pH 7.4, 0.2% 
Igepal. The column was washed with 5 volumes of 100 mM HEPES, pH 
7.4, containing 0.5% CHAPS, (150 mM KCl for the purification of 
mutants). The column was washed with 30 volumes of 100 mM HEPES, pH 
7.4, in the absence of detergent (150 mM KCl for the mutants). The enzyme 
was eluted with the same buffer additionally containing 150 mM histidine-
HCl and 200 mM imidazole. The eluate was concentrated to ~100-150 µM 
P450 and dialyzed against 100 mM HEPES, pH 7.4, containing 1 mM 
EDTA, 1 mM DTT, and 10% glycerol (150 mM KCl in the case of 
mutants). The dialysis was repeated three times with 100 volumes of fresh 
buffer used each time. All buffers contained 2 mM 2-mercaptoethanol (70 μl 
neat/100 ml), except for the buffers used for the 2nd Ni column and the 
dialysis, which contained 1 mM DTT instead. All buffer solutions used were 
saturated with Argon.  
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The purified protein was loaded onto a sodium dodecyl sulphate (SDS) gel and an SDS 
polyacrylamide gel-electrophoresis (SDS-PAGE) was run until clear separation of all bands of the 
protein sizer (PageRulerTM Prestained Protein Ladder Plus, Thermo Scientific) on the gel was 
obtained. The purity of the enzymes was also analysed by absorption spectroscopy and protein 
concentrations were quantified by comparison with spectral standards of CYP3A4 (CYP3A4 high-
spin, low-spin and P420 species) using the SpectraLab software package (131). 
2.2.2.2 PRODUCTION OF RAT NADPH-CYTOCHROME P450 REDUCTASE 
The rat NADPH-cytochrome P450 reductase (CPR) gene was expressed from the construct 
pETOR262 that was provided by James R. Halpert. The construct was generated by Greg R. Harlow 
and James R. Halpert (42) from cDNA obtained by Todd Porter. The construct is a T7 expression 
plasmid created by moving the XbaI – HindIII fragment from pOR262 (132) into pET29a(+) 
(Novagen, Madison, WI). This fragment contains the N-terminally modified rat reductase with a 
fused ompA-encoded signal peptide and ribosome binding site. The sequence of the amino-terminal 
region of the cloned reductase construct shown in Figure 10 displays the last 6 amino acids of the 
signal peptide from ompA. The arrow indicates the signal peptide cleavage site. It is followed by 8 
added amino acids from cloning (italics). The first three N-terminal amino acids of rat liver 
reductase are highlighted in grey: 
 
 
Figure 10: Sequence of the amino-terminal region of the cloned CPR expression construct (see 
text for details). 
 
The construct was expressed in E. coli HMS 174 (DE3) and purified via ionic exchange and 
affinity chromatography as described previously (42). Briefly, solubilized protein from a lysate of 
bacterial cultures was captured on a DEAE sepharose fast flow anion exchange support. The eluate 
was purified via affinity chromatography with an adenosine 2’,5’-diphosphate agarose support. The 
detailed protocol for the purification of CPR is described below.  
 
 
GCTACCGTAGCGCAGGCCGGAATTCCCGGGGATCCGACCAACATGGGGGAC 
AlaThrValAlaGlnAlaGlyIleProGlyAspProThrAsnMetGlyAsp 
                 ↑ 
45 
Chapter 2 
Protocol:  Expression and purification of rat NADPH-cytochrome P450 reductase 
Fresh E. coli HMS174 (DE3) cells were transformed with the plasmid 
pETOR262 and plated onto agar plates containing kanamycin (50 µg/ml) 
and incubated overnight. The grown colonies on the agar plates were 
resuspended in 100 ml LB medium containing kanamycin (50 µg/ml) in a 
250 ml flask at 37 °C and 250 rpm for 2-3 h. The culture was used to 
inoculate 250 ml TB medium (225 ml TB + 25 ml TB salts + 0.25 ml 
kanamycin (50 µg/ml) in a 1 L flask) and grown at 37 °C, 250 rpm, for ca. 
4 h, until the OD550 was > 0.8. IPTG was added to a final concentration of 
0.5 mM and the culture grown at 30 °C, 190 rpm, for 48 h. Cells were 
harvested by centrifugation at 5000 rpm, 15 min, and 4 °C. Cells were 
resuspended in 2 flasks of 100 ml buffer A (see below). 4 mg lysozyme was 
added and the solution stirred at 4 °C for 30 min. The solution was 
centrifuged at 5000 rpm at 4 °C for 30 min to pellet the spheroblasts. The 
pellets were resuspended in 130 (2x 65) ml affinity buffer without detergent. 
The cells were sonicated twice for 45 s (80% of time, 60% of power) on a 
VCX 750 Ultrasonic Processor. Igepal CO-630 to a final concentration of 
0.3% was added and the sample was shaken on ice for 1 h. The sample was 
then centrifuged at 32,000 rpm for 45 min and the supernatant was saved. 
Buffer A: 100 mM Tris-HCl, pH 8.0, 0.25 M sucrose, 0.5 mM EDTA (1 ml 
0.5 M stock). 
Affinity Buffer: 100 mM Tris-HCl, pH 7.7, 0.5 mM EDTA, 1 mM DTT 
(add from 1 M stock before using), 0.3% Igepal. 
 
A new column containing DEAE-sepharose was prepared by mixing 125 g 
(125 ml bed volume) of DEAE–sepharose with 8-10 bed volumes of 100 
mM Tris (pH 7.7). The column material was allowed to settle and the buffer 
was decanted. This was repeated for four buffer exchanges. The gel was 
washed in 10 bed volumes of H2O. After the gel had settled, an aliquot of 
the supernatant was taken and the pH was checked. If the pH was not 7.7, 
the column was washed again with 100 mM Tris buffer (pH 7.5) and the gel 
resuspended 1:3 in H2O. The column was then packed.  
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The DEAE-Sepharose column was equilibrated with 500 ml Affinity Buffer 
at 100 ml/h. The sample (250 ml) was loaded overnight and the column 
washed with 500 ml Affinity Buffer containing 1 µM FMN at 80-100 ml/hr. 
The column was washed with 125 mM KCl in Affinity Buffer containing 
1 µM flavin mononucleotide (FMN). The flavoprotein was eluted with 
Affinity Buffer containing 300 mM KCl and 1 µM FMN. 
 
A small column was prepared with 2.5 g of 2’5’ ADP Sepharose 4B in 150 
ml H2O. The supernatant was decanted and the gel resuspended in 25 ml of 
Affinity Buffer. The column was packed and equilibrated with 120 ml 
Affinity Buffer containing 1 µM FMN at 30 ml/h. The sample was applied 
at 9 ml/h and the column washed with 100 ml of Affinity Buffer containing 
1 µM FMN at 20 ml/h. The column was washed with 100 ml of Affinity 
Buffer containing 0.1% deoxycholate and 1 µM FMN. The sample was 
eluted from the column with 50 ml of 4 mM 2’-AMP or 8 mM of a 2’-/3’-
AMP mix in Affinity Buffer containing 1 µM FMN at 9 ml/h and small 
fractions were collected. OD455 was measured and the absorbing fractions 
were collected. Samples were concentrated on a 100,000 molecular weight 
cut-off concentrator to an OD455 of ca. 1.5-2. The concentrated flavoprotein 
was dialysed twice against 1 l of Dialysis Buffer. An absorbance spectrum 
from 250-700 nm was taken in a 1 mm cell and the protein concentration 
determined using SpectraLab. 
Dialysis Buffer: 100 mM HEPES, pH 7.4, containing 10% glycerol, and 
1 mM DTT (1 l, two changes, 1x overnight and 1x during the day).  
 
The purity of the enzymes was analyzed via SDS-polyacrylamide gel electrophoresis. The 
concentrations of the protein were quantified before and after all purification steps via: 
(1) Cytochrome c reduction kinetics in non-purified samples. 
(2) Spectral decomposition of recorded spectra using a linear least-squares fitting 
procedure with spectral standards of rat reductase by using the SpectraLab 
software package (131). 
Comments about the procedures for the CPR quantification assays:  
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(1) Spectra of samples were recorded from 340 – 700 nm. The spectral standard of 
CPR that was used in combination with spectral decomposition and determination 
of CPR concentrations in the samples is shown in Figure 11. CPR exhibits an 
absorption maximum at 𝜆 = 454 𝑛𝑚 (𝜖454 = 21.4 𝑚𝑀−1𝑐𝑚−1). 
 
(2) CPR-dependent cytochrome c reduction kinetics were determined under the 
following conditions: 50 µl of a 1 mM aqueous cytochrome c solution (stored 
at -20 °C) was mixed with 945 µl of 0.27 M potassium phosphate buffer solution, 
pH 7.4, in a 1 cm quartz cuvette. 0.1 - 1 µl of a purified CPR sample was added 
and the spectrophotometer was set on time-drive. The reaction was started via the 
addition of 5 µl of a 20 mM aqueous NADPH solution and a time series of 
difference spectra (550 – 541 nm) was recorded. The amount m of reduced CPR in 
the cuvette was calculated with the extinction coefficient ∆𝜀550−541 =18 𝑚𝑀−1𝑐𝑚−1 according to Eq. 2.2 (133) (in nmol of reduced cytochrome c 
min-1): 
 
 
550 541
550 541
Am
tε
−
−
∆
=
⋅  (2.2) 
 
The concentration of rat reductase was calculated with a reaction rate for rat P450 reductase 
of (134): 
 
 1.  2840 mincyt c reductionk
−=  (2.3) 
2.2.2.3 ABSORBANCE SPECTROSCOPY AND SPECTRAL ANALYSIS 
Spectra were recorded on a Specord S 250 UV-VIS spectrophotometer equipped with a Peltier 
thermostat and a stirring device (Analytik Jena, Jena, Germany) at 28 °C. The concentrations and 
the spin state of CYP3A4 were quantified based on the approximation of the heme protein 
absorbance spectra with a set of the prototype spectra of absorbance of the CYP3A4 (Fe3+) high-
spin, low-spin, and the ‘P420’ states (135). The concentration of CPR was determined based on the 
48 
Materials and Methods 
prototypic spectrum of the pure enzyme. In these calculations, the linear least-squares 
approximations of the spectra with combinations of the absorbance standards were performed with 
the SpectraLab software package (131). 
2.2.2.4 SPECTRAL STANDARDS OF CYP3A4 AND CPR 
Spectral standards of CYP3A4 species published in the Supplemental to ref. (95) and P450 
oxidoreductase were downloaded together with the SpectraLab software package9 (131), which 
includes, among others, the spectral standards shown in the following figures. The spectral 
standards of oxidised CPR, CYP3A4 high-spin, low-spin, and “P420” in solution shown in Figure 
11 were used to determine the concentrations of purified CPR, CYP3A4 and the mutant species of 
purified CYP3A4. The same standards were also used in the titration experiments with ligands. The 
CYP3A4 species exhibit absorption maxima at 417 nm (low-spin) or 391 nm (high-spin). The 
absorption spectrum with the peak at 425 nm is representative of a set of CYP3A4 species that 
consists of active CYP3A4 bound to a type-II ligand and inactivated cytochrome P420 forms of 
CYP3A4. 
The spectral standards of iron (II) carbonyl complexes of the P450 and P420 states of 
CYP3A4 were used for the assignment of the concentrations of iron (II) cytochrome P420 and CO-
bound cytochrome P450 in mixed samples. 
9 SpectraLab (SpLab) software package by D. R. Davydov: http://cyp3a4.ucsd.edu/spectralab.html. 
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Figure 11: Absorbance spectra of (a) cytochrome P450 high- and low-spin, and cytochrome 
P420 and (b) NADPH-P450 oxidoreductase (CPR) used for the determination of the enzyme 
concentrations in purified samples. The spectra shown here correspond to a concentration of 1 
μM of purified enzyme measured in a cuvette with an optical path length of 10 mm.  
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Figure 12: Absorbance spectra of the iron (II) carbonyl complexes of the P450 (red) and P420 
(black) states of CYP3A4. These spectra were used to determine the concentrations of iron (II) 
P450 and P420 in CO-saturated buffer. The spectra presented correspond to concentrations [P450] 
= 1 μM purified CYP3A4 measured in a cuvette with an optical path length of 10 mm. 
 
2.2.3 FUNCTIONAL RECONSTITUTION OF PURIFIED CYP3A4 AND CPR 
A functional mono-oxygenation system with CYP3A4 and CPR was reconstituted in a 
micellar system containing phospholipids – added as chloroform solutions of L-α-phosphatidyl 
choline, L-α-phosphatidyl ethanolamine, and L-α-phosphatidic acid mixed at a molar ratio of the 
phospholipids of 1:2:0.6 (108) – and 0.4% CHAPS. The pellet of phospholipids obtained after 
removal of the solvent under a flow of argon gas was resuspended in buffer A (100 mM HEPES, 
pH 7.4, 150 mM KCl, 0.5 mM EDTA, 1 mM DTT containing 10% (v/v) glycerol) to the final 
concentration of 10 mg/mL (13.3 mM) by vigorous shaking on a Vortex mixer. The resulting 
suspension was homogenized by extrusion through a 200 nm pore-size filter with a mini-extruder 
(Avanti Polar Lipids, Alabaster, USA). A mixture of CYP3A4 and CPR containing 10 μM of each 
protein was then supplemented with the 6.5 mM phospholipid suspension to a final concentration of 
1.5 mM, and buffer A containing 1.5% CHAPS was added to a final concentration of 0.4% CHAPS. 
The mixtures were incubated overnight at 4 °C under continuous shaking in a table-top 
thermomixer (Eppendorf, Hamburg, Germany; see Chapter 3.8).   
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The activities of the reconstituted CYP3A4 enzymes were compared in high-throughput 
CYP3A4 activity assays in 96-well plates on a Thermo Release Varioskan Flash Spectral Scanning 
Multimode Microplate Reader (Thermo Fisher Scientific, Waltham, MA, USA). In each well, an 
aliquot of a specified CYP3A4 reconstitute was incubated with either one of the fluorogenic 
substrates Vivid® BOMR (Figure 13a) or 7-benzyloxyquinoline (Figure 13b) and the fluorescence 
was monitored over time. 
 
Figure 13: Fluorogenic test substrates and reaction products used in the determination of the 
activity of reconstituted enzyme. (a) The resorufin derivative BOMR is metabolized by CYP3A4 
to resorufin (RES), which is fluorescent (λAbs = 530 nm, λEm = 585 nm). 7-benzyloxyquinoline 
(7BQ) undergoes metabolism to 7-hydroxyquinoline (7HQ), a fluorescent dye with λAbs = 410 nm, 
λEm = 538 nm. 
BOMR is a resorufin derivative that is metabolized to resorufin (RES) by CYP3A4. BOMR 
exhibits negligible fluorescence at optimal excitation and emission conditions for RES (λExc = 530 
nm, λEm = 585 nm) (156) and is therefore a powerful fluorogenic indicator of CYP3A4 activity. 
7BQ is metabolized to 7HQ (157, 158), which exhibits fluorescence around λEm = 538 nm upon 
BOMR RES
7BQ 7HQ
a
b
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excitation at λExc = 410 nm 10. Since excitation of the fluorescence of 7HQ interferes with NADPH 
fluorescence, the substrate BOMR was preferably used in most CYP3A4 activity assays 
2.2.4 FORMATION OF CARBAMAZEPINE-10,11-EPOXIDE (CHAPTER 4) 
Kinetics assay: formation of carbamazepine-10,11-epoxide – Reactions were carried out at 37 °C in 
micro-reaction tubes in a table-top thermomixer. The reconstituted enzymes were diluted 20-fold 
into 0.1 M HEPES buffer, pH 7.4. The final concentrations of CYP3A4 and CPR were 0.5 μM in all 
experiments, except for the incubations with CYP3A4 Bactosomes, where they were 0.05 μM. The 
working concentration of CHAPS was 0.02% or 325 µM. CBZ was added from methanol stock 
solutions such that in each incubation, a final methanol concentration of 1% was obtained. The 
addition of 20 µl of a 5× NADPH regeneration system containing 25 mM glucose 6-phosphate 
(GSP), 5 U/ml glucose 6-phosphate dehydrogenase (GSPDH), and 5 mM NADP+ in 50 mM 
potassium phosphate buffer, pH 7.4, brought the reaction volume to 100 µl at final concentrations 
of the regeneration system components of 5 mM, 1 U/ml, and 1 mM, respectively. The reaction 
mixture was buffered at pH 7.4 with 75 mM HEPES and 10 mM potassium phosphate. 
The linear ranges of product formation as a function of time were determined for each mutant 
by taking aliquots of the reaction mixture at 0, 5, 10, 15, 20, 25, and 30 min after initiation of the 
reaction. All incubations were conducted in triplicate. The enzymatic reactions were stopped by 
adding an equal volume of ice-cold methanol containing 20 µM of the internal standard 10-
methoxy-carbamazepine, followed by 1:1 dilution with deionized water for a final methanol 
concentration of 25%. The samples were analyzed by reversed-phase HPLC on an Ultimate 3000 
system (Thermo Fisher Scientific, Waltham, MA, USA) on a 150 mm × 4.5 mm diameter C18 
Gravity column (Macherey-Nagel GmBH & Co. KG, Düren, Germany) with 30:70 
acetonitrile:water containing 0.1% formic acid as the mobile phase. 
The rates of reactions as a function of substrate concentration were fit to either the regular 
Hill equation or the Hill equation complemented with an allowance for partial substrate inhibition 
by means of a combination of the Nelder-Mead and Marquardt non-linear regression algorithms as 
implemented in the SpectraLab software package by Davydov (131). 
10 Conditions and settings for a 7BQ plate reader assay were retrieved from 
http://www.cypex.co.uk/3a4plate.htm, January 8, 2013. 
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2.2.5 DERIVATION OF AN EQUATION THAT COMBINES AN ALLOWANCE FOR 
PARTIAL SUBSTRATE INHIBITION WITH AN APPROXIMATION OF 
COOPERATIVE INTERACTIONS IN TERMS OF THE HILL EQUATION* 
*D. R. Davydov is acknowledged for the derivations in this chapter 
 
The Hill equation was first introduced in 1910 by A. Hill (Hill, A.V. (1910), J. Physiol. 40 (Suppl): 
iv–vii) to depict the interactions of hemoglobin with oxygen. It is based on a simple model where 
the complex of a protein with ligand is formed via simultaneous binding of h molecules of ligand. 
Although the initial model considered the interactions of a protein oligomer (h-mer) with h 
molecules of ligand, the assumption of oligomerization of the protein is not necessary for this 
formalism to be applicable. The Hill equation in its modern representation may be obtained 
considering an equilibrium of simultaneous binding of h molecules of ligand S to protein E (either 
monomer or oligomer, or a subunit of an oligomer) with the formation of complex X (Scheme 5): 
 
SCHEME 5 
 
The equilibrium constant KD that defines the steady-state concentration of the complex [X] may be 
represented as: 
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Resolving this equation for [X] for the case where the total concentration of the ligand ([S]0) is 
much higher than the total concentration of the protein ([E]0), so that [X] << [S]0 and [S] ≈ [S]0, we 
obtain: 
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Now introducing a new parameter S50, defined as h DKS =50 , we get the Hill equation in its most 
common representation:  
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Let us complement this model with a binding of one more substrate molecule to the complex X 
resulting in the formation of complex X΄ (Scheme 6): 
 
SCHEME 6 
Considering the case where [S]0 >> [E]0 so that [S] ≈ [S]0, we obtain the following relationship for 
the dissociation constant KD of the complex X: 
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The dissociation constant of the (inhibitory) complex X΄ (KI) may be defined as: 
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Resolving the system of equations (2.7) and (2.8) for [X] and [X΄] and introducing the parameter S50, 
which is defined as h DKS =50 , we obtain the following equations: 
 
 
0
50
[ ] [ ][ ]
[ ] ( [ ])
h
I
h h
I I
K E SX
S K S S K
⋅ ⋅
=
⋅ + + ⋅  (2.9) 
 
and 
 
 
1
0
50
[ ] [ ][ ']
[ ] ( [ ])
h
h h
I I
E SX
S K S S K
+⋅
=
⋅ + + ⋅  (2.10) 
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Let’s now consider the case when the protein E is an enzyme, ligand S is a substrate, the complex X 
is the enzyme-substrate complex with the maximal rate of catalytic turnover, and the complex X΄ is 
an inhibitory complex, where the rate of catalysis is decreased due to the binding of an additional 
(inhibitory) molecule of substrate. We define the parameter α as a ratio of the turnover numbers 
(apparent catalytic constants) characteristic of the complexes X (kcat) and X΄ (k΄cat): 
 
  
'cat
cat
k
k
α =  (2.11) 
 
We may represent the overall rate of catalysis (V) as a function of [X] and [X΄]: 
 
 ])'[]([]'['][ max XXVXkXkV catcat ⋅+⋅=⋅+⋅= α  (2.12) 
 
Combining equations (2.9), (2.10) and (2.12) we obtain: 
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Considering the case when cooperativity of the interactions is eliminated (h = 1) and replacing 
S50 with KM we can obtain Equation 4.1 of chapter 4.3.1. 
Similar to the regular Hill equation, equation (2.13) is based on the presumption that the 
binding of several ligand molecules to the protein takes place simultaneously. Due to this outermost 
simplification, the parameter h (the Hill coefficient) cannot be straightforwardly considered as a 
number of binding sites involved in the formation of complex X. However, similar to the case of the 
regular Hill equation, it may be shown that, for a mechanism with a positive cooperativity (h > 1), 
this parameter is less or equal to the actual number of binding sites involved in the interactions (see 
reference (136), Chapter 7). 
2.2.6 SPECTRAL BINDING TITRATIONS (CHAPTERS 5-7) 
Substrate binding to ferric CYP3A4 was monitored by spectrophotometry at 28 °C under 
aerobic conditions. The spectra were recorded on a Specord 250 UV-VIS spectrophotometer with 
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an incorporated peltier thermostat (Analytik Jena, Jena, Germany). Substrate-free CYP3A4 wild 
type and mutants were diluted into HEPES buffer (0.1 M Na-HEPES, pH 7.4, 0.5 mM EDTA) into 
a 1 cm quartz cell to final concentrations specified in the respective results sections (≈ 1 – 3 µM). 
Small aliquots of stock solutions were added to the cuvette under continuous stirring.  
Table 5 shows the stock solutions that were employed in spectral binding titrations. 
Table 5: Stock solutions used in spectral binding titration experiments: 
Ligand [Ligand], mM Solvent 
Bromocriptine 0.3 20 mM Na acetate, pH 4.0 
Erythromycin 50 methanol 
Testosterone 30 methanol 
Estradiol 20 methanol 
7-benzyloxyquinoline 20 methanol 
CHAPS 150 ddH2O 
 
The absorbance spectra were generally recorded in the wavelength range of 340 – 700 nm. The 
series of absorbance spectra obtained during the titration experiments were background-corrected 
using the principal component analysis (PCA) combined with the fitting of the principal component 
spectra to a set of spectral standards, as described in chapter 2.2.7 on p. 58 and in ref. (135). The 
total volume of added methanol did not exceed 1% (v∕v). Where the contributions of the solvent 
methanol to the spin perturbations were significant compared to the total spin-shift (as for the 
minimal spin-shifts in peripheral binding of allosteric substrates to CYP3A4 S119A in chapter 6), 
spectra were corrected with the background signal obtained from titration series with pure 
methanol. Methanol induced a low-spin shift with ~linear [MeOH] dependence of (2.2 ± 0.4) 
%HS→LS (%v/v methanol)-1 (calculated for p = 0.05). Titration curves obtained with the substrate BCT 
were fit to the equation for equilibrium of binary association, also known as “tight binding or 
“square root” equation (ref. (137), p. 73, Eq. II-53): 
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In the case of allosteric substrate binding (except for bidirectional spin-shifts), data were fit 
to the Hill equation. For instances of bidirectional spin-shifts, data were fit to the equation for a 
two-site sequential ordered binding model: 
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In order to measure the presence and formation of cytochrome P420, the enzymes were 
diluted into 100 mM HEPES buffer, pH 7.4, containing 0.5 mM EDTA and saturated with carbon 
monoxide by slowly bubbling CO through the buffer for 10 minutes. Absorbance spectra from 340 
– 700 nm were recorded before and after addition of a few crystals of sodium dithionite. Spectral 
transition of the Soret band absorbance maximum to 447 nm was monitored via time-series of the 
difference spectra ΔAbs (450-490 nm). After ΔAbs (450-490 nm) reached a temporary maximum, the 
full spectra were recorded and evaluated by fitting it to spectral standards of the corresponding 
states of cytochrome P450 (CO bound to Fe2+-heme of cytochromes P450 and P420). 
2.2.7 PRINCIPAL COMPONENT ANALYSIS (PCA) 
For the quantitation of the substrate-induced changes in the series of spectra obtained in 
absorbance titrations, we used the Principal Component Analysis (PCA) method as implemented in 
SpectraLab (131). PCA is a mathematical procedure that is used to convert a set of data containing 
possibly correlated variables into a set of values of linearly uncorrelated variables via orthogonal 
transformation. In other terms, PCA is an orthogonal linear transformation of an N-by-M matrix. In 
our case, N is the number of spectra in the series and M is the number of data points in each 
spectrum. Through PCA, the data are transformed to a new coordinate system in a way that the 
greatest variance by projection of any sort comes to lie on the first coordinate, the second greatest 
variance on the second coordinate etc. The first principal component hence accounts for the largest 
correlated variability in the dataset. The uncorrelated variables are called principal components. The 
total number of principal components is equal to N-1. Each principal component comes along with 
N-dimensional vectors of so-called loading factors, which define its representation in each of the 
spectra in the series. An important feature of PCA is that the high-order principal components may 
be exempted from the analysis as accounting for “occasional”, non-systematic changes. In this way, 
the data may conveniently be compressed by reducing the number of dimensions without losing 
much information. PCA is very powerful for finding patterns in data of high dimension such as 
absorbance spectra and expressing data in such a way as to highlight similarities and differences in 
58 
Materials and Methods 
the data-set. PCA is the optimal orthogonal transformation for reducing the dimensionality of the 
data while keeping the subspace with the largest variance in the data-set. 
The principal component spectra were analysed by approximation with a linear combination 
of spectral standards of the three major cytochrome P450 states found under the given conditions 
(low-spin and high-spin cytochrome P450, and cytochrome P420), and a low-order, i.e., 2-nd to 4-th 
order, polynomial (for the approximation of the changes in turbidity), as described in ref. (138). 
After suppression of the turbidity changes by subtracting the polynomial components multiplied by 
the corresponding loading factors, the corrected data set was subjected to a second round of PCA. 
The spectra of the principal components hence obtained were approximated with linear 
combinations of the spectral standards of the P450 states, and the stoichiometric coefficients 
deduced from these approximations were used to determine the changes in concentrations of high-
spin, low-spin cytochrome P450 and cytochrome P420, from the set of loading factors of the 
significant principal components. 
2.2.8 CO BINDING TO IRON (II) CYP3A4 (CHAPTER 6) 
For the determination and quantification of the concentrations of functional and inactivated 
cytochrome P450, we monitored the binding of carbon monoxide to (ferrous) iron (II) heme of the 
enzyme via absorbance spectroscopy. The enzyme was diluted into 100 mM HEPES buffer, pH 7.4, 
containing 0.5 mM EDTA, saturated with CO by bubbling for 5 min. Where indicated, a CYP3A4 
ligand was added to a specified concentration and a spectrum was recorded. A few crystals of 
Na2S2O4 were directly added to the cuvette, the solution stirred, and the appearance of the 
absorption peak at 450 nm was monitored continuously via the difference spectrum (A450 –A490), 
which selectively measures binding of CO to the reduced iron (II) form of functional cytochrome 
P450. The data were analysed via spectral decomposition in the SpectraLab software package. 
2.2.9 KINETICS OF DITHIONITE-DEPENDENT REDUCTION OF CYP3A4 
(CHAPTER 7) 
Scanning stopped-flow kinetic experiments were performed on an Olis stopped-flow 
apparatus equipped with a rapid scanning monochromator (Olis, Bogart, GA, USA). The device has 
a mixing time of 1-2 ms and can record up to 1000 spectra per second within a range of 75 - 400 nm 
centered at a chosen wavelength. Experiments were carried out in 100 mM HEPES buffer, pH 7.4, 
containing 1 mM EDTA at 25 °C. The concentration of dithionite in the cell was 12.5 mM. The two 
syringes connected to the stopped-flow apparatus contained either 5 μM CYP3A4 enzyme or 25 μM 
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Na2S2O4 in HEPES buffer saturated with CO by bubbling for 5 min (Figure 14). Spectra were 
recorded from 380 – 600 nm with a spectral resolution of ~1.1 nm and a time-resolution of 12 to 16 
ms to a total of 40 s (2500 spectra). 
 
Figure 14: Schematic depiction of the mixing process and the compounds in the stopped-flow 
measurement.  
 
Data processing:  
Time-dependent changes were monitored by plotting the absorbance at 418 nm (low-spin Fe 
III) and 448 nm (CO-bound Fe II) against time. The kinetic curves were fit to a multiexponential 
equation: 
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with A0, At and A∞ corresponding to the absorbances at the beginning of the reaction, at time t, and 
at an infinite time, respectively. Fi and ki are the fractions and rate constants of the i-th exponential 
phase. The number of exponentials n was chosen to be three, as at least three exponentials were 
needed for fitting without systematic bias in the fit from the data. Hence, Eq. 2.16 can be written as: 
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2.3 COMPUTATIONAL METHODS (CHAPTER 4)* 
*This chapter describes methods used in simulation experiments that were performed by T. 
Knehans 
 
Molecular dynamics simulations - The simulations were performed with the coordinates extracted 
from the structure of the CYP3A4 complex with metyrapone (1W0G) (38). CBZ was superimposed 
on the bound structure of metyrapone, and water molecules, ions, and the metyrapone molecule 
were removed. Due to a lack of crystallographic density in flexible segments, spurious N- and C-
termini were neutralized with acetyl groups at Asp270 and Ala289 and with N-methyl-amide groups 
at Glu262 and Ile276, while the natural termini were considered charged. Missing side-chain atoms 
were added with CHARMM (139). Parameters for CYP3A4 and HEME were derived from the 
CHARMM27 force field (140). The partial charges of the Cys442 side chain thiolate were set as 
developed by Foloppe et al. (141). CBZ was parameterized according to the CHARMM general 
force field (142) and Paramchem (143, 144). 
To determine the modes of binding of CBZ to CYP3A4, five independent MD simulations of 
50 ns each were carried out with GROMACS (v 4.5.6) (145). First, the CYP3A4/CBZ complex was 
placed in a dodecahedral box, the size of which was set for a margin of at least 13 Å from any atom 
of the complex. The box was then filled with pre-equilibrated TIP3P water molecules (146), and the 
system was neutralized with Na and Cl ions at a concentration of 150 mM. Van der Waals and 
short-range electrostatic interactions were calculated up to a cutoff of 10 Å, long-range 
electrostatics were evaluated with the particle mesh Ewald method (147), and periodic boundary 
conditions were applied. All bonds involving hydrogen atoms were constrained by the LINCS 
algorithm (148), and a 2 fs time step was used. The temperature was kept constant at 310 K by 
means of the velocity rescaling algorithm implemented (149) in GROMACS, and the pressure was 
kept constant at 1 atm with a Parinello Raman barostat (150, 151). Mutations at the respective 
residue indices were introduced by simple remodeling in Pymol (152). For the simulations with 
multiple copies of CBZ bound to CYP3A4, the starting positions were generated by manually 
positioning two, three, or four molecules of CBZ in the active site so that no steric clashes were 
introduced. All systems were energy minimized for 10000 steps of the conjugate gradient algorithm 
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before starting the MD. Subsequently, the system was equilibrated in an NPT simulation for 1 ns. 
From the resulting atomic positions, the production runs were started with different random seeds 
for the initial assignment of the velocities. 
Clustering - The WORDOM (153) (version 0.22) implementation of the leader algorithm was used 
to cluster the snapshots saved along the MD trajectories by a criterion based on the root mean 
square deviation (RMSD) of the CBZ non-hydrogen atoms. Only the last 10 ns of each 50-ns run 
were used for clustering, i.e., the first 40 ns of each run were considered equilibration time. First, 
the CYP3A4 Cα atoms were used to structurally overlap the coordinate sets in the five 10-ns 
segments with the X-ray structure. Starting from one of the snapshots at 40 ns, which was taken as 
the first cluster, the leader algorithm proceeded iteratively by comparing each snapshot with the 
representative of the previously defined clusters. A snapshot was assigned to a cluster when the root 
mean square deviation was smaller than a threshold value, set equal to 2 Å. Simulations with two 
CBZ molecules positioned in the active site were clustered with a tree-based algorithm as provided 
in CAMPARI (154, 155). RMSD-based clustering over the entire 200 ns was performed for each of 
the two CBZ molecules separately with a threshold radius (CRADIUS) of 2 Å, a tree height 
(BIRCHHEIGHT) of 16, and a coarsest threshold (CMAXRAD) of 10 Å. CYP3A4 Cα atoms were 
aligned before clustering. All figures were prepared with the PyMol package (152). 
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3.1 SEQUENCING RESULT OF THE EXPRESSION 
PRODUCT 
The expression of the rat CPR gene produces a membrane-bound ~77 kDa protein that 
contains 1 mol of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) each per 
mol of enzyme. The expression of the human CYP3A4 gene produces a membrane-bound 57 kDa 
protein that contains 1 mol heme per mol of enzyme (Table 6) (44). 
Table 6: Key characteristics of CYP3A4 and CPR*  
 
 
 
 
*#(Residues), number of amino acids of the encoded protein; #(Basepairs), number of nucleotides of the 
gene. 
The entire open reading frame of each generated CYP3A4 construct was verified via DNA 
sequencing through a third-party sequencing service. In Figure 15, deviations of the amino acid 
sequence between the CYP3A4 version encoded by the expression plasmid pSE3A4 and the 
authentic human CYP3A4 are shown. 
 
Figure 15: Differences in amino acid sequences of pSE3A4-encoded CYP3A4 from authentic 
human CYP3A4. Upper alignment: The N-terminal alpha-helix encoded on pSE3A4 is truncated 
by 10 amino acids; amino acids 11, 12 and 18 are mutated. Lower alignment: The C-terminus of the 
recombinant protein contains a 4-histidine-tag to facilitate purification via Ni-affinity 
chromatography. Differences in the sequences are highlighted in green. 
                          10        20        30 
pSE3A4 ----------MALLLAVFLVLLYLYGTHSHGLFKKLGIPG 
                   ::::: :::::::::::::::::::::: 
Human  MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPG 
                10      20        30        40  
 
              480       490        
pSE3A4 GLLQPEKPVVLKVESRDGTVSGAHHHH 
       :::::::::::::::::::::::     
Human  GLLQPEKPVVLKVESRDGTVSGA---- 
              490       500        
Characteristic CYP3A4 CPR 
Mass, Da 57,343 76,690 
Cofactors 1 heme 1 FAD, 1 FMN 
#(Residues) 503 677 
#(Basepairs) 1509 2031 
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Figure 16 presents a complete amino acid sequence alignment of the translated open reading 
frames (ORFs) of the construct pSE3A4 (44), that expresses N-terminally modified CYP3A4, and 
authentic human CYP3A4. 
 
Figure 16: The full alignment of amino acid sequences of the construct pSE3A4 (CYP3A4 
ORF) with human CYP3A4. The alignment was generated using a web-based alignment tool on: 
https://www.ebi.ac.uk/Tools/psa/lalign/. The used parameter settings were: matrix file: 
BLOSUM50, gap open/ext: -100/ -4. Result returned from Lalign: 96.6% identity in 507 amino acid 
overlap; Global score: 3248. 
                         10        20        30        40        50 
pSE3A4 ----------MALLLAVFLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF 
                   ::::: :::::::::::::::::::::::::::::::::::::::::: 
Human  MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF 
               10        20        30        40        50        60 
 
               60        70        80        90       100       110 
pSE3A4 DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI 
               70        80        90       100       110       120 
 
              120       130       140       150       160       170 
pSE3A4 AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS 
              130       140       150       160       170       180 
 
              180       190       200       210       220       230 
pSE3A4 MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV 
              190       200       210       220       230       240 
 
              240       250       260       270       280       290 
pSE3A4 FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI 
              250       260       270       280       290       300 
 
              300       310       320       330       340       350 
pSE3A4 IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV 
              310       320       330       340       350       360 
 
              360       370       380       390       400       410 
pSE3A4 NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS 
              370       380       390       400       410       420 
 
              420       430       440       450       460       470 
pSE3A4 KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Human  KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG 
              430       440       450       460       470       480 
 
              480       490        
pSE3A4 GLLQPEKPVVLKVESRDGTVSGAHHHH 
       :::::::::::::::::::::::     
Human  GLLQPEKPVVLKVESRDGTVSGA---- 
              490       500        
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3.2 RECOMBINANT DNA MANIPULATIONS  
pSE3A4 plasmid mutants containing the following variants of CYP3A4 were created via the 
strategy described in Chapter 2.2.1: the I369L, I369F, A370V, A370L, and S119A point mutants 
and the I369F/A370V, I369F/A370L, I369L/A370V, and I369L/A370L double mutants. The 
mutagenized PCR products produced according to the described strategy were loaded on a 1% 
agarose gel and the DNA fragments were separated via gel electrophoresis according to their size. 
The amplified DNA constructs ran at their expected length of ca. 6000 base-pairs. Figure 17 
contains photographs of ethidium bromide-stained agarose gels after the separation of the PCR 
products. Panels (a) and (b) contain each two gel parts, a top and a bottom segment, both of which 
were loaded with the products of the respective PCR reactions. In the top part, unprocessed PCR 
product of finished reactions was loaded on the gel. In the bottom parts, DpnI-digested PCR product 
was loaded. Since the original (methylated) DNA templates added to the PCR reactions are 
selectively fragmented during DpnI digestion, the presence of bands at 6,000 bp in the bottom part 
of panels (a) and (b) indicates that DNA amplification during PCR was successful. On both sides of 
the gel, a mix of DNA fragments of variable lengths was loaded for size comparison (GeneRuler 1 
kb DNA ladder). The insets in Figure 17 show that the DNA in the sample was separated according 
to the expectations based on the sizer (DNA ladder). 
66 
Molecular Biology and Biochemistry of CYP3A4 and CPR 
 
Figure 17: Photograph of 1% agarose-gels containing the products of the PCR-based site-
directed mutagenesis. The desired mutations are indicated above the wells. Panel (a) and (b) show 
the separation of PCR products containing the indicated mutants. The gels in these two panels 
contain two separations each (top and bottom). Top: separations of the products of the undigested 
whole plasmid site-directed mutagenesis, bottom: the product of the DpnI-digested whole plasmid 
site-directed mutagenesis. The gel in panel (c) shows a separation of the PCR-generated DNA of the 
S119A mutant, both with templates pSE3A4 and pET28*3A4H01 (the latter is a plasmid based on 
the pET28 vector (Novagen, Merck Millipore, Darmstadt, Germany) and was designed for the 
expression of the authentic human CYP3A4). The wells containing GeneRuler 1kb DNA ladder are 
indicated with white dashed arrows. The insets in the red-black frames are shown for comparison of 
expected and actual separations of the marker. The white full arrows indicate the sample loading 
wells. * and ** stand for 3% and 10% dimethyl sulfoxide (DMSO) concentration in the PCR. The 
gels are not uniformly stained due to electrophoretic migration of the ethidium bromide gel stain 
towards the cathode. 
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Plasmid DNA from the transformants was isolated using the GeneJET Plasmid Miniprep Kit 
and submitted for sequencing to GATC biotech (Constance, Germany). The sequenced DNA was 
aligned with the sequence of the parent plasmid pSE3A4 and the presence of the desired mutations 
verified. The sequences of the mutagenized plasmids were translated into their amino acid 
sequences and were aligned with the sequence of human wild-type CYP3A4, analogously to the 
primary structure alignments of the protein shown in Figure 15 and Figure 16. The focus was set on 
the amino acids that were targeted for mutagenesis. Out of 24 PCR reactions, the DNA of 22 
reactions contained the desired mutations. One clone did not yield a readable sequence and another 
clone had the wild-type sequence instead of the desired mutation (A370L). Figure 18 shows 
excerpts of the alignments of the sequencing results with the original wild-type CYP3A4 sequence 
(as encoded on the PCR template DNA). Due to the already substantial alterations in the 
biophysical and biochemical properties of the generated point mutants, no double mutants were 
expressed. 
 
Figure 18: Alignments of the obtained amino acid sequences from mutagenized pSE3A4 
plasmids with the sequence of the original pSE3A4 template (wild type). Due to space 
constraints, only the excerpts of the relevant amino acid sequences are shown. The 1st lines contain 
the obtained sequences (mutagenized plasmids), and the 2nd lines contain the sequences of the 
parent plasmid pSE3A4. The 3rd lines contain the symbols used in alignment tools to visualize 
identities (*) or replacements (:)/(.). 
I369L ETLRLFPLAMRLER
pSE3A4 ETLRLFPIAMRLER
*******:******
I369F  ETLRLFPFAMRLER
pSE3A4 ETLRLFPIAMRLER
*******:****** 
A370L ETLRLFPLLMRLER 
pSE3A4 ETLRLFPLAMRLER
********.*****
A370V  ETLRLFPLVMRLER
pSE3A4 ETLRLFPLAMRLER
********.*****
S119A VGFMKSAIAIAEDE
pSE3A4 VGFMKSAISIAEDE
********:*****
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3.3 SPECTRAL CHARACTERISATIONS OF RECOMBINANT 
ENZYMES 
The presence of CYP3A4 was verified in partially purified or non-purified samples. In crude 
protein extracts, cytochrome P450 is commonly detected via binding of CO to Fe2+-heme. The 
absorbance spectra before and after addition of Na2S2O4 of a sample containing wild-type CYP3A4 
in a 100 mM HEPES buffer solution, pH 7.4, that is saturated with CO and contains 0.5 mM EDTA, 
are shown in Figure 19. 
 
Figure 19: Absorbance spectra of CYP3A4 in CO-saturated buffer solutions before (black) 
and after (red) reduction with sodium dithionite. Upon reduction, CYP3A4 binds CO with a 
concomitant shift in the Soret absorbance band from 417 nm to 447 nm. The conditions of the 
experiment were: 2 μM CYP3A4 wild type in CO-saturated 100 mM HEPES, pH 7.4, 0.5 mM 
EDTA before and after addition of Na2S2O4 (here shown for a purified enzyme sample). 
 
Absorbance spectra of the purified recombinant CYP3A4 enzymes (WT and mutants) and 
CPR are shown in Figure 20. All five substitutions probed in this study caused a notable increase in 
the amplitude of the heme protein absorbance band at 391 nm relative to the amplitude of the band 
at 417 nm. This is indicative of a displacement of the spin equilibrium towards the ferric high-spin 
state. A peculiarity of the two mutants A370V and A370L is the red-shift in the maximum of the 
Soret band in the low-spin state by ca. 1 nm.  
69 
Chapter 3 
 
 
Figure 20: Absorption spectra of the purified enzymes. Panel (a) shows the absorbance spectra 
of the wild-type CYP3A4 (blue) and its I369F (red), I369L (green), S119A (light green), A370V 
(turquoise), and A370L (black) mutants. The spectra were normalized to correspond to a heme 
protein concentration of 1 µM for comparison. The inset in panel (a) shows a zoom of the Soret 
band of the same spectra and displays the red-shift in the A370V and A370L mutants. Conditions: 
100 mM HEPES, pH 7.4, 1 mM DTT, 10% glycerol. The concentration of P450 was in the range of 
1.5 – 2.5 µM. Panel (b) shows a spectrum of NADPH-P450 reductase (CPR). 
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The absorbance spectra were reproduced with a combination of the spectral standards (see 
p. 49) of CYP3A4 high-spin, low-spin, and ‘P420’, in combination with a low-order polynomial. 
This allowed the determination of the respective species in the total enzyme pool. An example of 
how the individual species of cytochrome P450 present in the ensemble were quantified is shown in 
Figure 21, which shows the absorbance spectrum of a sample containing purified CYP3A4 I369L. 
 
Figure 21: Background-correction and quantification of the cytochrome P450 species that are 
present in an ensemble of purified hemoprotein of CYP3A4 I369L. The recorded spectrum of 
the purified CYP3A4 I369L mutant (black line) is approximated with the spectral standards for 
CYP3A4 high-spin (dotted red line), low-spin (dotted blue line), ‘P420’ (dotted violet line), and a 
low-order polynomial (dotted orange line). The dotted black line represents the approximation of 
the recorded spectra, i.e., the sum of the polynomial and the weighted spectral standards as shown 
in the figure.  
 
The analysis of the high-spin contents in the CYP3A4 mutants in the absence of substrate is 
shown in Figure 22. The displacement in the spin equilibrium is most pronounced in the mutants 
I369F and S119A, where the fraction of high-spin heme protein approaches 50%, in sharp contrast 
to the spin state of the wild-type CYP3A4, where the high-spin fraction at 28 °C does not exceed 
20%.  
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Figure 22: Effect of mutations on the spin state distribution in purified CYP3A4 proteins. 
Illustrated are the high-spin fractions of the expressed CYP3A4 variants. 
 
3.4 SDS-PAGE OF RECOMBINANT ENZYMES 
An SDS polyacrylamide gelelectrophoresis (SDS-PAGE) analysis of the purified enzymes is 
shown in Figure 23. As it is apparent from the gel, the recombinant enzymes were produced in high 
purity. In the peripheral wells to both sides, an aliquot containing proteins of known length was run 
for sizing the protein (PageRulerTM; contains a prestained mixture of ten recombinant proteins of 
sizes that range from 10 kDa to 170 kDa). The enzymes ran at their expected sizes of ca. 55-60 kDa 
(CYP3A4) and ca. 70-80 kDa (CPR). 
The obtained yields were low, which is typical for the expression of human CYP3A4 genes. 
The yields are shown in Table 7. 
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Figure 23: Separation of purified enzymes via sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Panel (a) shows a polyacrylamide gel loaded with the recombinant 
purified enzymes after electrophoresis. Protein bands of wild-type (WT) CYP3A4 and its mutants 
ran at a mass of ca. 55 kDa, CPR (= POR) ran at a molecular mass of ca. 75 kDa. These values are 
in accordance with the calculated molecular masses of 57 kDa and 77 kDa of the enzymes, 
respectively. For size comparison, the leftmost and rightmost wells were each loaded with 
PageRulerTM Prestained Protein Ladder Plus, a commercial mixture of proteins of known length. (b) 
SDS-PAGE profile of the commercial protein mix. 
Table 7: Recombinant expression and purification yields of the enzymes* 
Enzyme 
(CYP3A4 
variant) 
Volume, l 
(culture) 
Yield cell lysate, mg Yield pure enzyme, mg 
total per l total per l 
(WT) 4 620 155 257 64 
(A370V) 2 260 130 60 30 
(A370L) 2 240 120 55 28 
(I369F) 4 386 97 120 30 
(I369L) 4 600 150 170 43 
(S119A) 4 320 80 38 10 
CPR 4 429 107 32 8 
* The yields are shown both for the crude cell lysate and the purified enzyme and are given in mg 
and mg/l. 
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3.5 KINETIC CHRARACTERIZATION OF RECOMBINANT 
CYP3A4 AND CPR 
The activities of enzymes that had been reconstituted at 4 °C for 30 min or overnight were 
determined in an activity assay with the resorufin derivative Vivid® BOMR and compared (see p. 
51). The reproducibility of the procedure with overnight incubation was as good or even better than 
that with 30 min incubation. The subsequent activity measurements showed no decrease in the 
activity of the reconstituted enzyme after overnight compared to 30 min incubation in the 
thermomixer (Figure 24). The enzymes were henceforth reconstituted overnight in further 
experiments. 
 
Figure 24: Activity of CYP3A4 WT reconstituted either overnight (ON) or during 30 min in a 
thermomixer at 4 °C (turnover of Vivid® BOMR). The data represent the mean activities and the 
error bars represent the standard deviations from 3-4 experiments. 
In order to prove the presence of an active flavoprotein NADPH-P450 reductase (CPR) in 
crude cell lysates and along the purification steps, we applied a cytochrome c reduction assay to 
quantify CPR in non-purified samples as described in ref. (31). Although CPR donates electrons to 
P450, P450-based assays are uncommon due to the tendency of reduced P450 to react with air. A 
convenient approach is therefore the coupling of the reduction reaction to air-stable dyes or redox 
components such as cytochrome c. CPR accepts electrons from its native hydride donor NADPH 
and transfers them to cytochrome c, which acts as an electron acceptor surrogate. Even though the 
bacterial strains used for heterologous expression of cytochrome P450 genes contain other 
reductases that can accept electrons from NADPH and transfer them to cytochrome c, many of these 
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reductases are not membrane bound. Therefore, they do not interfere with the reduction of 
cytochrome c in partially purified cell lysates in the downstream processing of P450 isolations. The 
reduction of cytochrome c generates a prominent narrow absorption peak at λ = 550 nm (31), the 
emergence of which is detected via the monitoring of the difference in absorption between 550 nm 
and the isosbestic point at 541 nm.  
Figure 25 shows a sample cytochrome c reduction experiment (0.4 μl of a purified CPR 
sample to be quantified in 1 ml potassium phosphate, pH 7.4, containing 50 μM cytochrome c and 
100 μM NADPH).  
 
Figure 25: Time-series of absorbance difference spectra (ΔAbs550-541) versus time in the CPR 
activity assay. The concentration of the CPR stock can be calculated from the initial slope (red) of 
the ΔA550-541 nm vs. time curve (black). 
With the extinction coefficient of reduced cytochrome c (ε550-541 = 0.018 mM-1 cm-1), the CPR 
content in mixed samples can then be calculated by assuming a cytochrome c reduction rate of ca. 
3.0 · 103 min-1 at room temperature (133, 134). Masters et al. reported a rate of 2380 – 2840 min-1 in 
100 mM potassium phosphate, pH 7.7, 20% glycerol, 0.2 mM EDTA (134). In this example, the 
concentration of the CPR stock is calculated through (with dilution factor D): 
 [ ] 550 5411 1 3 1 1000.018 3.0 10    c
A DCPR M
mM minm
µ−− − −
∆
= ≈
⋅
⋅ ⋅
  (3.1) 
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Conversely, the activity of a CPR stock of known concentration can be determined by 
transforming equation 3.1. 
3.6 ILLUSTRATION OF THE PRINCIPAL COMPONENT 
ANALYSIS METHOD 
In substrate titrations of an enzyme, the number of principal components in theory 
corresponds to the number of the titration-associated transitions with distinct spectral signatures. In 
the case of CYP3A4, binding of type-I substrates or changes in temperature result in a shift of the 
equilibrium between the ferric high-spin and low-spin states of the hemoprotein component and 
yield a difference spectrum with prominent maxima and minima at ~390 nm and ~420 nm, 
respectively (Figure 26). In the presence of a temperature gradient and the absence of any other 
titration process, PCA is expected to yield only one significant principal component that 
corresponds to the temperature-induced equilibration of the spin state in cytochrome P450. 
In titrations with substrate, the changes in the spin state often overlap with the changes caused 
by the inactivation of the enzyme via its conversion into the so-called P420 state. A further 
important contribution to spectral changes in absorbance titration experiments is caused by changes 
in turbidity of the sample due to the limited solubility of substrates and substrate-induced changes 
in the aggregation state of the enzyme. In most titration data, at least these three independent 
sources of spectral changes are therefore present: (1) substrate-induced spin changes; (2) time- 
and/or substrate-dependent inactivation through the transition to the P420 state, and (3) changes in 
light scattering induced by increasing turbidity of the sample. Accordingly, titration-related spectral 
changes are distributed between three principal components. Each of these components represents a 
linear combination of the three types of spectral changes (Figure 27). 
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Figure 26: PCA of a temperature-gradient experiment with the CYP3A4 mutant S119A. (a) 
Corrected absorbance spectral series of the CYP3A4 mutant S119A recorded at temperatures 
increasing incrementally by 1 degree from 4 °C to 40 °C (spectra at 4 °C and 40 °C are presented as 
blue and red lines, respectively; the spectra between the extreme values are shown in black dotted 
curves). (b) The first principal component of the spectral series dataset taken in the temperature 
gradient experiment of CYP3A4 S119A. This principal component amounts to 99.84% of the total 
changes in the spectra. The spectrum clearly shows a difference spectrum characteristic of a type-I 
spin shift (HS – LS) with a minimum at 417 nm (absorbance maximum of LS P450). Whereas the 
Soret band at 417 nm shifts to ~391 nm, the α-band (absorbance maximum 562 nm) and to a lesser 
extent the β-band (absorbance maximum 534 nm) are attenuated in the course of the (LS → HS) 
spin shift. 
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Figure 27: Absorbance titration spectra of CYP3A4 I369L with the zwitterionic detergent 
CHAPS (a) before and (b) after correction. Panel (a) shows the unprocessed data of the titration 
experiment. Panel (b) shows this data after correction for background. The inset shows the three 
first principal components, which hold 93.6% (black), 5.9% (green) and 0.5% (magenta) of the total 
variation in the data. The components contain the changes [LS+HS] → [‘P420’], [LS] → [HS], and 
[LS]→[‘P420’], respectively. The sample contains 2.5 μM P450 in 100 mM HEPES buffer and 
CHAPS was incrementally added from 0 to a total concentration of 18.75 mM. 
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3.7 EFFECT OF SOLVENTS ON THE CYP3A4 S119A SPIN 
EQUILIBRIUM 
In titration experiments, diverse polar solvents, such as acetone, methanol, DMSO, or ethyl 
acetate are commonly used as stock solvents. The optimal solvent exhibits titrant solubility above 
the desired concentration of the stock solution and negligibly perturbs the spin equilibrium in the 
heme iron (III) cytochrome P450. In order to determine the best stock solvent for the titration 
experiments, we investigated the effect of the two solvents acetone and methanol on the spin state 
of the mutant S119A. Acetone and methanol have a similar effect on the spin equilibrium of 
CYP3A4 S119A (Figure 28). However, since evaporation of the stock solvent due to high gas 
pressure of acetone cannot be excluded, methanol was preferred as stock solvent due to its lower 
evaporation rate. 
 
 
Figure 28: High-spin proportion of total cytochrome P450 for the titration of the CYP3A4 
S119A mutant with the solvents acetone and methanol. 
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3.8 DISCUSSION  
The purified enzymes CYP3A4 and P450 reductase (CPR) were used in studies of the 
epoxidation kinetics of carbamazepine (Chapter 4), which resulted in a manuscript by Müller C. S., 
Knehans T., Davydov D.R., Bounds P.L., von Mandach U., Halpert J.R. Caflisch A., and Koppenol 
W.H. entitled “Concurrent Cooperativity and Substrate Inhibition in the Epoxidation of 
Carbamazepine by Cytochrome P450 3A4 Active Site Mutants Inspired by Molecular Dynamics 
Simulations”. The produced enzymes were also immobilized on electrodes, characterized and 
employed for the sensing of the cytostatic drug iphosphamide. The results from this work were 
submitted for a publication entitled “Faradic Peaks Enhanced by Carbon Nanotubes on P450 
Based Electrochemistry by Microsomes” by Baj-Rossi, C., Müller, C., von Mandach, U., De 
Micheli, G., and Carrara, S. 
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Chapter 4 
4.1 ABSTRACT 
Cytochrome P450 3A4 (CYP3A4) is the major human P450 responsible for the metabolism of 
carbamazepine (CBZ). To explore the mechanisms of interactions of CYP3A4 with this 
anticonvulsive drug, we performed multiple molecular dynamics (MD) simulations starting from 
the complex of CYP3A4 with manually docked CBZ. Based on these simulations, we engineered 
the CYP3A4 mutants I369F, I369L, A370V, and A370L, in which the productive binding 
orientation was expected to be stabilized, thus leading to increased turnover of CBZ to the 10,11-
epoxide product. In addition, we generated S119A as a control construct with putative 
destabilization of the productive binding pose. The evaluated kinetic profiles of CBZ epoxidation 
demonstrate that the CYP3A4-containing bacterial membranes (Bactosomes) as well as purified 
CYP3A4 wild type and I369L/F mutants in reconstituted systems exhibit substrate inhibition. In 
contrast, the mutants S119A and A370V/L exhibit S-shaped profiles indicative of homotropic 
cooperativity. MD simulations with two to four CBZ molecules provide evidence that the substrate 
binding pocket of CYP3A4 can accommodate more than one molecule of CBZ. Analysis of the 
kinetic profiles of CBZ metabolism with a model combining the formalism of the Hill equation with 
an allowance for substrate inhibition demonstrates that the mechanism of interactions of CBZ with 
CYP3A4 involves multiple (most likely three) substrate-binding events. Despite the retention of the 
multisite binding mechanism in the mutants, its functional manifestations reveal an exquisite 
sensitivity to even minor structural changes in the binding pocket introduced by such conservative 
substitutions as I369F, I369L, or A370V. 
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4.2 INTRODUCTION 
Cytochrome P450 3A4 (CYP3A4) is the most abundant cytochrome P450 enzyme in the liver of 
most adult humans (159). This enzyme, which metabolizes about 50% of drugs on the market (37), 
is the main hepatic cytochrome P450 involved in the metabolism of 5H-dibenzo[b,f]azepine-5-
carboxamide (carbamazepine or CBZ). CBZ is a commonly prescribed anti-convulsive drug, and its 
major metabolite is carbamazepine-10,11-epoxide (Figure 29) (160, 161). CBZ, for which the target 
for plasma concentration is 17 – 70 µM (51), qualifies as a “narrow therapeutic index drug” (123). 
As failure to maintain the target plasma range may cause toxic side-effects, continuous therapeutic 
monitoring is desirable for optimal outcome of CBZ therapies. A potential approach to continuous 
monitoring are biosensors constructed from electrodes with immobilized P450 enzymes to detect 
drug substrates such as CBZ (115, 118, 122). 
 
Figure 29: Structures of carbamazepine (left) and the major product of its CYP3A4-
dependent oxidation, carbamazepine-10,11-epoxide (right). 
 
Numerous studies on in vitro CBZ epoxide formation that include data from incubations with 
human liver microsomes (HLM) (51, 83, 161-163), recombinant enzyme expressed in microsome 
fractions from insect cells (164, 165), and reconstituted purified enzyme preparations (77, 161, 166) 
have been published: both hyperbolic and sigmoidal dependencies of the reaction rate on the 
substrate concentration have been observed. Differing degrees of homotropic cooperativity have 
been reported for HLM (51, 83, 161, 162) and microsomes from insect cells expressing 
recombinant human CYP3A4 (163, 164). Michaelis-Menten kinetics (161) as well as sigmoidal 
profiles (51) have been reported for purified and reconstituted CYP3A4. The apparent inconsistency 
among these reports demonstrates that epoxidation of CBZ by CYP3A4 is very sensitive to the 
experimental conditions and the enzyme source. Such inconsistencies in kinetic profiles have also 
been reported for other substrates, such as amitriptyline, nifedipine, and testosterone (167). 
10 11
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In this study, we sought to explore the mechanism of interaction of CYP3A4 with CBZ by 
engineering CYP3A4 variants with enhanced affinity for CBZ and/or increased epoxidation 
turnover. These studies were targeted towards elaboration of a CYP3A4-based electrochemical 
biosensor with improved capacity for determining CBZ concentration in clinical samples. Our 
approach to the optimization of CYP3A4 for CBZ binding encompasses explicit solvent MD 
simulations of the structure of the CYP3A4 complex with CBZ in combination with site-specific 
protein engineering to incorporate amino acid alterations in the enzyme active site. Based on our 
MD simulations, we cloned, expressed, and purified four CYP3A4 mutants with putative 
stabilization of the CBZ molecule in a predicted productive binding mode for increased affinity for 
CBZ and turnover to the epoxide product. As a negative control with putative disruption of a critical 
hydrogen bond, we also constructed the S119A mutant, for which we expected enzyme turnover 
with CBZ to be diminished. 
We report herein that the point mutations S119A, I369L, I369F, A370L, and A370V produce 
dramatic effects on the kinetic parameters of CBZ oxidation. These results demonstrate a profound 
sensitivity of the reaction kinetics of CYP3A4 to minor structural changes in the binding pocket. 
The observation of both homotropic cooperativity and substrate inhibition in the kinetics of CBZ 
epoxidation by the cloned CYP3A4 mutants suggests that the interactions of CYP3A4 with the drug 
involve the binding of at least two, but more likely three CBZ molecules to the enzyme. This 
conclusion is supported by multiple MD simulations, which demonstrate possible accommodation 
of multiple CBZ molecules in the CYP3A4 binding pocket. 
4.3 RESULTS 
4.3.1 CBZ EPOXIDATION BY CYP3A4-CONTAINING BACTOSOMES 
In good agreement with previous studies of CYP3A4-dependent metabolism of CBZ, we 
detected no product other than carbamazepine-10,11-epoxide in significant amounts (161). Upon 
examination of the substrate concentration dependence of the kinetic profiles, we extended the 
range of CBZ concentrations used in our analyses to 0 – 2000 µM, which includes considerably 
higher concentrations than reported in previous studies (161-164). The kinetic profile reveals a 
moderate but clearly pronounced substrate inhibition that becomes evident at CBZ 
concentrations > 700 µM (Figure 30). The fit of the initial parts of the titration curves ([CBZ] ≤ 
1000 µM) with the Hill equation (Figure 30, dashed line) is consistent with positive 
cooperativity, with a Hill coefficient h of 1.4 ± 0.4 (S50 = 162 ± 4 µM, kcat = 1.9 ± 0.3 min-1), in 
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agreement with a previous report in which CYP3A4-dependent epoxidation of CBZ was 
characterized as exhibiting inherent homotropic cooperativity with h of 1.4 – 1.7 (51). 
 
Figure 30: Substrate dependence of the rate of formation of carbamazepine-10,11 epoxide 
catalysed by recombinant CYP3A4 in Bactosomes. Data points represent the mean values of the 
results of three individual measurements and the error bars show the respective standard deviations. 
Fitting to the Hill equation (dashed line) and the Equation (4.1) are shown with dashed and solid 
lines, respectively. The inset shows the respective plots of the fitting residuals. 
 
However, the Hill equation fits of the titration curves are satisfactory only up to CBZ 
concentrations of ca. 700 µM; at higher concentrations, there is evident systematic deviation of 
the experimental data from the equation curve (Figure 30, inset). In an attempt to achieve an 
appropriate approximation of the experimental data over the entire range of CBZ concentrations, 
we fit the data sets to the Michaelis-Menten equation adapted for partial substrate inhibition: 
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Here V and kcat designate the reaction rate at substrate concentration [S] and the catalytic 
constant, respectively. The Michaelis constant and the dissociation constant of the enzyme complex 
with the inhibitory substrate molecule are designated as KM and KI, respectively, and the coefficient 
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α represents the fraction of kcat that is retained in the inhibitory complex with a second molecule of 
bound substrate. The derivation of this equation is described in the methods section (Chapter 2). 
As shown in Figure 30 (solid line), the fitting of the experimental data sets with Eq. 4.1 
results in a satisfactory approximation (ρ2 ≥ 0.982) with no systematic deviations over the entire 
range of CBZ concentrations studied (Figure 30, inset). The parameters for fitting Eq. 4.1, 
representing the averages of the results obtained in three individual experiments, are: kcat = 3.1 ± 0.5 
min−1, KM = 140 ± 10 µM, KI = 1600 ± 300 µM, and α = 0.21 ± 0.08. Therefore, the data obtained 
with bactosomes are consistent with a model whereby the maximal rate of CBZ metabolism is 
obtained in the complex of CYP3A4 with one substrate molecule, and subsequent low-affinity 
binding of a second CBZ molecule to this complex results in a ca. 5-fold decrease in the rate of 
CBZ metabolism. It appears probable, therefore, that earlier reports of positive cooperativity in the 
CYP3A4-dependent CBZ metabolism should be questioned, whether the titration curves thought to 
fit the Hill equation (Figure 30, dashed line) were recorded over a range of CBZ concentrations too 
low to effect pronounced substrate inhibition. 
4.3.2 PROBING THE CBZ BINDING MODE TO CYP3A4 WITH MD 
SIMULATIONS 
According to the above analysis, we infer that the complex of CYP3A4 with one substrate 
molecule in the substrate binding pocket may serve as an adequate initial model of the catalytically 
competent complex of the enzyme with CBZ. Thus, we selected a binary complex of CYP3A4 with 
one CBZ molecule as the subject for initial MD simulations aimed to elicit the structure of the 
CBZ-CYP3A4 complex and the orientation of the substrate molecule in the active site. 
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Figure 31: Results of MD simulations with the complex of wild-type CYP3A4 with one 
molecule of CBZ. Panel (a) shows the time series of the RMSD from the crystal structure (PDB 
code 1W0G) of the protein backbone after alignment of the Cα carbons. The RMSD reaches a 
plateau after about 20 ns in the five independent runs, which are plotted with different colors. Panel 
(b) shows a representative snapshot of the most populated cluster. The residues selected for 
mutation (S119, I369, and A370), CBZ, and the heme group are shown with stick models in green, 
cyan, and red, respectively. The protein backbone is shown in transparent grey, and the I-helix is 
shown in green. Panel (a): data and figure by T.K., panel (b): data by T.K., figure by C.M. 
Figure 31b shows that the time series of the backbone RMSD from the X-ray structure of 
CYP3A4 (1W0G) (38) reaches a plateau between 2 and 3 Å after about 10 ns (equilibration phase). 
We determined the binding modes of CBZ in five independent MD runs of 50 ns each, whereby 
only the last 10 ns of each run were evaluated. In the most populated, i.e., largest, cluster of the 
CBZ poses, the heme iron is located within 5 Å of the center of the bond between the carbon atoms 
10 and 11 (C10,11), compatible with the CYP3A4-catalyzed epoxidation of CBZ (Figure 31b). It 
should be noted, however, that the relevance of this binding mode to the actual mechanism of 
interactions is difficult to assess as it was primarily sampled in only one of five MD runs. The CBZ 
molecule that was initially superimposed at the position of the removed metyrapone did not exit the 
CYP3A4 binding site in any of the runs. The cluster representatives of the 5 most important clusters 
of the simulation are shown in Figure 32. 
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Figure 32: Relative orientations of CBZ and the heme in the cluster representatives of the five 
most populated clusters of the MD simulations of the CYP3A4 WT-CBZ complex. Cluster # 1 
corresponds to the structure shown in Figure 29b. Data and figure by T.K. 
4.3.3 SELECTION AND SUGGESTION OF MUTANTS 
Based on the binding mode of CBZ in the largest cluster of poses deduced from MD 
simulations (Figure 31b), we suggested five single-point mutants on the basis of the mean distances 
between the center of mass (COM) of the respective residues and the COM of CBZ in this cluster. 
The prime notion was that the effect of methylation of small molecules, which is done in iterations 
of drug optimizations to increase potency, can also be achieved by increasing the hydrophobic 
#1
#2
#3
#4
#5
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surface of the protein, since the structure of the ligand CBZ was to be maintained. Table 8 shows 
the centre of mass distances for the CBZ molecule in the largest cluster and the surrounding 
residues. While side chains featuring a hydrogen bond donor/acceptor were excluded from mutation 
due to unforeseeable influences on the charge distribution of the active site, only residues with a 
hydrophobic side chain in a certain distance were considered. Phe residues (already at maximal 
hydrophobic surface) were not considered either. Only residues close to the 5H-dibenzo[b,f]azepine 
moiety featuring a side chain which would be closer after mutation could potentially increase VdW 
interactions with the substrate. Considering these criteria, only Ala370 and Ile369 were left for 
mutagenesis. We predicted that the mutations I369L, I369F, A370V, and A370L would lead to 
improved steric complementarity, i.e., van der Waals interactions, between CYP3A4 and the 5H-
dibenzo[b,f]azepine ring system of CBZ. Mutation S119A was selected as a negative control, 
devised to disrupt the structural stability of the productive binding mode by eliminating the 
hydrogen bond between the carbonyl oxygen of CBZ and the Ser119 side-chain hydroxyl group. 
Ile301, Ala305, and Gly306 were not considered for mutation since an increase in the side-chain 
volume was assumed to introduce steric clashes and thus obstruct the binding mode. Ile120 was on 
the side opposite to the 5H-dibenzo[b,f]azepine moiety and too close to the hydrogen bond with 
Ser119 to be considered for mutation.  
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Table 8: Mean distance of center of mass (COM) for the respective residues to the COM of 
carbamazepine in the largest cluster.* 
 
*Based on the binding mode, the decision was made to investigate an increase of hydrophobic 
contacts without introducing either steric clashes or changing the biochemical property of the 
residue (e.g. a change of polarity). Thus, only Ala370 and Ile369 were left for consideration since 
other residues were either too close to CBZ or already large enough in terms of VdW size of the 
side chain. 
 
4.3.4 ENZYME PRODUCTION, PURIFICATION, AND RECONSTITUTION 
Based on the results of the MD simulations, we elected to probe the effect of the mutations 
S119A, I369L, I369F, A370L, and A370V on the metabolism of CBZ by CYP3A4. Expression of 
all five constructs in E. coli provided stable P450 holoproteins, in good agreement with earlier 
reports on the expression and purification of the mutants S119A (41), A370V (168), and I369F 
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(169). The expression yields obtained with the mutants were generally somewhat lower than the 
yield of wild-type CYP3A4. 
4.3.5 EFFECT OF MUTATIONS ON CYP3A4-DEPENDENT EPOXIDATION OF 
CBZ 
For most mutants, we obtained linear profiles for the increase in the product concentration in 
the time ranges longer than 20 min. The S119A and I369F mutants were exceptions because the 
product formation was linearly dependent on time for only ca. 15 min (Figure 33). Consequently, 
the incubations with wild-type CYP3A4, the I369L and the A370V/L variants were carried out for 
20 min and for 15 min with the S119A and the I369F mutants. 
 
Figure 33: Formation of carbamazepine-10,11-epoxide by CYP3A4-containing Bactosomes, 
purified wild-type, and purified mutants of CYP3A4. The graph shows the total product 
formation within 30 min. The black dotted lines represent linear extrapolations of the initial slopes 
from the first 20 min of incubation (first 15 min in the case of the S119A and the I369F mutants). 
In initial experiments, we assessed the turnover rate of CBZ epoxidation in the reconstituted 
system with the purified mutants and the wild-type CYP3A4 (rCYP3A4) at apparent subsaturating 
(0.1 mM) and saturating (1 mM) substrate concentrations (Figure 34, Table 9). When measured at 
subsaturating substrate concentration, the activities of the A370V and I369L mutants were 
essentially similar to that of the wild type, whereas a substantial increase in activity was observed 
with the I369F mutant and a substantial decrease was observed with the A370L mutant. The S119A 
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substitution, which was devised to abolish the putative hydrogen bond to the CBZ carbonyl oxygen, 
caused the most pronounced decrease in enzyme activity at subsaturating substrate concentration. 
However, at saturating CBZ concentration (1 mM), the activity of the S119A mutant became 
similar to that of the wild type and approximately two-fold the activity of the I369L variant. The 
A370V mutant exhibited the highest activity, and the activities of the A370L and I369F mutants 
were also higher than that of the wild type. 
 
Figure 34: Turnover rates of CBZ epoxidation by purified CYP3A4 wild type and mutants 
measured at CBZ concentrations of 0.1 (a) and 1 mM (b). The columns represent the means of 
three individual measurements and the error bars represent the respective standard deviations. 
 
Table 9: Turnover of CBZ by rCYP3A4 wild type and mutants*. 
Enzyme Wild type S119A A370V A370L I369L I369F 
100 
µM 
v 0.17 ± 0.02 0.027 ± 0.001 0.16 ± 0.02 0.07± 0.01 0.14 ± 0.06 0.4 ± 0.1 
(%) (100%) (16%) (94%) (39%) (84%) (224%) 
1 mM 
v 0.8 ± 0.1 0.7 ± 0.4 3 ± 2 0.9 ± 0.2 0.35 ± 0.04 1.1 ± 0.1 
(%) (100%) (81%) (362%) (113%) (43%) (140%) 
*The values given in the table represent the means of three individual measurements, and the “±” 
values show the respective confidence interval calculated for p = 0.05. 
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To analyze the effects of these substitutions in more detail, we evaluated full kinetic profiles 
of the wild-type enzyme and the mutants in the reconstituted system, increasing the range of CBZ 
concentration studied up to 2 mM (Figure 35). 
Although the overall quality of the fit (dashed line) of the substrate titration curves obtained 
with the wild-type CYP3A4 to the Hill equation (h = 2.0 ± 0.9, S50 = 300 ± 100 µM and kcat = 1.0 ± 
0.3 min-1) appears acceptable (ρ2 = 0.957), systematic deviations of the experimental points (Figure 
35a, circles) suggest the presence of substrate inhibition at higher concentrations, similar to that 
observed with the CYP3A4-containing Bactosomes. While for the I369F and I369L mutants 
substrate inhibition is much more evident than in the wild type (Figure 35a), S119A, A370V, and 
A370L mutants show no visible signs of substrate inhibition (Figure 35b). In contrast, the S-shaped 
kinetic profiles obtained with these mutants are indicative of a high degree of cooperativity. 
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Figure 35: Substrate dependence of the carbamazepine-10,11 epoxide formation rate 
catalyzed by purified CYP3A4 and its mutants in the reconstituted system. Incubations were 
carried out with 0.5 µM CYP3A4. Data points represent the mean values of three individual 
measurements and the error bars show the respective standard deviations. Fits to the Hill 
equation (dashed line) and to Eq. 4.2 (solid line) are shown. Panel (a) shows the plots obtained 
with the wild-type enzyme (circles) and the I369F (squares) and I369L (triangles) mutants; 
panel (b) shows the data obtained with the mutants S119A (circles), A370V (squares), and 
A370L (triangles). 
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Table 10: Parameters of CYP3A4-dependent epoxidation of carbamazepine* 
System 
Hill equationa 
kcat, min-1 S50, mM h ρ2 
Bactosomes 1.9 ± 0.3 0.16 ± 0.04 1.4 ± 0.4 0.979 
rCYP3A4 WT 0.9 ± 0.3 0.3 ± 0.1 2.0 ± 0.9 0.957 
rCYP3A4 I369L 0.42 ± 0.06 0.14 ± 0.02 1.80 ± 0.10 0.884 
rCYP3A4 I369F 1.4 ± 0.2 0.20 ±0.07 1.3 ± 0.5 0.932 
rCYP3A4 S119A 0.8 ± 0.1 0.61 ±0.07 2.5 ± 0.4 0.985 
rCYP3A4 A370V 5 ± 1 1.0 ±0.3 2.1 ± 0.9 0.991 
rCYP3A4 A370L 1.3 ± 0.4 0.6 ±0.3 2.0 ± 0.6 0.993 
 
System 
Hill equation complemented with substrate inhibition (Eq. 4.2) 
kcat, min-1 S50, mM h Ki, mM α ρ2 
Bactosomes 2.9 ± 0.7 0.3 ± 0.2 1.06 ± 0.08 1.3± 0.8 0.3 ± 0.3 0.991 
rCYP3A4 WT 1.4 ± 0.4 0.50 ± 0.04 1.4 ± 0.4 0.79 ± 0.04 0.6 ± 0.5 0.964 
rCYP3A4 I369L 0.8 ± 0.4 0.3 ± 0.2 1.4 ± 0.3 1.1 ± 0.5 0.2 ± 0.1 0.989 
rCYP3A4 I369F 3 ± 1 0.6 ± 0.4 1.2 ± 0.3 1.1 ± 0.6 0.2 ± 0.4 0.971 
rCYP3A4 S119A 1.2 ± 0.1 0.94 ± 0.08 2.1 ± 0.3 1.0 ± 0.2 0.5 ± 0.1 0.990 
rCYP3A4 A370V 4.6 ± 0.9 1.1 ± 0.3 1.9 ± 0.6 5 ± 8 0.96 ± 0.07 0.991 
rCYP3A4 A370L 1.2 ± 0.2 0.77 ± 0.07 1.7 ± 0.2 5 ± 9 1.4 ± 0.7 0.993 
*The values given in the table represent the averages of 3 individual measurements, and the “±” 
values show the confidence intervals calculated for p = 0.05. a In the cases with clearly pronounced 
substrate inhibition (CYP3A4 bactosomes, reconstituted systems with I369L and I369F mutants), 
the fitting to the conventional form of the Hill equation was performed with the data subsets 
corresponding to the CBZ concentration range of 0 – 1 mM. The square correlation coefficients 
given in the table correspond to the fitting to the entire CBZ concentration range (0 – 2 mM) in all 
cases. 
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To justify the apparent combination of positive cooperativity and substrate inhibition 
mechanisms observed in the mutants, we approximated the experimental data with an equation that 
combines the Hill formalism with an allowance for substrate inhibition: 
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The derivation of Eq. 4.2 is described in the methods section (see Chapter 2.2.5, p. 54). The 
S50 term in Eq. 4.2 is defined in a way similar to the definition in the regular Hill equation, as the h-
th root of the apparent dissociation constant of the catalytically competent enzyme-substrate 
complex. In the case where h = 1, Eq. 4.2 reduces to Eq. 4.1, and S50 is equivalent to KM. 
The fits of Eq. 4.2 to the data are shown in Figure 35 (solid lines), and the respective 
parameters are summarized in Table 10. Eq. 4.2 clearly provides a better model for fitting datasets 
obtained with the wild-type enzymes, whether in the form of Bactosomes or in reconstituted 
systems, and with the I369L and I369F mutants. For the data obtained with the A370L and A370V 
mutants, the fit to Eq. 4.2 is as good as to Eq. 4.1. The values obtained for the parameter α with the 
A370L and A370V mutants are close to unity, which suggests that the binding of additional 
substrate molecules does not affect the activity of these enzymes. Hence, we conclude that substrate 
inhibition is completely abolished in these mutants. 
The analysis of the kinetic parameters suggests that, over the five mutants probed in this 
study, only the I369F and especially the A370V substitution cause considerable increases in enzyme 
turnover with CBZ compared to wild type (Table 10). In the case of I369F, the increase in the kcat 
value is attenuated by enhanced substrate inhibition caused by a decrease in the fraction of activity 
retained in the inhibitory complex (α). However, for the A370V mutant, where substrate inhibition 
is eliminated, the increase in the CBZ turnover is substantial Figure 35b, Table 10). 
Clearly pronounced positive cooperativity in CBZ metabolism observed with the mutants 
A370V, A370L, and S119A suggests that the formation of the catalytically competent complex with 
CBZ in these mutants requires the binding of at least 2 substrate molecules per molecule of the 
enzyme. At the same time, in contrast to A370V and A370L, where substrate inhibition is 
eliminated, the fit of the data obtained with S119A to Eq. 4.2 indicates that the metabolism of CBZ 
by this mutant is characterized by a combination of a prominent positive cooperativity (h = 2.1 ± 
0.3) with a moderate degree of substrate inhibition (α = 0.5 ± 0.1). It further suggests that the 
mechanism of interactions with CBZ involves at least three separate substrate binding events.  
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4.3.6 MD SIMULATIONS OF 2-4 CBZ MOLECULES IN CYP3A4 BINDING 
POCKET 
Based on the analysis of the kinetic profiles for CBZ metabolism, we concluded that changes 
in CBZ metabolism caused by the mutations at positions 369, 370, and 119 cannot be accurately 
described by simulations with a single CBZ molecule bound. Therefore, we conducted MD 
simulations with two, three, or four CBZ molecules positioned in the CYP3A4 binding pocket. Five 
MD simulations each with two copies of CBZ in the active site were performed with CYP3A4 wild 
type, I369F, and A370V. Cluster analyses yielded non-identical largest clusters for both mutants 
and wild type. The simulation times of 0.2 µs per MD run – equal to a total sampling time of 1 µs 
for each of the three CYP3A4 variants – were intended to achieve convergent data. Importantly, 
similar to the single-CBZ simulations, the obtained clusters stem mainly from only one of the five 
runs, which is indicative of a lack of convergence. The largest clusters for each of the wild type, 
A370V, and I369F variants are shown in Figure 36. For the A370V mutant only (Figure 36b) is the 
binding mode, i.e., the position and orientation, of the CBZ closest to the heme essentially identical 
to that of the most populated cluster in the single-CBZ wild-type run with the C10–C11 bond close 
to the heme iron (Figure 32, cluster #1). Interestingly, the hydrogen bond observed between Ser119 
and the carbonyl oxygen of one CBZ molecule is retained in all panels in Figure 36. This lends 
further evidence that Ser119 plays an important role in substrate binding. 
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Figure 36: Results of MD simulations with the complex of two molecules of CBZ and wild-
type CYP3A4 (a), A370V (b), and I369F (c). Each panel shows two representatives corresponding 
to the most populated clusters obtained with each of the two CBZ molecules for clustering. 
Clustering of the non-hydrogen atoms of the CBZ molecules was carried out upon structural 
alignment of all snapshots of the MD trajectories to the X-ray structure via the Cα atoms of the α-
helical residues of CYP3A4. Only in panel (a) are the orientations of the CBZ molecules different 
depending on which of the two CBZ molecules was subjected to clustering, which indicates that the 
sampling did not converge. Data and figure by T.K. 
Partial dissociation of a single CBZ molecule was observed in one of the MD simulations 
(Figure 37 and Figure 38). Analysis of the unbinding pathway reveals that the CBZ molecule moves 
to the periphery of CYP3A4 through the F’-helix β-sheet-1 putative substrate binding channel 
predicted by Williams et al. (38). To assess the ability of CYP3A4 to accommodate more than two 
CBZ molecules, we performed five independent MD runs of 100 ns each with wild-type CYP3A4 
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plus three or four CBZ molecules (Figure 37). No dissociation events were observed, and the 
distance of the CBZ molecule furthest from the heme iron was never larger than 18 Å. These results 
indicate that the CYP3A4 binding pocket is large enough to accommodate up to four CBZ 
molecules, and that the A370V and I369F mutations considerably affect the mobility of CBZ 
molecules bound in the binding pocket. 
 
Figure 37: Time series of the distance between the center of the C10-C11 bond in CBZ and the 
heme iron. Each color corresponds to a single CBZ. Five 200 ns simulations were performed with 
two CBZs with the A370V mutant (a-e), the I369F mutant (f-j), and the wild-type CYP3A4 (k-o); 
five 100-ns simulations were performed with the wild type with three (p-t) and four (u-y) CBZ 
molecules. All figures were generated with xmgrace. No full dissociation event is observed in the 
MD runs. The largest separation of CBZ from the heme is observed in panel (k) and several 
snapshots from the corresponding MD run are combined in Figure 38. Data and figure by T.K. 
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4.4 DISCUSSION 
This study represents the first attempt to employ MD simulations to suggest CYP3A4 mutants 
with enhanced activity of epoxidation of carbamazepine combined with subsequent in vitro 
corroboration of the impact of the mutations on kinetics parameters. Our initial studies of the 
kinetics of CBZ epoxidation by CYP3A4-containing Bactosomes reveal pronounced substrate 
inhibition. This leads us to suggest that the apparent positive cooperativity reported in earlier 
studies of CBZ metabolism might be due to the limited range of substrate concentrations examined. 
We demonstrate that the kinetic profiles obtained with bactosomes adequately approximate the 
Michaelis equation complemented with an allowance for partial substrate inhibition (Eq. 4.1). The 
complex of CYP3A4 with one substrate molecule bound in the substrate binding pocket (Figure 31) 
may be taken as an adequate model of the catalytically competent complex. 
In the MD simulations performed with a single CBZ molecule, the most populated cluster 
displays a productive CBZ binding mode compatible with substrate epoxidation. The distance 
between the COM of CBZ carbon atoms 10 and 11 to the heme iron is less than 5 Å. On the basis of 
the analysis of the structure in this cluster, we identified mutants I369L, I369F, A370V, and A370L 
that could lead to improved steric complementarity via Van der Waals interactions of the enzyme 
with the three-ring system of CBZ. The S119A mutation was devised to abolish the hydrogen bond 
to the carboxyl function of CBZ to decrease the stability of the binding mode and, thus, the overall 
binding affinity.  
Although the approach based on MD-simulations with one CBZ molecule was successful in 
constructing mutants with a considerable increase in maximal CBZ turnover rate (in the case of the 
I369F and A370V mutants), our examination of the kinetic profiles of CBZ metabolism with the 
full series of our mutants reveals certain limitations of this simplified model. We demonstrate that 
the best approximation of the kinetic profiles obtained in vitro with the wild type or the mutants is 
obtained by means of a model that combines the positive cooperativity mechanism with an 
allowance for partial substrate inhibition (Eq. 4.2). According to our analysis with this model, the 
cooperativity exhibited by the wild type and with the I369L and I369F mutants is only marginal, but 
is clearly pronounced (h ≈ 1.7 – 2.1) in the S119A, A370V, and A370L mutants. On the other hand, 
substrate inhibition is quite modest in the wild type and the S119A mutant (α ≈ 0.5) and eliminated 
in the A370V and A370L mutants (α ≈ 1), but is considerably enhanced in the I369L and I369F 
mutants (α ≈ 0.2). This complex mix of positive cooperativity and substrate inhibition in CBZ 
metabolism is consistent with the results of Egnell and co-workers (51), who compared the kinetic 
profiles for CBZ epoxidation by HLM to those obtained with purified CYP3A4 in a reconstituted 
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system. They demonstrated that, although data obtained with HLM are consistent with a two-site 
model where binding of the first CBZ molecule increases the enzyme affinity for binding of a 
second substrate molecule, the reconstituted system instead exhibits substrate inhibition (51).  
On the basis of our findings, we suggest that the CYP3A4-CBZ interaction is best explained 
with a model that involves binding of three or more CBZ molecules in the active site. MD 
simulations of the complex of CYP3A4 with two to four CBZ molecules provide strong support for 
this suggestion; no complete egress of substrate was observed in five MD simulations involving 
three or four CBZ molecules bound to CYP3A4. In the simulations of two molecules of CBZ bound 
to the CYP3A4 wild-type enzyme or the I369F or A370V mutants (Figure 36), the most populated 
binding mode of the single-copy simulations of CBZ was observed only for A370V: in this case, 
one of the two CBZ molecules is bound in a putative catalytic pose. The finding that this pose 
appears to be stabilized by the second CBZ molecule provides a plausible explanation for 
homotropic cooperativity in CBZ epoxidation. Indeed, the A370V mutant is the only one of the 
three enzyme variants probed with simulations that exhibits prominent homotropic cooperativity 
(Figure 35 and Table 10). However, given the limited sampling in the simulations, we caution that 
this observation may be coincidental. 
In the 15 simulations – 5 simulations each with wild type, A370V, and I369F – of 2 CBZ 
molecules in the active site of CYP3A4, only one partial egress of substrate was observed in the 
case of wild-type CYP3A4 (Figure 38). We compared the cumulative volume of the dissociation 
trajectory of the egress of CBZ via the sampled volume of the COM of C10/11 (Figure 38c) to the 
position of the substrate access channel predicted by Williams et al. on the basis of the x-ray 
structure (1W0G) of CYP3A4 (38). We found that the volumes largely match; hence, our 
simulation supports the geometry of the substrate- and solvent-accessible binding pocket of 
CYP3A4 previously proposed. 
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Figure 38: Egress pathway of one of the two bound CBZ molecules from the heme pocket of 
the wild-type CYP3A4 to a distance > 20 Å from the heme iron. (a) Structure of CYP3A4 
showing the positions of the CBZ molecule during its dissociation: The initial position of the CBZ 
molecule is highlighted in green and the positions after 50 ns, 100 ns, 150 ns, and 200 ns are shown 
in cyan, magenta, yellow, and maroon, respectively. The second CBZ molecule is not shown. (b) 
Time series of the COM distance between the CBZ C10-C11 bond and the heme iron. The distance 
of the bound CBZ molecule is shown in black, whereas the distance of the unbinding CBZ molecule 
is shown in red with colored arrows indicating the positions on the time axis corresponding to the 
colored structures shown in panel (a). The green arrow indicates the starting position of the 
molecule. (c) Surface circumscribed by the central nitrogen atom of the dissociating CBZ molecule 
over the course of a single 200 ns simulation. The protein backbone from the first snapshot of the 
simulation is shown in white and does not account for changes during the simulation. The arrows 
indicate the general direction of the movement of the CBZ molecule. Data and figure by T.K. 
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Although a multisite binding mechanism in the mutants is retained, the enzyme is exquisitely 
sensitive to the minor structural changes in the binding pocket introduced by the point mutations 
S119A, I369F, I369L, A370L, and A370V. The observation of the hydrogen bond between the CBZ 
molecule adjacent to the heme and the Ser119 residue (Figure 36) provides a clue to the effects of 
the S119A substitution (Figure 35). Importantly, this bond is found in the structures of all simulated 
variants (wild type, A370V, and I369F). The absence of the stabilizing hydrogen bond in the S119A 
mutant may explain the reduced affinity of this mutant for CBZ. Furthermore, enhancement of 
homotropic cooperativity in CBZ epoxidation by this mutation reveals an increased role for the 
binding of a second substrate molecule in stabilizing the catalytically competent complex. These 
results further support the conclusion that the residue Ser119 plays a key role in substrate binding in 
CYP3A4 (11, 40, 45, 62, 168, 170), in agreement with a recent study in which it was shown that the 
association of CYP3A4 with ritonavir analogues is strongly facilitated by polar interactions 
mediated by Ser119, even in cases where the ligand does not engage in hydrogen bonding to this 
serine (170). 
Possible effects of the mutations on the structure of CYP3A4 are illustrated in Figure 39, 
which shows the largest clusters obtained in simulations with two CBZ molecules of the wild type 
and the I369F and A370V mutants compared to the X-ray crystal structure of CYP3A4 with 
metyrapone (1W0G) (38). The π-π stacking interactions between residues Phe316 and Phe367 
found in most X-ray structures are likely to be structurally important. The residues Ile369 and 
Ala370 reside in the 1.4 K/β-loop (residues 368–372), which connects the α-helix K (shown in 
violet) with the subsequent β-strand (shown in blue) and adjoins the active site in Van der Waals 
contact to the α-helix I (shown in green). The structural changes upon substitution of Ile369 by 
phenylalanine are apparently important for the increased substrate inhibition observed in the I369F 
mutant (Figure 35, Table 10). The replacement of Ile369 with phenylalanine (or leucine) is likely to 
affect hydrophobic interactions in the active site and, thereby, promote inhibitory substrate-binding 
and/or steric or conformational effects. The I369F substitution may reduce the volume of the active 
site and concomitantly restrict access to the heme (Figure 39c). The bulky phenylalanine residue 
369 in the vicinity of the heme is likely to destabilize the association of a water molecule to the iron 
(III) and may be the source of the observed increase in the proportion of high-spin cytochrome P450 
in the substrate-free I369F mutant. The I369F substitution may also reduce the free space between 
the 1.4 K/β-loop and the I-helix that face each other in the active site. An analysis of the trajectories 
of Phe304 and residue 369 in the MD simulations (Figure 40) reveals a decrease of the mean 
distance between the side chains (SC) of these residues (blue dashed line) from ΔSC(WT) ≈ 11.6 Å in 
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the wild type (Figure 39b) to ΔSC(I369F) ≈ 8.0 Å in I369F (Figure 39c) averaged over the total 
simulation. The corresponding distance in the A370V mutant was ΔSC(A370V) ≈ 13.0 Å (Figure 39d). 
The formation of a kink in the helix near the Phe304 residue indicated with a black arrow in 
Figure 39c may further restrict access to the active site in the I369F mutant (the conformational 
change was however only seen in one out of five simulations). Furthermore, although not revealed 
in the simulations, a direct interaction of the I369F phenylalanine with residue F304 may be 
possible and contribute to the changes in the kinetics observed with this mutant. In the I369L 
mutant, the side-chain γ-methyl groups of leucine may more closely interact with the T309 side 
chain to move the K/β -loop and to induce a similar conformational change in the I-helix as seen in 
the simulation of the I369F mutant. A direct effect of the leucine on the accessibility to the heme 
may also be plausible.  
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Figure 39: Comparison of the X-ray structure 1W0G with the simulated structure (cluster 
representatives). (a) The active site of CYP3A4 structure 1W0G with metyrapone (light blue) 
bound (38). Panels (b-d) show cluster representatives of MD simulations of CYP3A4 (b) wild type 
and the (c) I369F and (d) A370V mutants with two CBZ molecules (marine blue). Residues Phe316 
and Phe367 shown in orange apparently engage in π-π stacking interactions. The K-β-(1.4) loop 
consisting of residues 368–372 (PIAMR) that joins the K-helix (violet) to the sequential β-sheet 
(blue) makes Van der Waals contacts with the long I-helix (green). Mutated residues are shown in 
yellow. Note in panel (c) that the bulky phenylalanine in the I369F mutant projects into the active 
site to reduce accessibility of the heme. Over the length of one simulation of the I369F mutant, the 
I-helix exhibits a kink (black arrow) around residue Phe304 and additionally constricts the access to 
the active site due to a dramatic decrease in the distance between the side chains of F304 and 
residue 369 (blue dashes). Data by T.K., figure by C.M. 
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Figure 40: Time-series of distances between the ends of the side chains of residues 369 and 
Phe304 of the five simulations with complexes of two CBZ molecules with the wild type (light 
green) and the mutants A370V (black) and I369F (red). The data stems from the analysis of the 
simulations that are also the matter of Figure 37 (a-o). Data and figure by T.K. 
Stabilization of substrate binding by the additional phenylalanine residue near the heme 
moiety in the I369F mutant via stacking interactions of the aromatic rings may contribute to the 
high rate of CBZ turnover observed with this mutant at low CBZ concentrations (Table 9). At 
higher CBZ concentrations, stacking of several CBZ molecules above the heme may prevent 
dissociation of product and be responsible for the observed substrate inhibition (Table 10).  
Elimination of substrate inhibition in the mutants A370V and A370L (Figure 35, Table 10) is 
associated with a significant increase in the S50 value for these mutants compared to the wild type. 
The decreased affinity for CBZ provides further support for the importance of the K/β loop region 
for CBZ binding. It seems plausible that the steric clashes between the larger aliphatic side chains 
of the valine and leucine of these mutants and the metabolized or stabilizing CBZ molecule may 
disfavor substrate stacking, which is hypothesized to be a potential reason for substrate inhibition. 
The observation that the mutants with higher affinity for CBZ display more pronounced substrate 
inhibition provides additional support for the above hypothesis that the mechanism of substrate 
inhibition is based on binding of additional CBZ molecules that impede egress of product. In 
contrast, the finding that the mutants with lower affinity for CBZ exhibit homotropic cooperativity 
is consistent with the stabilization of the catalytically competent enzyme-substrate complex upon 
binding of a second CBZ. Whether these correlations are specific to metabolism of CBZ or 
represent a general characteristic of CYP3A4-catalyzed reactions requires further experimentation.  
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Determination of crystal structures of the CYP3A4 variants investigated in this study, such as 
I369F and S119A, is expected to yield important insights regarding the relevance of structural 
aspects to mechanisms of substrate inhibition and homotropic cooperativity in CYP3A4. In spite of 
the structural plasticity of CYP3A4 (45, 48), we have been able to use MD simulations to identify 
plausible productive and non-productive binding modes for one or more substrate molecules in the 
substrate binding pocket of the enzyme. In particular, the combination of MD simulations and pose 
clustering to guide site-directed mutagenesis has resulted in the generation of enzyme variants that 
exhibit altered functional properties, such as homotropic cooperativity, substrate inhibition, and 
substrate affinities in vitro. This approach may prove to be generally applicable to other enzyme-
substrate pairs as a means to probe binding interactions and mechanisms and modulate 
functionality. 
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5.1 ABSTRACT 
The presence of a water network in the binding pocket of cytochromes P450 stabilized via 
polar interactions is crucial for the proper function of the enzyme. Failure in maintaining the 
regulation of reactivity can lead to futile redox cycling and to the generation of the oxidising 
compounds in the absence of substrates that can harm the enzyme and the surrounding tissue. In the 
case of type-I substrates, the interactions upon ligand association modulate the spin equilibrium of 
the enzyme, which is assumed to be a determinant of redox coupling and catalytic efficiency. In 
cytochrome P450 3A4 (CYP3A4), we suspected that the maintenance of its native water network in 
the active site relies on polar interactions to hydrophilic amino acid residues lining the active site 
such as Ser119 and Thr309, which facilitate water access to its hydrophobic binding pocket. 
In order to investigate the role of the active site residues S119, I369 and A370 for substrate 
binding, we exploited the characteristic spectral shift in the Soret band upon binding of the 
prototypic type-I substrate bromocriptine (BCT), a dopamine agonist and substrate of CYP3A4. We 
analyzed the spectral changes upon association of BCT to the five CYP3A4 mutants S119A, I369F, 
I369L, A370V, and A370L, and the wild type. While affinities of several mutants for BCT were 
considerably altered, S119A exhibited the lowest affinity and a unique inverse type I-shift in a 
substrate-concentration dependent manner, which is not commonly associated with CYP3A4. The 
S119A mutant also exhibited a spin equilibrium shifted towards the high-spin state in the absence of 
substrateas a result of a decreased probability of a water molecule ligating to the heme iron (III) at 
the distal ligand site. In order to investigate whether the unusual behaviour of the S119A mutant in 
ligand binding is not an isolated feature that is restricted to binding of BCT, we extended our 
studies to titrations with the type-I ligand erythromycin (ERY), which confirmed this peculiar 
inverse spin shift in the S119A mutant. Our data therefore present evidence for the crucial role of 
Ser119 in both the association of ligands and the native regulation of enzymatic activity via 
stabilization of a water network in the CYP3A4 active site in the absence of substrate. 
5.2 INTRODUCTION 
Bromocriptine (BCT), an ergot alkaloid and dopamine receptor agonist, is prescribed for the 
treatment of pituitary tumors, Parkinson disease, type 2 diabetes, hyperprolactinaemia and 
neuroleptic syndrome. It is a type-I substrate that does not exhibit cooperativity in binding to 
microsomal or recombinant CYP3A4, but they form a high-affinity complex (KD ≈ 0.3 – 1 µM) 
(171). It consists of a lysergic acid part and a cyclic tripeptide, which is important for the specific 
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interaction with cytochromes P450 of the 3A family. Binding of BCT to CYP3A4 was studied in 
several publications (48, 171, 172) and a crystal structure of the CYP3A4-BCT complex showing a 
productive binding mode of BCT has been presented recently (171). The CYP3A4-BCT 
interactions were found to be predominantly non-polar (171). Extensive Van der Waals interactions 
were reported between the tripeptide group of BCT and the residues Ile301, Ph304, and Ala305 of 
the I-helix, as well as residues Arg105, Arg212, Ala370, and Arg372, whereas the lysergic moiety 
of BCT was sandwiched between the side chains of Arg106 and Phe215 and H-bonded to Thr224. 
In titration experiments, monitored via the spectral transition in the Soret band from 416 nm to 391 
nm that accompanies the low- to high-spin shift, the substitution of Thr224 for alanine reduced the 
affinity for BCT ca. 6-fold (171).  
In order to investigate the role of the amino acids S119, I369, and A370 in the association of 
BCT, we performed equilibrium binding titrations with the mutants S119A, I369F, I369L, A370V, 
and A370L. Whereas the wild type and all mutants except for S119A exhibited a regular type-I spin 
shift, the latter underwent an inverse (i.e. high to low-spin) shift. In order to study whether this 
peculiarity of the CYP3A4 S119A mutant is restricted to the association with BCT, we also studied 
the binding of erythromycin (ERY). ERY is a macrolide antibiotic drug used in the treatment of a 
number of bacterial infections and it is a substrate of CYP3A4. A structure of the CYP3A4-ERY 
complex has been presented with the drug in a non-productive configuration (45). ERY is known to 
form inactive protein accumulates with CYP3A4 due to its formation of metabolite complexes (C-
nitroso:iron, R-N=O:Fe) (29). The structures of BCT and ERY are shown in Figure 41. In this 
chapter, we report that the CYP3A4 S119A mutant appears to exclusively undergo reverse type-I 
spin transitions upon binding of non-allosteric substrates, such as ERY and BCT. The abnormal 
transition in the S119A mutant provides support for the importance of the side chain of Ser119 in 
the control of redox cycling and enzymatic activity of CYP3A4. 
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Figure 41: Structures of the two CYP3A4 type-I ligands bromocriptine (BCT) and 
erythromycin (ERY). 
 
5.3 RESULTS 
5.3.1 BROMOCRIPTINE TITRATIONS 
The association of BCT to CYP3A4 induced spin shifts that were sufficient to obtain 
reproducible fitting parameters for CYP3A4 wild type and all tested mutants. The strongest spin 
shift was obtained in wild-type CYP3A4 (48%) and the least was found for the S119A mutant 
(24%, Table 11). All recombinantly produced CYP3A4 variants displayed type-I spin shifts as 
reported for CYP3A4 (67, 82, 171), except for S119A, which exhibited an inverse type-I spin-shift 
(Figure 42 and Figure 43). Titration of the S119A mutant with BCT resulted in an increase in low-
spin at the expense of high-spin enzyme. The mutants I369F and I369L exhibited 2.4-fold and 1.5-
fold higher affinities to BCT than the wild type, respectively, whereas the affinities of the A370V, 
A370L, and S119A mutants were decreased by 1.8-fold, 7.0-fold, and 11-fold, respectively. All 
results of the fits to the data are shown in Table 11. 
 
Bromocriptine Erythromycin
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Figure 42: BCT Titrations of (a) purified CYP3A4 wild type, and the mutants S119A (b), 
A370V (c), A370L (d), I369F (e), and I369L (f) in solution. In the corrected series of absorbance 
spectra, the initial spectra of BCT-free enzyme are shown with blue dots, titration end-points are 
shown with red dots. Insets: High-spin fractions are plotted against BCT concentrations; solid lines 
represent fits to the equation of bimolecular association.  
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Figure 43: Comparison of all titration curves (black, wild type; blue, I369L; purple, I369F; 
beige, A370V; red, A370L; green, S119A). The data represents a compilation of the data of Figure 
42. 
 
Table 11: Bromocriptine titrations of CYP3A4 wild type and five mutants*. 
Fitting Results 
Mutant KD, µM Spin Shift HSFin 
WT 
S119A 
A370V 
A370L 
I369F 
I369L 
0.6 ± 0.2 0.48 ± 0.05 0.62 ± 0.02 
6.3 ± 1.0 -0.24 ± 0.04 0.22 ± 0.07 
1.1 ± 0.4 0.32 ± 0.04 0.65 ± 0.04 
4.2 ± 1.7 0.26 ± 0.07 0.56 ± 0.05 
0.25 ± 0.07 0.25 ± 0.03 0.70 ± 0.02 
0.40 ± 0.15 0.30 ± 0.04 0.63 ± 0.02 
*Results for the parameters KD (affinity constant), total spin shift and (asymptotic) endpoints of the 
high-spin fractions are shown. Spin shifts are given in fractions of the total cytochrome P450; HSFin 
denotes the (theoretic) asymptotic estimation of the proportion of high-spin P450 for BCT-saturated 
CYP3A4. The values given in the table represent the mean values of triplicates, and the “±” values 
show the respective confidence interval calculated for p = 0.05. 
The UV-VIS spectrum recorded at saturating BCT conditions revealed a maximum of the 
Soret band at 417 nm, a characteristic of low-spin heme iron (III). Consistent with this, the first 
principal component obtained in the analysis of the titration series (which accounts for the highest 
variability in the data) exhibited a maximum at ca. 420 nm (Figure 44). In order to confirm that the 
nature of the spin-shift in S119A is inverse type-I, we investigated the binding of CO to Fe2+-heme. 
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This revealed no involvement of the inactivated P420 form in BCT titration, as we concluded from 
the essentially identical levels of [‘P420’] in the absence of substrate and at saturating BCT 
concentration (20 µM). 
 
 
Figure 44: The first principal components, which represent the highest variation in the 
respective titrations, are shown for CYP3A4 wild type and the S119A mutant. 
 
5.3.2 ERYTHROMCYCIN TITRATIONS 
In order to examine whether the inverse type-I binding of the CYP3A4 S119A mutant is 
restricted to BCT, we explored the transition upon binding of ERY, another ligand that shows no 
cooperativity in its association to CYP3A4. The results of the titrations of the S119A mutant with 
ligands that exhibit cooperativity in association or turnover of CYP3A4 are reported in Chapter 6. 
In the titration with CYP3A4 wild type, ERY did not induce a type-I spin shift, but induced a red-
shift of ca. 1 nm (417 nm → 418 nm) in the absorption maximum of the Soret band (Figure 45, 
panels a/c). This shift was captured and quantified via spectral decomposition with the help of the 
spectral species that exhibits a Soret band maximum at 424-426 nm. The ‘P420’ spectral standard 
represents either type-II ligated CYP3A4 or one of the inactivated cytochrome P420 forms of 
CYP3A4, which are spectrally not distinguishable due to their similar position of the Soret band 
maximum. The shift in the absorbance maximum was concentration dependent and was fit to the 
equation of bimolecular association (Eq. 2.14, Figure 45a, c). Similar to BCT, ERY titration 
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resulted in an inverse spin shift in the S119A mutant (Figure 45b). The extent of total spin shift 
amounted to (-33 ± 2)%, which exceeds the total apparent type-II transition in the wild type (18 ± 
2)% (Table 12). The 1st principal component of the spectral titration series of the S119A mutant 
exhibited a maximum and a minimum at 389 nm and 421 nm, respectively, and reveals an inverse 
type-I spin perturbation. The first principal component obtained from the analysis of the wild-type 
titration data exhibited a maximum at 426 nm (Figure 45d). This supports the findings that the wild 
type exhibits a red-shift in the Soret band indicating an apparent type-II transition (max = 426 nm). 
The S119A mutant showed an inverse type-I spin shift (max = 421 nm). 
 
Figure 45: Titrations of CYP3A4 wild type (a) and S119A (b) with erythromycin. In panel (a) 
and its zoom into the Soret band (c), titration data with wild-type CYP3A4 reveals a spectral red-
shift in the absorbance maximum. This was captured in the form of an apparent type-II shift in the 
analysis. The data for the S119A mutant in panel (b) indicates a pure inverse type-I spin-shift. Insets 
represent the dependence of the respective spectral species on ERY concentration ([P450HS] / 
[P450]Tot or [‘P420’] / [P450]Tot vs. [ERY], respectively). Panel (d) shows the first principal 
components of the analysis of the two spectral titration series.  
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Table 12: Fitting parameters for the ERY titrations.* 
Fitting Results 
Mutant KD, µM Spin Shift Endpoint 
WT 
S119A 
(1.9 ± 0.7) · 103 0.18 ± 0.02 0.23 ± 0.061 
(3.5·± 0.3)   103 -0.33 ± 0.02 0.17 ± 0.02 
*Results are presented for the affinity parameter KD, for the total spin shift in fractions of total 
cytochrome P450, and the (asymptotic) endpoints of the transition. 1The values were determined for 
the analysis with respect to the appearance of the spectral ‘P420’ species in the case of wild-type 
CYP3A4 due to absence of type-I transition. Endpoint denotes the (theoretical) asymptotic endpoint 
proportions of the respective spectral species in ERY-saturated solution. The values given in the 
table represent the mean values of four measurements and the “±” values show the respective 
confidence interval calculated for p = 0.05. 
 
Table 13: Positions of the maxima and minima of the first principal components that were 
obtained in the principal component analysis of the spectral titration series (see Figure 42g 
and Figure 45d). 
Substrate CYP3A4 Max., nm Min., nm 
Bromocriptine WT 387 417 S119A 420 389 
Erythromycin WT 426 392 S119A 421 389 
 
5.4 DISCUSSION 
The calculated affinity of BCT for wild-type CYP3A4 (KD = 0.6 µM) is in accordance with 
previous reports on the formation of a complex with CYP3A4 (KD of 0.3 - 1.0 µM) (171). The 
affinities of the generated mutants are between 0.25 μM and 6.1 μM, which corresponds to an 
overall variation factor of ca. 25. The considerable variation in affinities can be explained on the 
basis of the X-ray structure of the BCT-CYP3A4 complex shown in Figure 46 (PDB-code 3UA1) 
(171). 
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Figure 46: X-ray structure of the binding mode of BCT in a CYP3A4-BCT complex (structure 
ID 3UA1): Panel (a) displays the entire structure, and panels (b-c) zooms into the active site. 
Residue Ile369 interacts with Thr309 of the adjacent I-helix through hydrophobic interactions. The 
side chain of Arg212 projects into the active site and makes possible contacts with the Ile369 
backbone carbonyl. Ser119 and Ala370 form a hydrogen bond and engage in hydrophobic 
interactions with BCT, respectively. BCT is in VdW contact to Ala370 and forms an H-bond to 
Ser119. 
 
In 3UA1, no direct interactions of Ile369 with BCT can be identified; in fact, the side chain of 
Ile369 is separated from BCT by > 6 Å. This allows substitution of Ile369 with a residue that 
comprises a larger hydrophobic side chain and explains why the I369F and I369L substitutions are 
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both well tolerated. The affinities of these mutants for BCT are both increased, in the case of the 
I369F mutant ca. 2.5-fold. We concluded from the evaluation of the distance trajectory between the 
side chains of residue 369 and Phe304 in the respective MD simulations (see chapter 4, Figure 40) 
that the substituted phenylalanine residue projects further into the active site cavity than Ile369. A 
possible shift of the I-helix is seen in one of five MD simulations of the 2CBZ-CYP3A4 I369F 
complex along with direct hydrophobic interactions of Phe369 with the tricyclic peptide of BCT. 
This shift may allow for a tighter fit of BCT and result in the increased affinity obtained in the 
equilibrium titrations. Arg212 of the FF’-loop (residues 210-214) and Thr309 of the I-helix are in 
close contact with Ile369 in the CYP3A4-BCT X-ray structure (side-chain distances ≤ 4 Å). The 
I369L substitution may affect the hydrophobic interactions with the two residues mentioned above 
and may account for the slight increase in affinity seen in the titrations. Ala370 is in close contact 
with the valine of the tricyclic tripeptide of BCT (Δ(BCT:A370) = 3.3 Å in the X-ray structure in Figure 
46c). Extension of the side chain of A370 by two or three methyl groups (which corresponds to the 
A370V or A370L substitutions, respectively) is expected to cause steric clashes in the binding mode 
of BCT shown in Figure 46. Therefore, this is in agreement with the 2- and 7-fold decreased BCT 
affinities obtained for the two mutants A370V and A370L, respectively. Based on the interatomic 
distances between the β-hydroxyl oxygen atom of Ser119 and the backbone amide oxygen atom of 
the tricyclic peptide of BCT (Δ(BCT-O:O-S119) = 3.3 Å), a hydrogen bond is likely to be formed. The 
substitution of Ser119 for an alanine abolishes the hydrogen-bonding partner of the amide oxygen 
and may account for the major portion of the strong, 10-fold decrease in affinity with respect to the 
wild type.  
In our BCT titrations carried out in solution, the high-spin content does not exceed 70% at 
saturating ligand concentration (Figure 42), which is in agreement with earlier reports (105, 171). In 
CYP3A4 associated to native-like membrane bilayer mimics (Nanodiscs), BCT and testosterone 
binding have completely converted CYP3A4 to the high-spin state (> 90% high-spin content) (86). 
However, in reconstituted or detergent-solubilised CYP3A4, the conversion to high-spin does 
usually not exceed 2/3 (44, 173) due to interactions between the enzyme monomers to form 
oligomers. This suggests that only a portion of the total enzyme pool participates in substrate 
binding (105). 
In the titrations of wild-type CYP3A4 with ERY, we detected a spectral red-shift of ca. 1 nm 
upon ligand association. Whether this represents a type-II transition or the formation of some 
species of cytochrome P420 was not determined by binding of carbon monoxide to the reduced 
heme iron (II) enzyme. It may be of interest to mention that the absorption maximum of the Soret 
band was displaced by ca. 1 nm in the absorbance spectra of the A370V and A370L mutants in the 
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substrate-free form. Titration curves obtained with the substrates BCT and ERY fit well to the 
isotherm of bimolecular association and allow the determination of affinity constants (Table 11).  
Our data of the mutant S119A exhibiting inverse spin shifts with BCT and ERY confirm a 
major role of Ser119 for the configuration of the active site of CYP3A4. The S119A mutant was 
shown to be a functional CYP3A4 enzyme (41). In chapter 4, we demonstrated that the mutant is 
capable of catalysing the turnover of the substrate carbamazepine to its epoxide product. In chapter 
7, we will show that the mutant also catalyzes the conversion of the fluorogenic quinoline and 
resorufin derivatives used in this work to probe for active CYP3A4 enzymes. The S119A mutant 
equilibrates into approximately equivalent proportions of low and high-spin P450 in solution in the 
absence of ligands, whereas the wild type exhibits less than 20% high-spin cytochrome P450 under 
identical conditions (see chapter 4, Figure 22 on p.72). Modulation of the spin equilibrium in the 
heme iron (III) of the enzyme is thought to be an important determinant of its redox coupling and 
catalytic efficiency. Partitioning into similar proportions of the two most common spin states of iron 
(III) cytochrome P450 requires a substantial decrease in the occupancy of the heme iron (III) ligand 
site trans to the cysteinate ligand by a water molecule. Strikingly, the increase in low-spin iron upon 
titration with the substrates ERY and BCT appears to re-establish the native water network in the 
active site of CYP3A4 S119A, which is decisive for the predominant low-spin form of the heme 
iron of CYP3A4 in the absence of substrate.  
There is an increasing interest in the role of Ser119 in ligand association to CYP3A4 
demonstrated by several recent studies involving experiments with the S119A mutant (11, 170, 
174). In addition to an apparent alteration of the mechanism of ligand association, S119A generally 
exhibits reduced affinity to the probed substrates. The example of BCT showed a 10-fold decrease 
in affinity in the S119A mutant with respect to the wild type. Sevrioukova and coauthors studied the 
effect of the mutation of S119A on equilibrium binding as well as the kinetics of the association and 
inhibitory binding of a series of ritonavir analogues to CYP3A4. The S119A mutation reduced the 
affinity to all investigated ligands by at least three-fold and up to two orders of magnitude. The 
kinetics of association of the ritonavir analogues to the mutant were significantly perturbed (170).  
The S119A substitution may involve considerable reorganization of the active site in the 
substrate-free form, leading to (i) thermodynamically unfavorable ligation of water that leads to 
partial water displacement and a concomitant high-spin transition and (ii) some restriction to the 
access of large ligands to the active site. We argue that the residue Ser119 is of critical importance 
for the hydration of the active site of CYP3A4 via the formation of a meta-stable water network. Its 
absence appears to involve a reorganization of the hydrophobic binding pocket to form an 
energetically favorable conformation that is less suitable for the turnover of some of the substrates 
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probed here at low concentration (see Figure 34, p. 92; note also the reduced activity towards 7-
benzyloxyquinoline at [S]7BQ = 5 µM in Figure 59 on p. 153). Support for the hypothesis stated 
above is provided by studies in which the thermal stability of wild-type CYP3A4 and the S119A 
mutant were compared (174). It is known that tight-binding ligands often increase the melting 
temperatures Tm of their target proteins. The melting temperature of the ligand-free S119A mutant 
was increased by 1.4 °C with respect to the wild-type enzyme. This led the authors to conclude that 
the protein fold of the mutant is somewhat stabilized upon mutation of Ser119 to an alanine. 
Surprisingly, the stabilization through association with ritonavir analogues obtained for the wild-
type enzyme, that was considerable for some of the analogues (ΔTm = 1.1 – 6.7 °C), was mostly or 
completely eliminated (ΔTm = (-0.2) – 1.6 °C) in the mutant. These authors concluded that the 
Ser119-mediated H-bond both assists the association of ritonavir analogues and stabilizes the 
resulting complexes (170). 
It is therefore of interest to examine existing structural data with respect to Ser119 in order to 
obtain further insight into its functional relevance. A distance of 4.1 Å between O-atoms of 
metyrapone and Ser119 was reported in the crystal structure 1W0G (38) of the CYP3A4-
metyrapone complex. In an MD simulation study of Park et al. in which the X-ray coordinates of 
the 1W0G structure were employed, the hydrogen bond to Ser119 was rapidly formed and remained 
stable over the course of the simulations (40). The evolution of the enzyme in silico therefore 
suggests that distances up to and possibly larger than 4 Å can account for hydrogen bonds. X-ray 
structures of complexes of CYP3A4 with several ligands (e.g. BCT (3UA1) (171), ritonavir 
(3NXU) (62), or ketoconazole (2V0M) (45)) show shorter separations between the β-hydroxyl 
oxygen atom of Ser119 and H-bond donating/accepting atoms of ca. 3 Å and therefore represent 
hydrogen bonding (Table 14). In the MD simulations of the complex of wild-type CYP3A4 with 
CBZ (see Figure 31, p. 87 of chapter 4), Ser119 was also identified to engage in a hydrogen bond to 
the CBZ ligand. In summary, Ser119 is directly involved in ligand binding in most of the available 
X-ray structures of CYP3A4 complexes with ligands. 
On the other hand, in one of the available structures of ligand-free CYP3A4 (PDB-ID 4I3Q) 
(174), only three water oxygen atoms are resolved in the active site of the enzyme. Interestingly, the 
resolved water oxygen atoms appear to connect Ser119 to the heme iron (see Figure 47). This seems 
to be important for the stabilization of a fully functional active site and to be affected upon the 
elimination of the β-hydroxyl of Ser119. 
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Table 14: Currently available X-ray structural data of CYP3A4* 
Structure (PDB) Ligand S119-O···O-L, Å 
3NXU Ritonavir 3.0 
2J0D Erythromycin 3.3 
3UA1 Bromocriptine 3.3 
2V0M Ketoconazole 2.7 
1W0G Metyrapone 4.0 
1TQN water 3.3 
4I3Q water 4.1 
 
*Indicated are the distances of the Ser119 β-hydroxyl oxygen atom to the closest oxygen atom of 
the ligand or the water molecule in cases where no ligand is present. 
 
Figure 47: Close-up of the active site of CYP3A4 in the ligand-free X-ray structure 4I3Q. The 
three resolved water oxygen atoms in the binding pocket (shown as red spheres) connect Ser119 to 
the heme iron. The oxygen atoms of the water molecules are connected with black dashed lines and 
the distances between the oxygen atoms are indicated in the figure. This figure was prepared with 
the X-ray structural coordinates published with ref. (174). 
In summary, we report herein that CYP3A4 S119A exhibits inverse type-I spin transition 
upon binding of the type-I ligands BCT and ERY. To the best of our knowledge, there is no 
previous account on mutants of CYP3A4 that exhibit similarly intriguing effects on the mechanism 
of ligand association. CYP3A4 S119A is therefore a unique point mutant of CYP3A4 that engages 
in inverse spin transition upon titration with native type-I ligands of CYP3A4. In chapter 6, our 
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spectral titration studies of CYP3A4 S119A will be extended to substrates that are known for their 
sigmoidal, or cooperative, binding curves. The fast growth in the number of X-ray structures in the 
last decade along with the mutagenesis studies presented here as well as recent experimental work 
with ritonavir analogues (170, 174) altogether disclose important roles for Ser119 in the association 
of ligands and the stabilization of the water network in the binding pocket of substrate-free 
CYP3A4. A crystal structure of the S119A mutant would give additional decisive insight into the 
atypical function of this mutant and may reveal important conformational changes. 
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Chapter 6 
6.1 ABSTRACT 
The binding of allosteric ligands to the periphery of the microsomal cytochromes P450 is 
predicted to be the basis for many important occurrences of atypical kinetics in CYP3A4 that lead 
to drug-drug interactions. Binding of multiple molecules of steroids that exhibit homotropic 
cooperativity in binding to CYP3A4 has been predicted to occur at spatially separate binding sites 
in the active site and at the periphery of CYP3A4. However, this has never been directly observed. 
In order to elucidate peripheral ligand binding of cooperative CYP3A4 ligands, we studied the 
spectral effects of ligand association to CYP3A4 wild type and the S119A mutant. The results 
presented in chapter 5 showed a unique inverse spin shift upon binding of the type-I ligands 
bromocriptine (BCT) and erythromycin (ERY) to this mutant, which were not found for the wild 
type. While these two non-allosteric substrates ERY and BCT induced a simple reverse type-I shift 
upon ligand association to CYP3A4 S119A, we report here bidirectional spin-shifts for the 
allosteric substrates testosterone (TST), estradiol (EST), and 7-benzyloxyquinoline (7BQ). Minor 
initial high-spin shifts were followed by transitions to the low-spin iron (III) cytochrome P450, the 
extents of which varied among the substrates. The phenomenological cooperative behaviour was 
often attributed to the fact that several substrate molecules are required to bind within a large 
binding pocket in order to overcome the loose binding and to attain the formation of a productive 
complex with at least one of the substrate molecules. The most common conclusion from data with 
several simultaneously metabolized substrates was, however, that most likely several substrate 
molecules have simultaneous access to the oxidizing species in cytochrome P450, which requires 
direct binding to the active site. The data presented in this chapter provide evidence for initial 
binding of these cooperative ligands to a high-affinity binding site that does not induce a substantial 
spin transition and therefore is ‘spectrally silent’. This feature, which appears to be exclusively 
related to the CYP3A4 S119A mutant, promotes the notion of a ‘true allosteric’ effect, i.e. binding 
to an allosteric site that does not take part in catalysis itself, but promotes substrate metabolism in 
the active site.  
6.2 INTRODUCTION 
Cytochrome P450 3A4 (CYP3A4), the most abundant human cytochrome P450 expressed in 
liver and small intestine (37), is a prominent example of a cytochrome P450 showing functional 
variability. CYP3A4 metabolizes about 50% of all currently marketed drugs and is a determinant of 
important drug-drug interactions. Many reactions catalysed by CYP3A4 obey non-hyperbolic 
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kinetics indicative of homo- and heterotropic cooperativity, as seen from sigmoidal substrate 
turnover or binding in vitro. Important examples of non-hyperbolic substrate dependencies were 
documented in CYP3A4-dependent oxidations of native steroids (e.g. testosterone 6β-
hydroxylation, estradiol 2-hydroxylation, and progesterone 6β-hydroxylation) or of xenobiotic 
compounds and pharmaceutical drugs (e.g. aflatoxin B1, amitriptyline N-demethylation, 
carbamazepine 10,11-epoxidation, or diazepam 3-hydroxylation) (166). However, it is still not 
understood how and to what extent putative peripheral ligand binding translates into drug-drug 
interactions that can lead to adverse drug interactions. The complex non-hyperbolic kinetics and 
ligand binding may though in many instances be explained via allosteric ligand binding to a 
“spectrally and functionally silent” peripheral ligand binding site (58). 
Recent studies of the function and regulation of cytochrome P450 have revealed increasing 
attention to the functional significance of the mechanism of substrate binding to such a putative 
peripheral binding site (38, 46, 49, 100, 171). Peripheral binding is thought to cause an effector-
induced conformational rearrangement in the enzyme along with multiple ligand binding (67, 71, 
166, 172, 175). We studied the spectral effects of the spin transition upon binding of cooperative 
substrates to the CYP3A4 S119A mutant. It has been shown that this mutant involves inverse type-I 
spin transitions along with the binding of the type-I substrates BCT and ERY. Specifically, we 
studied the effect of the binding of the substrate 7BQ, and the steroid hormones TST and EST to 
CYP3A4 (Figure 48). 7BQ is a fluorescent substrate and activity marker that is used in activity 
assays that are aimed at the investigations involving novel drug candidates (176-179). The substrate 
is metabolized by CYP3A4 via debenzylation to 7-hydroxyquinoline (7HQ), which exhibits altered 
fluorescent properties. The compound is used by the pharmaceutical industry for testing of the 
potency of new chemical drugs for CYP3A4 inhibition in order to predict potential drug-drug 
interactions of the novel drug candidates (176, 178). TST and EST are both endogenous CYP3A4 
substrates that are metabolized to their predominant native products 6β-hydroxytestosterone and 2-
hydroxyestradiol, respectively. 
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Figure 48: Structures of the CYP3A4 ligands studied in this chapter. 
 
6.3 RESULTS 
6.3.1 EFFECT OF SOLVENTS ON SPIN EQUILIBRIUM 
As reported in the following section, titrations of the CYP3A4 S119A mutant with allosteric 
substrates may initially induce minimal spin perturbations. Even the minor contributions from the 
methanol used as stock solvent may significantly bias the obtained spin transitions and conceal the 
effects caused by the actual substrates. For this reason, the spectra needed corrections for the 
solvent background effect. Obtained titration curves were therefore corrected for solvent 
contributions. To this end, control titrations with methanol were performed with CYP3A4 S119A 
and the obtained spectra analysed for the quantification of the induced spin shift. An example of a 
spectral series of methanol titration and the analysed titration curve are shown in Figure 49. Panel 
(b) in this figure shows a plot of the high-spin proportion as a function of methanol concentration. 
The linear dependence of the high-spin (HS) cytochrome P450 fraction on [MeOH] allowed a linear 
fitting of the data, from which the following parameters were obtained (𝑦 = 𝑎𝑥 + 𝑏, the shown 
parameters represent the mean of three independent measurements and the “±” values represent the 
confidence interval calculated for p = 0.05):  
7-Benzyloxyquinoline
TestosteroneEstradiol
128 
Spectrally Silent Allosteric Ligand Binding  
 
[P 450 ] 
[P 450 ] 0.022 0.004
[ ]
HS
Tota
MeOH
∂
= = − ±
∂
 (6.1) 
` ( )
[ ] 0
[ 450 ]0.494 0.007  
[ 450 ]
HS
Tot MeOH
Pb
P
=
= ± =  (6.2) 
129 
Chapter 6 
 
Figure 49: Methanol background: titrations of CYP3A4 S119A. (a) Series of absorbance spectra 
of titrations of CYP3A4 with methanol as the solvent. (b) Dependence of high-spin P450 on 
methanol content. The markers and error bars show the mean and standard deviations of the 
experimentally determined high-spin fractions of P450, respectively. Titrations were performed in 
triplicate. Linear fitting of the data yielded a concentration dependence of – (2.2 ± 0.4) % high-spin 
(% methanol (v/v))-1. 
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6.3.2 TITRATIONS OF CYP3A4 WILD TYPE AND S119A WITH ALLOSTERIC 
SUBSTRATES 
Titration with the native substrate testosterone (TST) induced a strong spin-shift of (45 ± 2) 
% in wild-type CYP3A4, with an S50 = (56 ± 14) µM, which is in agreement with data from 
previous studies (82). Binding of TST was found to occur with a moderate cooperativity with a Hill 
coefficient h = (1.15 ± 0.08; Figure 50a). Titration of the wild-type enzyme with estradiol (EST) led 
to a considerably smaller spin-shift of (19 ± 4) %, compared to the one obtained with TST, and 
exhibited increased affinity with an S50 = (39 ± 7) µM. Homotropic cooperativity in EST binding 
was somewhat more pronounced than with TST: h = 1.24 ± 0.12 (see Table 12). In order to explore 
the binding of a non-steroidal cooperative CYP3A4 ligand, we extended our titrations to 7-
benzyloxyquinoline (7BQ). Analysis of the spectral series of the titrations of wild-type CYP3A4 
revealed an S50 of (75 ± 16) μM and a spin-shift of (38 ± 6) %. Cooperativity was considerably 
higher compared to the probed steroids: h = 1.73 ± 0.12 (Figure 50c). 
Table 15: Fitting parameters for the analysis of the titrations of CYP3A4 wild type with 
cooperative substrates.* 
Fitting Results (CYP3A4 Wild type) 
Substrate S50, µM Spin Shift h Endpoint 
TST 56 ± 14 0.45 ± 0.02 1.15 ± 0.08 0.59 ± 0.03 
EST 39 ± 7 0.19 ± 0.04 1.24 ± 0.12 0.33 ± 0.01 
7BQ 72 ± 17 0.36 ± 0.03 1.70 ± 0.08 0.54 ± 0.01 
*Results for the parameters S50, the Hill parameter h, total spin shift, and (asymptotic) spin 
transition endpoints for the titrations of wild-type CYP3A4 with the cooperative substrates 
testosterone (TST), estradiol (EST), and 7-benzyloxyquinoline (7BQ). Spin shifts and titration 
endpoints are given in fractions of total cytochrome P450. The values given in the table represent 
the mean values of at least three experiments, and the “±” values show the respective confidence 
interval calculated for p = 0.05. 
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Figure 50: Titrations of CYP3A4 WT with testosterone (a) (TST), (b) estradiol (EST), and 7-
benzyloxyquinoline (7BQ). Spectral series of the titrations insets show plots of the high-spin 
fractions total cytochrome P450 ([HS]/[P450]Tot) as a function of ligand concentration. The analysis 
of the spectral series of the 7BQ-titrations of the wild-type enzyme reveals a pronounced 
homotropic cooperativity (h = 1.7). 
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In contrast to the titrations with ERY shown in chapter 5, the mutant S119A exhibited only 
minor perturbations of the spin equilibrium upon TST binding. Most notably, the analysis of the 
data of the S119A mutant showed a bidirectional spin shift, i.e. a combination of an initial type-I 
spin shift followed by an inverse spin transition. The initial “regular” transition leads to a maximum 
for the high-spin content of total cytochrome P450 at ca. 45 µM TST. The corresponding spectrum 
Figure 51 is shown in green. Further titration beyond [TST] ≈ 45 µM led to an inverse type-I 
transition, such that this part of the titration resulted in spectral changes similar to those obtained for 
the non-cooperative substrates BCT and ERY (chapter 5). A spectral analysis of the titration data 
with respect to an apparent type-II transition resulted in a concentration dependent increase in the 
population of this species (Figure 51b). Since the absolute amounts of the individual spin 
perturbations were minor (in the range of ca. 1-7%, see Figure 51b and c), we expanded our studies 
to the substrate EST, a steroid hormone closely related to TST. Interestingly, in contrast to TST 
binding, the overall spin shift for EST binding to the S119A mutant was clearly inverse type-I, 
although comprising a “lag-phase” in which the spin state was hardly perturbed ([EST] ≈ 0 – 15 
μM; Figure 52c). Inspection of this range of substrate concentration revealed a maximum of the 
high-spin portion at ca. 10-20 μM. Analogous data were obtained for the titrations of the S119A 
mutant with 7BQ, the analysis of which yielded a minor increase in high-spin with a maximum at 
ca. 6 μM that was followed by a ca 20% inverse spin-shift (Figure 53).  
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Figure 51: Testosterone (TST) binding to CYP3A4 S119A. Panel (a) shows a series of spectra of 
CYP3A4 S119A titrations with TST, and the inset to this panel displays a zoom of the Soret band; 
the blue and the red dotted line depict the starting and end points of the titration, respectively. The 
spectrum recorded at 45 µM TST is shown in green in order to highlight the transient maximum in 
high-spin cytochrome P450. Panels (b) and (c) display the proportions of the apparent type-II and 
the high-spin form of total cytochrome P450 as a function of [TST], respectively. The data in panel 
(b) were fit to the Hill equation; the data shown in (c) were fit to the equation of the two-site model 
(Eq. 1.9). 
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Figure 52: Estradiol (EST) binding to CYP3A4 S119A. Panel (a) shows a series of spectra of 
CYP3A4 S119A titrations with EST, and the inset to this panel displays a zoom of the Soret band; 
the blue and the red dotted line depict the starting and end points of the titration, respectively. The 
spectrum recorded at 8 µM EST is shown in green in order to highlight the transient maximum in 
high-spin cytochrome P450. Panels (b) and (c) display the contents of the ‘P420’ (b) and the high-
spin (squares) and low-spin (triangles) forms (c) of the total cytochrome P450 as a function of 
[EST]. The data in (b) were fit to the Hill equation; the data shown in (c) were fit to the equation of 
the two-site model (Eq. 1.9). 
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Figure 53: 7-benzyloxyquinoline (7BQ) binding to CYP3A4 S119A. Panel (a) shows a series of 
spectra of CYP3A4 S119A titrations with EST, and the inset to this panel displays a zoom of the 
Soret band; the blue and the red dotted line depict the starting and end points of the titration, 
respectively. Panels (b) and (c) display the contents of the ‘P420’ (b) and the high-spin (c) forms of 
the total cytochrome P450 as a function of [7BQ]. The data in (b) were fit to the Hill equation; the 
data shown in (c) were fit to the equation of the two-site model (Eq. 1.9). 
In order to explore the nature of the uncommon spin transition exhibited by the S119A 
mutant, the results from the principal component analysis (PCA) are shown in Figure 54 and the 
position of the maxima of the first principal components (PC) are shown in Table 13. The first PC 
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of the spectral titration series of the wild type with testosterone reveals a pure type-I spin-shift. 
Analysis of the first two PCs of the titration data of the S119A mutant demonstrates that a decrease 
in both high- and low-spin cytochrome P450 accounts for the bulk of the difference (1st PC), 
whereas the 2nd most variation in the data is due to a common type-I spin shift similar to the case of 
wild-type CYP3A4. PCA of the tirations with EST and 7BQ illustrate a nearly inverse spectral 
transition in the S119A mutant, but in both cases, the peak positions of the maximum values are 
somewhat red-shifted with respect to the peak position of the minimum obtained from the analysis 
of the wild-type data (Table 16). 
Table 16: Maxima and minima extracted from the 1st principal components after principal 
component analysis (PCA) of the substrate titrations of CYP3A4 wild type and S119A.*  
Substrate Mutant Max., nm Min., nm 
Estradiol WT 385 418 S119A 423 389 
7-Benzyloxyquinoline WT 388 420 S119A 430 391 
Testosterone WT 387 418 S119A -1 411 
*The positions of the extreme values that were extracted from the 1st principal components shown 
in Figure 54 are listed. 1In the titration of S119A with TST, a minor overall spin shift was obtained, 
which led to a broad minimum in the 1st principal component due to a high noise level. Whereas in 
the case of BCT and ERY the maximum for the S119A mutant coincides with low-spin CYP3A4 
(inverse type-I transition, see chapter 5, Table 13 on p. 117), the binding of 7-benzyloxyquinoline 
and estradiol appears to induce a type-II transition starting from high-spin iron (III). 
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Figure 54: First principal components (PC) of the titration data. The first PCs of the data from 
the titration with (a) TST, (b) EST, and (c) 7BQ are compared. In (a), the second PC of for the data 
with the S119A mutant is shown, too. The first PC contains a decrease in low- as well as high-spin 
cytochrome P450, and the second PC contains regular type I shift. In (c), the maximum of the 
principal component shows a red-shift with a maximum at ~430 nm which may reflect either 
inactivation to a cytochrome P420 form of the enzyme or a type-II transition.  
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The titration experiments of the CYP3A4 S119A mutant with the cooperative substrates 
probed here do not comprise simple inverse type-I spin shift as in the titrations with BCT and ERY 
(chapter 5). This can be concluded from the displacement of the maxima of the first principal 
components. The maximum of the 1st PC appears red-shifted with respect to low-spin cytochrome 
P450 (λmax ≈ 417 nm), in particular in the case of the titration data with 7BQ (λmax ≈ 430 nm), and to 
a lesser extent in the binding of estradiol (λmax ≈ 423 nm).  
6.3.3 FORMATION OF CYTOCHROME P420 UPON BINDING OF 7BQ 
In order to explore whether binding of 7BQ leads to the transition of cytochrome P450 to the 
cytochrome P420 form, we studied binding of CO to Fe2+-heme in the presence and absence of 7BQ 
in both the wild-type CYP3A4 and the S119A mutant. The spectra that were obtained from a 
sample containing CYP3A4 wild-type enzyme in buffer solution saturated with CO before and after 
adding Na2S2O4 to the sample are shown in the absence of substrate (a) and in the presence of 150 
µM (b) and 300 µM (c) of 7BQ for CYP3A4 wild type and the S119A mutant in Figure 55. The 
proportion of cytochrome P420, which does not exhibit a Soret band absorption maximum at ca. 
450 nm upon binding of CO, was calculated with the respective standards. The data show that 
titration of both enzyme variants with 7BQ leads to the inactivation of CYP3A4 with the emergence 
of an absorption peak at ca. 424 nm. The spectra were decomposed with the help of spectral 
standards for the CO-bound cytochrome P450 and the cytochrome P420 form of CYP3A4 (see 
chapter 2.2.2.4 on p. 51). The results from this analysis are shown in Table 17.  
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Figure 55: Absorbance spectra of (a, c, e) CYP3A4 wild type and (b, d, f) the S119A mutant in 
buffer solution containing CO before (black) and after (red) the Fe (III) → Fe (II) reduction 
of the heme iron by the addition of Na2S2O4. The portion of the total heme protein that is 
inactivated through the transition to a cytochrome P420 form of CYP3A4 increased with the 
concentration of the titrant 7BQ and was determined via spectral decomposition (Table 17). 
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The CO-binding data identified a process that entails the formation of the inactivated 
cytochrome P420 form of CYP3A4 both in the wild type and in the S119A mutant enzyme. 
Strikingly, upon binding of the 7BQ ligand to the wild type, the proportion of cytochrome P420 
strongly increased. For instance, at 300 µM 7BQ, the CYP3A4 wild type only exhibited (11 ± 3)% 
of inactivated enzyme. Upon reduction with sodium dithionite, the portion of cytochrome P420 
increased to (34 ± 1)%. In strong contrast, the proportions of inactivated enzyme in the S119A 
mutant were not affected during reduction of the heme iron with Na2S2O4 (see Table 17). 
Table 17: Proportion of cytochrome P420 in the total enzyme pool determined before and 
after reduction of the heme iron by the addition of Na2S2O4.* 
7BQ, µM Wild type S119A 
 - Na2S2O4 + Na2S2O4 - Na2S2O4 + Na2S2O4 
0 0 0.061 ± 0.002 0 0.06 ± 0.01 
150 0.06 ± 0.02 0.23 ± 0.03 0.13 ± 0.01 0.15 ± 0.01 
300 0.11 ± 0.03 0.34 ± 0.01 0.21 ± 0.02 0.24 ± 0.02 
*The values given in the table represent the mean values of at least three experiments, and the “±” 
values show the respective confidence interval calculated for p = 0.05. 
 
6.4 DISCUSSION 
Titration with the two steroids EST and TST and the marker substrate 7BQ are in contrast to 
the simple inverse type-I spin shifts that result from the association of ERY and BCT to the S119A 
variant (chapter 5). Principal component analysis of a spectral series of substrate titrations was 
employed in order to monitor the fractions of the different cytochrome P450 species in the total 
enzyme pool during the course of the titration experiment. Initial binding causes a minor high-spin 
shift, whereas additional substrate leads to a low-spin shift, the extent of which depends on the 
substrate. The variant S119A exhibits contrary effects of substrate binding to the putatively 
distinguishable binding sites in CYP3A4: initial binding causes normal type-1 spin-shift, whereas 
further increase in ligand concentration leads to an inverse type-1 shift, most likely due to binding 
in the active site of CYP3A4. 
The analysis of the spectral series was therefore employed to demonstrate the binding of 
cooperative ligands to spatially separated locations of the enzyme via the identification of different 
spectral transitions. This allows us to differentiate the binding of 2-3 molecules of the steroids 
testosterone, estradiol, and the CYP3A4 marker substrate 7BQ. Theoretically, the data allow us to 
141 
Chapter 6 
calculate and obtain three different affinity constants, which may correspond to the binding of up to 
three, but at least two, substrate molecules to the S119A mutant: The first substrate binding event 
appears almost spectrally silent and leads to a slight LS → HS transition (type-I shift) similar to the 
first binding of these substrates to the CYP3A4 wild type. The binding of a second substrate leads 
to an inverse type-I spin shift (HS → LS) with a stronger spectral response with both EST and 7BQ 
than with TST. A third spectrally different transition similar to a type-II transition may be assigned 
to binding of an additional substrate molecule. The apparent spectral type-II transition may be 
caused by binding of the third steroid molecule, or it may be caused by the combined effects of the 
binding of the first two ligand molecules.  
The predominant human hepatic microsomal P450 isoform CYP3A4 has been studied 
extensively with regard to atypical kinetics, (58). Models used to explain the cooperative behavior 
of this enzyme rely on the binding of multiple substrates to different sites in CYP3A4. The initial 
binding of the ligand to a high-affinity, “spectrally silent” and/or “functionally silent” binding site 
has been proposed (72, 95, 98, 100). This binding has been suggested to occur at a site on the 
protein globule in the region of the progesterone binding site in the X-ray structure 1W0F (38, 49). 
Often, evidence for separate binding sites has remained elusive with the exception of very few 
cases. The mechanism(s) of cooperative behavior have therefore remained obscure in most cases. In 
particular cases, there are both evidence of multiple binding sites in the binding pocket (45, 50) and 
binding at a peripheral site on the surface of the protein globule in the F-G loop region (38, 49, 
100). Homotropic cooperativity of TST has been extensively studied in both equilibrium binding 
and turnover (44, 166, 173). It has been indirectly shown in several works in the lab of Sligar and 
others (58, 72, 79, 86, 94, 97, 98) that binding of individual TST molecules to CYP3A4 
differentially influence functional properties of the enzyme, such as spin state, NADPH 
consumption, and the rate of substrate hydroxylation. The binding of the first TST is assumed to 
have a minor effect on the spin equilibrium, but to induce a critical conformational change in the 
protein (80). The binding of the second molecule is likely to cause the largest part of the spin-shift 
via binding within the active site and this leads to maximal turnover of TST. The Formation of a 
quaternary complex does not further increase the turnover rate, but improves coupling of NADPH 
consumption with product formation.  The quantitative contributions of the binary, tertiary, and 
quaternary complexes to the observables spin equilibrium, NADPH consumption and/or TST 
turnover were derived with a global fitting approach (58, 72, 86, 94). 
The initial binding of the other cooperative substrates, such as Nile Red (100), α-
naphthoflavone (79), and 1-pyrenebutanol (95), have also been proposed to occur without 
significant contribution to spin-shift or turnover of the substrate. Nile Red, a fluorescent CYP3A4 
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substrate that is sequentially metabolized to the N-monoethyl and N-desethyl products, binds to the 
active site of CYP3A4 with a concomitant blue-shift in the maximum of the fluorescence emission 
band from ~ 660 nm to ~ 620 nm (100). The binding of an additional red-shifted spectral 
component emitting at 660 nm is selectively eliminated by the titration with the known allosteric 
effectors of CYP3A4, α-naphthoflavone and TST. The affinity of the blue spectral component to the 
active site was much higher (KD = 0.05 µM) than that of the red spectral component (KD=2.2 μM) to 
the allosteric site. This is in contrast to the affinities of TST, where peripheral binding occurs prior 
to active site binding. In contrast to Nile Red, no spectral resolution of TST binding to different 
binding sites has been achieved. A conformational transition upon first ligand binding was 
supported by the finding of an increase in the spatial separation between the α- and β-domains of 
CYP3A4 induced by α -naphthoflavone and TST in a study involving luminescence resonance 
energy transfer (LRET). If substrate binding is spectrally silent, initial binding takes place without 
perturbing the water network that stabilizes distal water ligation of the heme iron and occurs 
therefore either at a site distant from the heme in the binding pocket or at a peripheral ligand 
binding site. In summary, previous work hypothesized that initial binding of TST is spectrally silent 
to a high-affinity binding site that is likely to reside at the periphery of the protein globule close to 
the progesterone binding in the reported X-ray structure (38, 49).  
We reported here for the first time a direct observation of a differential effect of binding of 
steroids and 7BQ on the spin equilibrium in a CYP3A4 variant. We infer that the mutation S119A 
leads to a significant interference with binding of a water ligand to the sixth ligand-binding site in 
the heme iron. It is possible that the perturbation of the water ligation entails a structural change in 
the flexible binding pocket of CYP3A4. In the case of CYP3A4 S119A, addition of substrates that 
bind tightly in the vicinity of heme may lead to an opening of a channel that allows water molecules 
to access the distal ligand site. A stark decrease in substrate affinity to the active site leads to an 
alteration of the occupancy of the individual binding sites. As a result, the binding site close to the 
heme iron becomes saturated only at high substrate concentration. Similar to the model for apparent 
binding cooperativity that was recently presented by Denisov and coworkers (58), a high relative 
occupancy at an unproductive binding site distant from the heme produces a more sigmoidal 
binding curve.  
Our experimental data demonstrate that all type-I substrates studied in chapters 5 and 6 induce 
an inverse spin-shift in the S119A mutant, either initially or as the result of multiple substrate 
binding in the case of cooperative ligands. CYP3A4 S119A therefore represents an intriguing 
enzyme variant that is useful in the identification of allosteric substrates due to its unique properties 
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of inducing bidirectional spin shifts. In addition to the alteration in the mechanism of substrate 
binding, S119A generally exhibits lower affinity to the probed substrates than the wild type. One 
possible explanation is that the general affinity of the substrates to the active site strongly decreases 
as a result of the active site mutation in the S119A mutant, while the affinity of allosteric substrates 
to the periphery remains largely unaffected. The strong relative separation in affinities together with 
the opposite direction of spin shifts lead to a clearly visible maxima and inflection points in the 
high-spin proportions of total cytochrome P450. Our data with the cooperative substrates TST, EST, 
and 7BQ therefore convincingly demonstrate the existence of a binding site distant from the heme, 
most likely at the periphery of the enzyme, and provide support for a true allosteric ligand binding 
mechanism. 
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7 ADDITIONAL STUDIES 
 
 
This chapter contains additional studies involving the CYP3A4 mutants introduced in the previous 
chapters. Specifically, the two following projects: 
 
- A study of ligand binding to the I369F mutant of CYP3A4 involving the substrates 
introduced earlier and the discussion of potential applications of this mutant in drug 
detection with biosensors. 
- A study of the kinetics of heme iron (III) → iron (II) reduction in CYP3A4 by dithionite 
and its implication for conformational diversity of the enzyme. 
Equation Chapter 7 Section 7 
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Chapter 7 
7.1 CYP3A4 I369F - AFFINITY AND ACTIVITY STUDIES  
This chapter contains references and figures generated based on MD simulation data that were 
performed by T. Knehans. 
7.1.1 INTRODUCTION 
Despite fundamental advances in the development of pharmaceutical drugs with intensive 
drug testing and expensive clinical trials, still a majority of the available drugs exhibit a beneficial 
therapeutic effect in less than half of the treated individuals (180, 181). There are several causes that 
potentially affect treatment success, such as pathogenesis and severity of the treated disease, drug 
interactions, nutritional status, renal and liver function, age, and concomitant illnesses (182). 
Therapies based on information about the individual’s drug metabolising capability would aid to 
increase the success rate in drug therapies and reduce adverse drug reactions (180). Hence, there has 
been a rising demand for the development of personalized therapy. Glucose sensors can be viewed 
as prototypic biosensors that are increasingly used to monitor glucose levels in diabetes therapy. 
The need for long-term implantable automatic glucose sensors are acknowledged by the diabetes 
care community. Continuous glucose monitoring has been achieved with percutaneous glucose 
sensors that are inserted with needle introducers into subcutaneous tissues (183), but these sensors 
face drawbacks such as the need for frequent replacement (every 3 – 7 days) due to adverse 
reactions, e.g. encapsulation of the subcutaneous sensor part by the body (184). They are however 
generally capable of reliably measuring glucose levels and have been developed to the commercial 
product stage. Such advances in the diabetes care have translated into a stimulation of the research 
on electrochemical biosensors for the detection of other human metabolites, or xenobiotic 
compounds such as drugs. It was suggested that electrochemical biosensors based on cytochromes 
P450 should be combined with chip-based assays on marker genes in the next generation of 
diagnostic sensing devices (115, 180). 
Cytochromes P450 have the third position after glucose oxidase and cytochrome c in the 
number of publications on protein electrochemistry (180). Because they cover a broad substrate 
range, they theoretically offer intriguing opportunities for the application in drug detection and 
therapeutic monitoring. The first cytochrome P450-based enzyme electrode was presented in 1978, 
and a whole spectrum of P450-dependent sensors have been characterized since that were targeted 
at the detection of drugs, metabolites, or environmental pollutants (115, 180). In contrast to glucose 
sensors, the major limitation of drug sensors based on cytochromes P450 are their low sensitivity to 
their target drugs. Whereas normal plasma glucose levels lie in the range of 4-8 mM, the therapeutic 
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target concentrations of most drugs are in the low micromolar or even nanomolar range11. Since 
most drugs exhibit affinity parameters (e.g. S50, KD, or KM) to the microsomal cytochromes P450 
that are >> 1 µM, they are in most cases not suitable for the detection of drugs in the therapeutic 
window and hence for therapeutic drug monitoring. Novel enzyme variants that exhibit improved 
affinity to target pharmaceuticals on the basis of the extensively studied wild-type enzymes are 
therefore required for applications in the novel enabling technologies for cytochrome P450-based 
therapeutic drug monitoring.  
The original scope of this thesis was the development of CYP3A4 mutants with improved 
activity or affinity towards pharmaceuticals such as the model compound carbamazepine (CBZ) for 
the implementation of the enzymes as recognition elements in drug sensing. In view of our original 
goal to generate CYP3A4 variants to be used in CBZ biosensors, the A370V variant may seem to be 
the best candidate, as it exhibits the highest maximal rate of CBZ turnover among the probed 
enzyme variants (see chapter 4). However, taking into account that the target therapeutic 
concentrations of CBZ in blood plasma should fall in the range of 17 – 70 µM (51), we argue that 
the decreased affinity of A370V to CBZ (S50 = 1.1 mM) undermines its practical utility. We believe 
that the most promising enzyme variant for practical use is the I369F mutant, where the rate of CBZ 
turnover was increased two-fold and the S50 value obtained with the use of Eq. 4.2 remained 
unaffected p. 94). Moreover, the CBZ epoxidation kinetics showed that the turnover at 100 μM and 
50 μM CBZ is 2.2- and 2.7-fold that of the wild type, respectively (see Table 9 on p. 92). 
The two CYP3A4 mutants, I369F and I369L, exhibited increased affinities to bromocriptine 
(BCT; see Table 11, chapter 5, on p. 114). The KD of the mutants I369F and I369L was reduced 2.5-
fold and 1.5-fold compared to the wild type, respectively. For further exploration of alterations in 
substrate affinities in the mutants, we performed titrations of the I369F mutant with the cooperative 
ligands testosterone (TST), estradiol (EST), and 7-benzyloxyquinoline (7BQ) and compared the 
data to CYP3A4 wild type. We also probed the activities of all generated mutants with the 
fluorogenic marker substrates 7BQ and BOMR in a screening assay. The results are discussed with 
respect to the potential application of the generated enzyme variants to drug detection and drug 
monitoring. 
11 The Vademecum 2007 contains a list of therapeutic levels of many drugs (Institute of Clinical 
Chemistry, University Hospital Zürich, Switzerland). 
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7.1.2 RESULTS 
Titrations of the CYP3A4 I369F mutant with cooperative substrates resulted in type-I spin 
shifts that were fit to the Hill equation for determination of the affinity parameter S50. EST did not 
induce a spectral transition that was sufficient for the analysis. The fitting parameters are presented 
in Table 18 below and compared to the results of the titrations of the wild-type enzyme. The S50 
parameter for the titrations with TST, 7BQ, and BCT of the I369F mutant was, on average, 2.1 
times smaller than the wild type. The titrations were not performed with ERY, as this non-
cooperative ligand does not induce a type-I transition in the wild-type enzyme (see chapter 5). 
Table 18: Comparison of investigated ligand affinities to CYP3A4 wild type and the I369F 
mutant.* 
Fitting Results 
Substrate S50, µM Spin Shift h HSFin 
Testosterone w/t 56 ± 14 0.45 ± 0.02 1.15 ± 0.08 0.59 ± 0.03 I369F 28 ± 10 0.21 ± 0.03 1.2 ± 0.3 0.67 ± 0.01 
Estradiol w/t 34 ± 6 0.18 ± 0.02 1.22 ± 0.07 0.32 ± 0.02 I369F - - - - 
7-Benzyloxy-
quinoline 
w/t 72 ± 17 0.36 ± 0.03 1.70 ± 0.08 0.54 ± 0.01 
I369F 40 ± 5 0.17 ± 0.02 1.58 ± 0.14 0.62 ± 0.03 
 KD, µM Spin Shift HSFin 
Bromocriptine§ 
w/t 0.6 ± 0.2 0.48 ± 0.05 0.62 ± 0.02 
I369F 0.25 ± 0.07 0.25 ± 0.03 0.70 ± 0.02 
*The titration data with the cooperative substrates testosterone, estradiol, and 7-benzyloxyquinoline 
were fit to the Hill equation for the comparison of the affinity parameters. § The bromocriptine 
titration data were presented in chapter 5 (see p. 114) and are shown here for the completeness of 
the data. The values given in the table represent the mean values of at least three experiments, and 
the “±” values show the respective confidence interval calculated for p = 0.05. 
The series of spectra obtained upon titration of the CYP3A4 I369F mutant with testosterone, 
estradiol, and 7-benzyloxyquinoline are shown in Figure 56, Figure 57, and Figure 58, respectively. 
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Figure 56: Titration of the CYP3A4 I369F mutant with testosterone (TST). Panel (a) shows the 
spectral series of the titration with the substrate and a zoom into the peak of the Soret band in the 
inset. Panel (b) represents a comparison between the titrations of the I369F mutant (triangles) and of 
the CYP3A4 wild type (squares). The parameters from the fitting of the Hill equation are shown in 
Table 18. 
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Figure 57: Titration of the CYP3A4 I369F mutant with estradiol (EST). Panel (a) shows the 
spectral series of the titration with the substrate and a zoom into the peak of the Soret band in the 
inset. Panel (b) represents a comparison between the titrations of the I369F mutant (triangles) and of 
the CYP3A4 wild type (squares). The parameters from the fitting of the Hill equation are shown in 
Table 18. The analysed spin shift in the I369F mutants was not sufficient for the determination of 
affinity parameters. 
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Figure 58: Titration of the CYP3A4 I369F mutant with 7-benzyloxyquinoline (7BQ). Panel (a) 
shows the spectral series of the titration with the substrate and a zoom into the peak of the Soret 
band in the inset. Panel (b) represents a comparison between the titrations of the I369F mutant 
(triangles) and of the CYP3A4 wild type (squares). The parameters from the fitting of the Hill 
equation are shown in Table 18. 
Cytochrome P450-based biosensors measure redox cycling, more precisely the consumption 
of electrons by the P450 enzymes that are directly “plugged” into the electrodes. The enzymatic 
activity in solution may therefore give more direct information about the sensitivity of a 
corresponding biosensor. For instance, in a recent report, Taurino and coworkers compared the 
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enzyme kinetics of L-lactate oxidases to electrochemical studies. They reported similar substrate-
dependencies from the spectrophotometric detection of product formation and the amperometric 
signal of the electrode (185). We therefore studied the activity of all expressed mutants and the 
wild-type enzyme in a kinetic assay that detects the turnover of a fluorogenic substrate. The 
conditions for these assays are described in the methods section on p. 51. Specifically, we measured 
the turnover of the CYP3A4 substrates 7BQ and the resorufin derivative Vivid® BOMR. The 
turnover measurements of the two substrates monitored on a multi-well plate reader were specified 
in absorbance units min-1 and normalized with respect to the turnover of the wild type. The 
activities towards the substrates 7BQ and BOMR of the individual CYP3A4 mutants were 
determined at concentrations of 5 µM and 3 µM, respectively, and are compared in Figure 59. 
These concentrations represent the typical conditions employed for the screening of enzymatic 
activity, e.g. in inhibition assays. 
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Figure 59: Turnover of the fluorogenic marker substrates (a) 7BQ and (b) BOMR by the 
generated mutants. The obtained activities in ΔAbs min-1 were normalized and expressed in units 
of wild-type turnover. The bars represent show the mean values of the measurements that were 
performed in triplicates, error bars represent the standard deviations. 
The most interesting result from these assays are the markedly increased activities for the 
I369F mutant, which amounted to ca. 3-fold and 7-fold wild-type activity for 7BQ and BOMR, 
respectively. 
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7.1.3 DISCUSSION 
In order to compare the relative affinities of CYP3A4 wild type and the I369F mutant, we 
recorded series of spectra for the titration of the two enzymes with ligands that show either 
sigmoidal or regular non-cooperative binding behavior. In our analysis of the series of absorbance 
spectra recorded upon titration with the ligands BCT, 7BQ, and TST, the substrates show on 
average double the affinity for the CYP3A4 I369F mutant with respect to the wild-type enzyme. In 
some cases, no reproducible values for the affinity constant for both enzymes could be determined 
and the affinities could thus not be compared. This was the case with the substrates ERY and EST, 
which did not induce a type-I spin shift in the wild-type enzyme and the I369F mutant, respectively. 
The 2-fold increase in affinity is yet to be explained. However, the simulations presented in chapter 
4 suggest that the phenylalanine introduced by the I369F mutation in the vicinity of the active site 
projects further towards the Phe304 residue of the opposite I-helix (Figure 40 on p. 106). The 
phenylalanine substitute may block the free space adjacent to the active site that is available to non-
productive substrate binding in the wild-type enzyme. It is plausible that this confinement causes a 
channeling of the substrates towards the heme iron (or the oxidizing species of the active site), and a 
displacement of the distal water ligand. 
It is of interest to discuss the structural basis that allows the I-helix to adopt a strong kink as 
seen in MD simulations of the I369F mutant shown in chapter 4 (Figure 39, p. 105). This 
astonishing feature was only found in one of five MD simulations of the CYP3A4 I369F-(CBZ)2 
complex and therefore may be purely coincidental. However, it can be assumed as a possible 
structural constraint on this helix induced by the I369F mutation. In some X-ray structures of 
cytochromes P450, a functionally important water molecule is located between the highly 
conserved residues of the I-helix Ala305 and Thr309 that line the active site (38). The two 
conserved residues are located near the distal face of the heme ring. Indeed, in most bacterial 
structures of cytochromes P450, a water molecule has been identified inside the I-helix in this 
region. In some of the structures, the water molecule interacts with the side chain of a threonine of 
the I-helix. Most importantly, this causes an expansion of the helical groove and induces a kink that 
is characteristic for this helix in cytochromes P450. (38, 186). Although no water molecule was 
resolved in the first published CYP3A4 structure, a moderate kink in the I-helix is still present (38). 
In a CYP3A4 crystal structure published in the same year (2004), a water molecule that is in 
hydrogen bonding distance both to the backbone carbonyl oxygen of Phe304 and Glu308 (Figure 
60) is resolved (187). Glu308 is another highly conserved residue that is (together with Thr309) 
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thought to position a water molecule for proton transfer to the reduced oxygen intermediates bound 
to the heme (187).  
 
Figure 60: Structurally important water molecule in CYP3A4 X-ray structure 1TQN (187). 
The oxygen atom of water is equidistant (2.9 Å) from each carbonyl oxygen atom of Phe304 and 
the amide nitrogen atom of Glu308 of the I-helix (green). The heme is shown in red (structure 
reproduced in PyMol). 
Interestingly, the pronounced kink that is found in one of the simulations of the I369F mutant 
with two carbamazepine molecules (chapter 4, Figure 39, p. 105) is accompanied by the disruption 
of the hydrogen bond between the side chain of Thr309 and the carbonyl oxygen of Ala305, which 
is present in the X-ray structure of the metyrapone-CYP3A4 complex (Figure 61a) (38). In the 
simulation of the I369F mutant, the β-hydroxyl group of Thr309 is shifted away from Ala305, but is 
in close distance to the carbonyl oxygen of the backbone of Phe304. This altered hydrogen bonding 
pattern likely permits the intrinsically destabilized conformation with the pronounced kink in the 
helix (Figure 61b). 
F304
E308
155 
Chapter 7 
 
Figure 61: Structure of the CYP3A4-metyrapone (light blue) complex (a) compared to the 
largest cluster representative of the MD simulation of CYP3A4 with two carbamazepine 
molecules (marine) bound (b). In panel (a), Thr309 is hydrogen-bonded to the backbone of 
Ala305, whereas the interaction is disrupted and Ala305 replaced by Phe304 for side chain-
backbone interactions in panel (b). Thr309 and Phe304 of the I-helix (green) are shown in orange, 
Phe369 and Ala370 in the I369F mutant are shown in yellow. The figure in (b) is based on the 
coordinates obtained from the simulations by T.K. (Chapter 4). 
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The 7-fold increase in the turnover kinetics of CBZ, BOMR, and 7BQ in the I369F mutant at 
low substrate concentrations is unlikely to be explained solely based on the moderate 2-fold 
increase in affinity. It may however result from a combination of the mutually reinforcing effects of 
increased substrate affinity and eased reduction of the iron (III) heme due to the high proportion of 
high-spin P450 in the I369F mutant in the absence of substrate. In conclusion, we have generated a 
CYP3A4 mutant that exhibits increased affinity and/or higher turnover to a broad spectrum of 
structurally different substrates and ligands. The I369F variant may be coupled (“plugged” (188)) as 
a recognition element to the electrodes of cytochrome P450-based sensors for drug monitoring. This 
mutant is expected to contribute to the development of cytochrome P450 biosensors with improved 
sensitivity to and detection capability of a broad spectrum of drugs that are substrates of the highly 
promiscuous CYP3A4. Yet, the actual relationships between the faradaic current to the electrodes 
and the enzymatic turnover are barely known. Therefore, further assessment of the utility of 
CYP3A4 for the use in drug detection requires investigations with the enzyme immobilized and 
coupled on an electrode surface. 
 
7.2 KINETICS OF DITHIONITE-DEPENDENT REDUCTION 
OF CYP3A4 POINT MUTANTS 
7.2.1 INTRODUCTION 
In the last two decades, cooperativity in cytochromes P450 and its implications for drug-drug 
interactions have attracted increasing interest. Studies of the mechanistic basis of cooperativity 
focused to a large part on cytochrome P450 3A4 (CYP3A4) that metabolizes a broad range 
pharmaceutical drugs. Evidence for the presence of persistent conformational heterogeneity in the 
total CYP3A4 enzyme pool has accumulated, such that this divergence into functionally diverse, 
stable populations was assumed to be key to the complete understanding of the mechanisms of 
cooperativity (67, 81, 189). The divergence of the enzyme into several stable subpopulations with 
different functional properties is required to be considered for understanding the mechanism of 
cooperativity. Due to very slow transitions between the populations of distinct conformers, the 
distribution of the enzyme between these conformers stays constant within the time-frame of most 
experiments. The formation of cytochrome P450 oligomers in the microsomal membrane is 
believed to be a most probable explanation for persistent conformational heterogeneity (105). Even 
though the formation of oligomers is primarily a determinant for the competition of individual P450 
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molecules for NADPH-P450 reductase (CPR), it is known to affect other functional properties of 
the microsomal monooxygenases. 
Some evidence for oligomerization in solution is given by the fact that CYP3A4 (57 kDa) can 
be concentrated above membranes of a molecular weight cut-off of 100 kDa without passing 
through the membrane. Moreover, while substrates induce an almost complete spin-shift of > 90% 
in monomerized CYP3A4, for instance in enzyme incorporated as monomers into nanodiscs (a 
protein scaffold for co-integration of membrane proteins with lipids)(56, 86, 190), the total high-
spin shift induced in CYP3A4 in solution is limited and usually does not increase to fractions >70% 
of total cytochrome P450 (see chapters 5-7). In studies of pressure-induced transitions of CYP2B4, 
only 65 – 70% of the enzyme was susceptible to a pressure-induced P450 → P420 transition (70, 
131). Such non-uniform behaviour disappears upon monomerization of cytochrome P450 upon 
treatment with detergent. Oligomerization may lead to differences between the oligomer subunits in 
their interaction with substrates or sensitivity for pressure-induced inactivation (P450 → P420 
transition) (105). 
In their work, Davydov and coworkers demonstrated important differences in the kinetics of 
reduction of CYP3A4 by Na2S2O4. Reduction by dithionite is used in routine quantification of 
cytochrome P450 (see chapters 3 and 5) (31).  
Here we apply our generated CYP3A4 site-directed mutants to studies involving rapid mixing 
of the enzymes with a dithionite-containing solution to monitor the reduction kinetics in solution. 
The overall stoichiometry of the reaction that takes place upon mixing in the chamber of the 
stopped-flow is: 
 
 
3 2
2 2Fe SO CO Fe CO SO
+ − ++ + → +   (7.1) 
 
Since the accessibility of water to the heme iron appears to be restricted in some of the 
mutants (predominantly I369F and S119A), we assumed that the investigations may add some 
important insight into the relevance of the active site amino acids to the native function of CYP3A4.  
7.2.2 RESULTS 
The kinetics of the reaction were determined via the appearance of the Soret peak of the iron 
(II) cytochrome P450 3A4 that was centred at 448 nm. The absorbance at 448 nm of the dithionite-
dependent reduction reaction is shown as a function of time in Figure 62. Figure 62a shows the 
evolution of the absorbance in the reactions with the individual mutants, while Figure 62 compares 
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the normalised relative changes. The results of the fits to a sum of three exponentials are shown in 
Table 19. The results for wild-type CYP3A4 are in good agreement with previously published data 
(105). We obtained an equal distribution between the species that react with the slow, intermediate, 
and fast exponential phase of the reduction. Mutants I369F and A370L showed the slowest overall 
reduction kinetics and we obtained the highest proportion of slow phase in the two mutants I369F 
and S119A. These mutants both exhibit ca. equivalent proportions of low- and high-spin 
cytochrome P450 in absence of substrate.  
To the naked eye, it appears that S119A is the most peculiar case due to the very fast partial 
reduction of the enzyme pool that is followed by comparably slow reduction of the rest of the 
enzymes. This leads to a crossing of the curves in Figure 62b, in which the total changes in 
absorbance are normalized. Apparently, the difference between the rates of reduction of high-spin 
and low-spin P450 is particularly strong in this mutant.  
 
Table 19: Kinetic parameters of dithionite-dependent reduction of CYP3A4 wild type and 
mutants.* 
Mutant k1 k2 k3 F1 F2 F3 
w/t 3.6 ± 0.3 0.56 ± 0.02 0.095 ± 0.005 0.36 ± 0.03 0.31 ± 0.01 0.34 ± 0.02 
S119A 4.7 ± 0.5 0.43 ± 0.02 0.048 ± 0.002 0.24 ± 0.02 0.173 ± 0.005 0.59 ± 0.01 
I369F 1.5 ± 0.4 0.30 ± 0.04 0.058 ± 0.06 0.11 ± 0.02 0.32 ± 0.03 0.57 ± 0.05 
I369L 3.7 ± 0.2 0.59 ± 0.04 0.099 ± 0.05 0.433 ± 0.008 0.291 ± 0.005 0.28 ± 0.01 
A370L 1.8 ± 0.3 0.36 ± 0.02 0.066 ± 0.02 0.11 ± 0.01 0.39 ± 0.01 0.50 ± 0.01 
A370V 2.9 ± 0.9 0.47 ± 0.06 0.086 ± 0.08 0.19 ± 0.02 0.40 ± 0.01 0.41 ± 0.02 
*The values given in the table represent the mean values at least three experiments, and the “±” 
values show the respective confidence interval calculated for p = 0.05. 
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Figure 62: Kinetics of dithionite-dependent reduction of CYP3A4 wild type and mutants. In 
panel (a), the absorbance at λ = 448 nm is plotted against time. In panel (b), the total Δ absorbance 
is normalised and plotted against time.  
7.2.3 DISCUSSION 
It was demonstrated by Hintz and Peterson that the kinetics of reduction of substrate-free 
cytochrome P450 101 (P450cam) by dithionite obeys pseudo-first order kinetics. (191). Our data 
presented could be fit to the sum of three exponential functions which are thought to correspond to 
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the pseudo-first order reaction of three different species present in the enzyme pool. The fitting to 
the sum of two exponential functions lead to systematic deviations between the spectroscopy data 
and the fits. A model based on the existence of the enzyme in only two species such as the high-spin 
and low-spin iron (III) cytochrome P450 is therefore not sufficient to explain the data. Hence, at 
least two functionally diverse populations with different functional properties are assumed to be 
present in solution, which are formed in the natural environment in the lipid bilayer (78).  
In the work reported on CYP101, binding of the substrate camphor strongly decreased the rate 
constant of reduction. This finding was attributed to the restriction of the access of the charged 
reducing species 2SO
−  to the P450 heme iron upon ligand binding (191). Later, it was shown by 
Davydov and co-workers that the binding of type-I ligands perturbs the distribution between the 
species F1 and F3 that correspond to the fractions of the total enzyme which are reduced with 
reaction rates k1 and k3 (fast and slow phases), respectively. Type-I transition led to a shift towards 
the species F3, and the content of high-spin cytochrome P450 CYP3A4 correlated with the fractions 
of the slow reduction rate of the iron (III) heme (105). In our work, the mutations S119A and I369F 
show similarly high proportions of the F3 species that reacts at the slow rate k3 ((59 ± 1)% and (57 ± 
5)%, respectively), whereas the proportion of the fast rate is strongly decreased with respect to the 
wild-type enzyme.  
Figure 63 shows that there some correlation between the high-spin proportion in the total 
cytochrome P450 pool and the slow reaction rate. There are however other factors adding to the 
complexity of this system, such as the unknown influence of the amino acid substitutions on the 
iron (III) → iron (II) reduction rates of the different (spin) species in the sample. For quantitative 
statements, it may be tested whether global fitting of a joint set of rate constants to all of the data 
elucidates better correlations between the spin proportions and the fractions Fi in the model. Due to 
the fact that this mutant exhibits inverse spin shift upon ligand binding (see chapter 5), the S119A 
mutant offers the possibility for an interesting experiment to explore whether the presence of a 
ligand in the active site or rather the spin state of the heme iron in cytochrome P450 is critical for 
the redistribution between the fast and slow kinetic phases of the reduction. If the main effect is 
assumed to stem from the change in spin equilibrium, an increase in the fast phase of the reaction is 
expected. This is however not true if the presence of a ligand is assumed to be decisive for the 
reduction of the rate constant. 
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Figure 63: The fraction of the slow phase of dithionite-dependent reduction (F3) is plotted 
against the high spin content in the substrate-free enzyme mutants. A correlation coefficient of 
ρ2 = 0.56 was obtained. The values for the fraction of the slow phase of the reduction and the HS 
content are shown in panel (b). 
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Cytochrome P450 3A4 is the most abundant cytochrome P450 in the microsomes of human 
liver and metabolizes > 50% of all pharmaceutical drugs. It exhibits numerous forms of atypical 
kinetics that can lead to drug-drug interactions and adverse drug reactions in drug therapy, which is 
an issue of high importance for the pharmaceutical industry. More than 2000 papers that list the 
keyword CYP3A4 have been published in 2013, with a tendency to rise each year. Some functional 
features of this enzyme remain unresolved. Complex functional aspects of CYP3A4 were 
investigated in this thesis. In our study, we combined molecular dynamics simulations, performed 
within a scientific collaboration, to generate CYP3A4 mutants via site-directed mutagenesis, with 
biophysical and biochemical techniques for the analysis of the generated mutants. This strategy 
proved to be useful for the production of enzyme variants with altered functional properties, the 
study of which was presented in this thesis. 
CYP3A4 S119A differs from the wild type by a hydroxyl group. The removal of this 
functional group produces an enzyme that exhibits spin transitions that occur in the opposite 
direction of the most frequent transition in cytochromes P450 upon substrate binding (type-I 
transition). The mutant I369F exhibits higher affinity for several structurally different ligands than 
the wild type and shows higher turnover rates of some substrates at low concentrations. One of the 
key findings in this work is that the five generated enzyme mutants differ in cooperative kinetics 
and substrate inhibition in the epoxidation reaction of CBZ. Whereas low affinity to CBZ goes 
together with cooperative CBZ epoxidation kinetics, an increased affinity results in a more 
pronounced substrate inhibition than in the wild-type enzyme. 
Most of the numerous substrates of CYP3A4 bind weakly to the enzyme and give rise to low 
turnover numbers. Some determinants for improved binding of certain ligands are known from 
cases where X-ray structures of CYP3A4-ligand complexes have been determined. The preference 
of CYP3A4 for certain substrates over others is, however, poorly predictable, particularly due to the 
large flexibility in some parts of the enzyme. We expected based on structural data and MD 
simulations that substitutions of the amino acid residues Ser119, Ile369, and Ala370 affect the 
binding of carbamazepine and most likely many other substrates. However, two of the mutations, 
S119A and I369F, revealed entirely unforeseen changes in the enzyme. 
The largest reduction in the affinity for bromocriptine ensues from the S119A mutation. For 
this mutant, it was reported that the association of a class of peptidomimetic analogues of the drug 
ritonavir does not lead to a rise in thermal stability of the enzyme, and that the kinetics of ligand 
association with these drugs are perturbed (174). The water network in the active site of this mutant 
must be disrupted, which follows from its inverse spin shift seen upon titration with a type-I 
substrate and its existence to high proportions in the high-spin state in the absence of substrate. The 
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findings of inverse and bidirectional spin shifts are unique to this mutant and hopefully will provide 
an incentive for other researchers to explore the challenging question about the exact mechanism of 
this transition.  
Since the appearance of the first crystal structures of CYP3A4 in the year 2004 (38, 187), few 
mutants of CYP3A4 have been explored. This is also a result of the fact that the identified single 
nucleotide polymorphisms in CYP3A4 studied to date do not translate into very important inter-
individual variability in metabolism in vivo. Even though 28 polymorphisms of CYP3A4 exist, their 
implications for human metabolism are less important when compared to the polymorphisms of the 
major polymorphic microsomal cytochromes P450, examples of which are CYP2D6 and 2C19 
(192). Induction of expression and drug-drug interactions are however factors that strongly affect 
CYP3A4-based metabolism. The many types of atypical kinetics exhibited by CYP3A4 contribute 
to the variability in the metabolism in vivo.  
Further progress in the development of cytochrome P450-based biosensors is desirable for 
drug detection and for therapeutic monitoring similar to the one with glucose sensors that have 
revolutionized diabetes care. CYP3A4 exhibits a large flexible binding pocket suitable to 
accommodate large molecules (e.g. the 734 kDa erythromycin or the 1200 kDa cyclosporine). The 
development of a mutant that is specific for a small molecule like carbamazepine for the 
incorporation into CYP3A4 biosensors requires a substantial reduction in the volume of the active 
site. Most likely, this implicates several rounds of mutagenesis combined with the verification of 
the activity of the generated mutants, and finally a design of the active site to specifically 
accommodate the desired drug. Retention of normal function in a CYP3A4 variant that has been 
extensively mutagenized is unlikely in the light of the drastic changes that are exerted already by 
minor modifications of single amino acids, as demonstrated in this thesis. Minor substitutions (such 
as the exchange of serine for an alanine in the S119A mutant) and possibly even conservative 
substitutions may strongly affect enzyme function. The generation of a substrate-specific enzyme 
variant from a very promiscuous wild-type enzyme that metabolizes hundreds of substrates would 
be extremely challenging. Therefore, the design of a specific mutant based on a bacterial 
cytochrome P450 with a narrow native substrate range and a smaller binding pocket, e.g. 
cytochrome P450cam, appears to constitute a more promising approach. 
With the mutant I369F we were able to show that it is possible to modulate the affinities of 
CYP3A4 for substrates. I369F shows a ~3-fold higher turnover of carbamazepine to the epoxide 
product than the wild type at a concentration of 50 μM substrate. The mutant metabolizes the 
resorufin derivative BOMR ca. 7 times faster than the wild type at 3 µM substrate. The turnover of 
7-benzyloxyquinoline is about 3 times that of wild type CYP3A4 at [7BQ] = 5 µM. In addition to 
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the results from turnover studies, I369F binds all tested substrates with higher affinity than the wild 
type. More data could be gathered, but a tendency is already clear: I369F appears to be a mutant 
that exhibits a higher affinity to several structurally different classes of small molecule CYP3A4 
substrates and shows increased rates of turnover at low (sub-KM) substrate concentration. 
Rationalization of this affinity shift based only on the paradigm of enzyme-substrate interaction 
(‘induced fit’) appears problematic, since the I369F mutant exhibits a lower affinity constant to 
structurally diverse substrate classes. In CYP3A4, also other determinants are key to ligand 
association, for instance flexible domains that allow the proper arrangement of ligands in the 
binding pocket (45), or an efficient direction of the ligand through the substrate access channel to 
the deeply buried active site. It remains unclear whether a putative switch in the hydrogen bonding 
pattern and the resulting predicted kinked I-helix of CYP3A4 are actually relevant to the structure 
of CYP3A4 I369F. Such a conformational change was obtained in only a fraction (20%) of all 
snapshots of the performed MD simulations of a I369F-(CBZ)2 complex. However, it may 
constitute a possible conformational switch. The kinked I-helix along with the extended side chain 
of the phenylalanine introduced at position 369 could entail a decrease in the volume of the active 
site and thus offer a tighter fit for small ligand molecules. 
The development of cytochrome P450-dependent biosensors for drug detection based on the 
CYP3A4 I369F mutant may seem problematic due to substrate inhibition. A direct consequence 
from substrate inhibition is that one value for the response of the sensor corresponds to two 
substrate concentrations. This problem could be solved by the implementation of several 
compartments on the sensor, which would each contain a different CYP3A4 mutant as the substrate 
recognition element. Each of the selected mutants should exhibit a different range of linear response 
to substrate that would optimally mutually overlap. With such an approach based on a combination 
of building blocks into a single sensor, unambiguous allocation between signal and substrate 
concentrations would be possible. It remains in the hands of both engineers and biochemists to build 
new biosensors that are sufficiently sensitive to detect drugs at therapeutic levels. The development 
of such biosensors would pave the way for an application of this enabling technology in 
biomedicine and eventually in wearable devices for therapeutic drug monitoring in personalized 
medicine. 
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